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Sepsis is a life-threatening systemic inflammatory condition that is 
characterized by a high degree of patient heterogeneity, making it notoriously 
difficult to diagnose and treat. Among the most common and lethal causes of 
sepsis are strains of Extraintestinal Pathogenic Escherichia coli (ExPEC). These 
genetically diverse pathogens are becoming increasingly problematic due to the 
rise of multidrug resistant strains. During sepsis, the infecting microbes are 
commonly viewed as generic inducers of inflammation, while the host 
background is considered the primary variable affecting disease progression and 
outcome. My doctoral research challenges this assumption and establishes a 
novel zebrafish embryo infection model to study the effects of ExPEC strain 
differences on the maladaptive immune responses that are induced during 
sepsis.  
Zebrafish embryos infected with ExPEC isolates display many of the key 
pathophysiological features seen in human septic patients, including 
dysregulated inflammatory responses (cytokine storms), tachycardia, and 
endothelial leakage. Mirroring what is seen in human patients, antibiotic therapy 
reduces bacterial titers in infected embryos and improves host survival rates, but 
is only effective within limited time frames, and surviving animals often develop
  
inflammatory (e.g., IL-1 β, TNF-α) and immunomodulatory (e.g., IL-10) 
mediators. These variances are attributable to differential activation of TLR5 by 
these strains, which vary in the levels and the serotypes of flagellin that they 
express. To examine the specific effects of IL-10 on disease progression, I 
created and begun to characterize engineered gene knockout and inducible 
transgenic zebrafish lines for this cytokine. Altogether, my graduate research 
establishes zebrafish as a relevant model for studying sepsis and highlights the 
ability of genetically distinct ExPEC isolates to induce divergent host responses 
independent of baseline host attributes and implicates bacterial flagellin as a key 
mediator of inflammation during sepsis. 
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Escherichia coli: a Diverse Opportunist 
 Escherichia coli is an incredibly diverse organism both genetically and 
phenotypically. It is a Gram-negative rod-shaped organism commonly found in 
the lower intestines of warm-blooded animals, but can also be found 
environmentally in water and soil. Within the intestinal tract, it is often viewed as 
a benign commensal that provides the host with essential vitamins and aids in 
the digestion of metabolites. However, there are strains of enteropathogenic E. 
coli that are capable of causing lethal diarrheal disease. E. coli isolates causing 
disease outside of the gastrointestinal tract, termed Extraintestinal Pathogenic 
Escherichia coli (ExPEC), are also very problematic causing a diverse range of 
conditions including meningitis, sepsis, and urinary tract infections (UTIs) [1]. 
UTIs are the one of the most common bacterial infections, with an estimated 8 
million UTIs in the United States each year and 50% of women experiencing at 
least one during their lifetime [2]. ExPEC are the predominant organism 
responsible for UTIs, representing >80% of these infections.  E. coli is also a 
leading cause of sepsis. The role of this organism during sepsis will be discussed 
in greater detail later in this chapter as well as in Chapters 2 and 3. 
 The genomes of ExPEC strains are comprised of a set of core genes 
common to nonpathogenic and pathogenic E. coli strains, but also contain 
virulence factors such as iron acquisition systems, capsular antigens, adhesins, 
and secreted toxins. Strikingly, gene content between individual clinical ExPEC 
strains can differ by as much as 30% and the pan genome, or total number of 
	 3 
distinct genes among all ExPEC isolates is estimated to be upwards of 14,000 [3-
5]. This diversity has evolved likely as a means to allow ExPEC strains to survive 
and replicate under myriad environmental conditions and stresses. However, this 
genetic variation also presents significant challenges for the diagnosis and 
treatment of E. coli-initiated disease and no single gene or collection of genes 
has been identified as a universal indicator of pathogenesis or responsiveness to 
treatment. 
 
Sepsis and the Role of E. coli in Disease 
 Sepsis is the overwhelming maladaptive activation of the immune system 
in response to invading microorganisms. More than 1 million individuals are 
admitted to the hospital with sepsis every year in the USA. With a mortality rate 
of 25-50% it kills more people in the US annually than prostate cancer, breast 
cancer and AIDS combined [6, 7]. Hospitalization rates for sepsis are also on the 
rise and have more than doubled since 2000 [7]. In addition to its unacceptably 
high mortality rate, sepsis places a significant financial burden on the healthcare 
system, being the most expensive cause for hospitalization and costing the 
healthcare system over $20 billion dollars per year in total [8]. 
While anyone can get sepsis, immunocomprimised populations such as 
the elderly, neonates and infants, AIDS patients, and people undergoing 
chemotherapy are particularly vulnerable. Following the widespread activation of 
pathogen recognition receptors and the corresponding increase in immune signal 
transduction cascades, a “cytokine storm” of inflammatory mediators is released, 
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leading to disseminated intravascular coagulation, endothelial leakage, 
pulmonary and systemic edema, and organ damage.  
One of the key issues concerning sepsis is the heterogeneity seen in the 
patient population, making diagnosis and treatment especially difficult. 
Differences in host background are often viewed as the root cause of this, but the 
contribution of bacteria even within the same species remains largely unexplored. 
On account of this heterogeneity there are currently no satisfactory biomarkers 
for the diagnosis of sepsis or specific antisepsis therapies, so patient 
management relies on early administration of antibiotics and resuscitation with 
intravenous fluids and vasoactive drugs when needed. Antibiotic therapy should 
be initiated within 1 hour of a sepsis diagnosis. Each hour this is delayed is 
associated with a 7% increase in mortality [9]. Finally, those lucky enough to 
survive sepsis are often left with long term complications such as cognitive 
impairment and organ dysfunction and suffer a high rate of hospital readmission 
[10-13].   
E. coli is the leading cause of bacteremia and the second most common 
cause of sepsis, with only Group B Streptococcus and Staphylococcus aureus 
being more prevalent in neonates and adults, respectively [14-18]. Strikingly E. 
coli is generally more inflammatory and more likely to cause death during sepsis 
relative to Gram-positive pathogens and other Gram-negative bacteria [19, 20]. 
Adding to the problem is the ongoing rise of multidrug resistant E. coli strains that 
are encroaching on the ability to effectively treat the underlying infection during 
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sepsis [21, 22]. Given the functional redundancy in virulence factors utilized by 
ExPEC strains to deal with host defenses and the challenges of a systemic 
infection, epidemiological and genomics-based studies have failed to identify a 
single set of bacterial genes that consistently correlates with the survival or 
lethality of ExPEC strains within the bloodstream of the human host [3, 23-28]. 
Despite a large volume of research on sepsis (at the time of writing there 
are greater than 150,000 results on PubMed for a search of “sepsis OR 
septicemia”), no novel drugs have been approved for the treatment of sepsis. 
This has been attributed partially to difficulties in moving findings from basic 
research into clinical trials and has brought up questions regarding the validity of 
many commonly used sepsis models [29, 30]. The most basic of sepsis models 
is simply the in vitro addition of bacteria or microbial products (i.e. LPS) to whole 
blood, endothelial cell lines, or innate immune cell lines [31-33]. Nevertheless, 
the predominant model system for the experimental study of sepsis is the mouse, 
where sepsis is initiated through the administration of LPS, viable pathogens, or 
cecal ligation and puncture (CLP) where the cecum is surgically punctured, 
releasing fecal material into the peritoneal cavity. Models involving LPS challenge 
of young mice in particular have come under fire in recent years, as it is 
becoming increasingly clear that the complex pathophysiological mechanisms of 
sepsis are not being modeled under these conditions [30, 34]. CLP has 
historically been the gold standard for the study of sepsis, but it is labor intensive 
and also reliant on the enteric microbiota of the mouse, which can vary between 
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animal facilities and differing environmental factors. In Chapter 2, I introduce 
zebrafish embryos as a novel, high throughput model system for the study of 
sepsis that recapitulates many key physiological hallmarks of disease. 
Furthermore, in Chapter 2 I demonstrate that genetically distinct E. coli strains 
are capable of causing markedly diverse host responses during sepsis, offering a 
partial explanation for the heterogeneity seen during sepsis. In Chapter 3 I 
explore the contributions of bacterial diversity to host response further and go on 
to demonstrate that for two ExPEC strains, these differences are attributable to 
variable levels of flagellin expression and differences in the ability of discrete 
flagellin variants to stimulate the host receptor TLR5.   
  
Zebrafish as a Model for Host-Microbe Interactions 
 Early zebrafish research focused on embryonic development. However 
given its compelling advantages, it is now emerging as a valuable model for the 
study of host-microbe interactions, inflammation, and the immune system. 
Zebrafish are hardy, easy to maintain, and feature external development, optical 
transparency during early life, forward and reverse genetics, and vertebrate 
physiology. Additionally, they possess high fecundity where a single pair of fish 
can produce hundreds of offspring per week for almost no cost, allowing for large 
sample sizes. 
 The immune system of zebrafish is exceptionally well conserved 
compared to that of mammals. Analogous myeloid-derived immune cells 
including monotcytes, macrophages (of both M1 and M2 subtypes), neutrophils, 
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eosinophils, mast cells, and cytotoxic cells similar to NK cells have all been 
characterized in the zebrafish [35-39]. Hematopoiesis occurs in the developing 
zebrafish at 22 hpf. By 48 hpf embryos have fully competent macrophages and 
neutrophils that can respond to bacterial pathogens [40-42]. Embryos hatch from 
their chorion at roughly 3 dpf and become colonized by a microbiota at this point 
[43]. Rag-dependent rearrangements in B and T cell progenitors also occurs in 
this window, though functional adaptive immunity is not achieved until larvae are 
approximately 4 weeks old [44, 45]. Sensing the presence of microbes is 
paramount for being able to initiate an effective immune response, so mammals 
and zebrafish contain multiple families of pattern recognition receptors such as 
Toll-like receptors, NOD-like receptors, RIG-I-like receptors, and peptidoglycan 
recognition proteins [46-51]. Following the triggering of an innate immune 
response in zebrafish, well conserved transcriptions factors including NFkB, AP-
1, IRF, and STAT are induced. There is also conservation of most cytokines and 
chemokines that function as important messengers of the immune system [50, 
52]. 
 The zebrafish is an attractive model for the study of a wide range of 
bacterial, fungal, and viral diseases [reviewed in 39, 53]. The advantages of the 
model are maximal during the early stages of development (days 1-7) so most of 
the research has focused on these stages, but adult zebrafish are also used to 
study host-microbe interactions. Work in zebrafish examining the pathogenesis of 
Mycobacterium marinum, a fish pathogen related to Mycobacterium tuberculosis, 
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revealed that macrophages play a dual role during infection. While they are 
required to curtail bacterial growth during early infection and wall off bacteria in a 
granuloma, they also serve to benefit the bacteria through facilitating their 
expansion and dissemination [54, 55]. A zebrafish embryo model of E. coli 
infection has also proved valuable in resolving diverse virulence phenotypes and 
niche-specific restrictions among closely related strains, including the strain’s 
varying reliance on secreted toxins such as HlyA and CNF1 [42]. The zebrafish 
has also been used in combination with bacterial forward genetic screens to 
successfully identify novel virulence determinants in E. coli, M. marinum, and 
Streptococcus pyogenes [56-58]. Finally, a screen performed in the zebrafish to 
identify mutations that mediate sensitivity or resistance to Mycobacterium 
infection also proved the utility of using zebrafish to identify novel host 
determinants that impact infection [59].  
It is only during recent years that the substantial contributions made by 
resident microflora have been realized. Given the relative ease in generating and 
maintaining gnotobiotic (germ free) zebrafish [60], it is now being used as a 
model to study the assembly and behavior of intestinal microbial communities 
and how these communities shift in response to genetic, environmental, and 
dietary perturbations [61-63]. Zebrafish are also an appealing model for 
screening chemical libraries that for the ability to modulate both microbe and host 
biological processes. Compounds can easily be taken up through the skin of 
developing embryos and drug efficacy can be assayed simultaneously with 
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general toxicity [64]. Additionally, when screening for antimicrobials, using an in 
vivo model system avoids complications that arise from the fact that in vitro 
microbial culture conditions are usually very different than the environment 
microbes encounter in vivo during infection. 
 The transparency of zebrafish embryos and larvae allows for the 
interactions between microbe and host to be monitored in vivo in real time and 
with enough clarity to identify morphological changes in leukocytes [65-68]. 
Taking advantage of transgenic lines where phagocytes are fluorescently 
labeled, reagents that allow for the fluorescent visualization of phagocyte 
respiratory burst, and fluorescently tagged Candida albicans, a zebrafish model 
was able to show for the first time in vivo that NADPH oxidase is required for C. 
albicans filamentation [66, 69]. Given its transparency, the zebrafish is also an 
attractive model for immune cell migration and chemotaxis as well as resolution 
of inflammation and wound healing [70-72].  
 Currently the use of zebrafish as a model for the study of host-microbe 
interactions and immunology is limited by paucity of available reagents, such as 
genomic disruption in immune genes, antibodies that recognize zebrafish 
epitopes, and other molecular tools. In Chapter 3, I will discuss the generation of 
several novel zebrafish lines to study the contributions of IL-1β and IL-10 to 
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LETHAL STRAINS OF ESCHERICHIA COLI TRIGGER  
MARKEDLY DIVERSE HOST RESPONSES  






Sepsis is a life-threatening systemic inflammatory condition caused by the 
presence of microorganisms in the bloodstream. In septic individuals, the 
infecting microbes are commonly viewed as generic inducers of inflammation 
while the host background is considered the primary variable affecting disease 
progression and outcome. To study the effects of bacterial strain differences on 
the maladaptive immune responses that are induced during sepsis, I employed a 
zebrafish embryo infection model using extraintestinal pathogenic E. coli 
(ExPEC) isolates. These genetically diverse pathogens are a leading cause of 
sepsis and are becoming increasingly problematic due to the rise of multidrug 
resistance strains. Zebrafish infected with ExPEC isolates exhibit many of the 
pathophysiological features seen in septic human patients, including 
dysregulated inflammatory responses (cytokine storms), tachycardia, endothelial 
leakage, and progressive edema. Mirroring the situation with human patients, 
antibiotic therapy reduced ExPEC titers and improved host survival rates, but 
was only effective within limited time frames, and surviving animals often 
developed lasting edema and other defects. However, only a limited subset of 
ExPEC isolates can trigger a sepsis-like state and death of the host when 
introduced into the bloodstream. Intriguingly, I find that phylogenetically distant, 
but similarly lethal, ExPEC isolates can stimulate markedly different host 
responses, including disparate levels of inflammatory mediators. Altogether, this 
work establishes zebrafish as a relevant model for key aspects of human sepsis 
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and highlights the ability of genetically distinct ExPEC isolates to induce 
divergent host responses independent of baseline host attributes. 
 
Introduction 
Escherichia coli is an incredibly diverse species, both genetically and in 
terms of its ability to colonize numerous niches in the environment and within 
animal hosts. The relationship between E. coli and its animal hosts can be 
mutualistic, as is thought to be the case for most E. coli strains within the 
intestinal tract of mammals, or pathogenic, causing diarrheal diseases, urinary 
tract infections, meningitis, sepsis, and other maladies. Strains that can instigate 
disease outside of the intestinal tract, termed extraintestinal pathogenic E. coli 
(ExPEC), are very common and have a huge impact on human health and 
mortality [1]. The ability of some ExPEC strains to gain access to and 
disseminate within the bloodstream is especially problematic and oftentimes 
lethal. ExPEC are the principal cause of bacteremia and a leading cause of 
sepsis, second only to Group B Streptococcus in neonates and Staphylococcus 
aureus in adults [2-5]. Over the past few decades there has been a concerning 
increase in the rates of E. coli-induced sepsis in both adults and neonates, but 
the pathogenesis of these infections remains for the most part undetermined.   
During sepsis, the generation of excessive inflammatory mediators, 
including cytokines and reactive oxygen species, can result in vascular leakage, 
disseminated intravascular coagulation (DIC), and organ failure. Clinically, septic 
patients may present with highly variable symptoms that can make it difficult to 
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assess disease severity or predict outcomes [6, 7]. Much of the variability in 
disease progression in septic patients has been attributed to differences in the 
genetic background and immune status of individual hosts [8-10], but the nature 
of the infecting microbes can also impact disease outcome. For example, relative 
to Gram-positive pathogens and other Gram-negative bacteria, ExPEC are 
generally more inflammatory and more likely to cause death during sepsis [11, 
12]. Animal models indicate that the survival, growth, and virulence of specific 
ExPEC isolates within the bloodstream can be influenced by myriad bacterial 
genes, including those involved in adhesion, iron utilization, metabolism, 
membrane transport, toxin biosynthesis, and the production and modification of 
lipopolysaccharide and capsules [13-19]. However, in epidemiological and 
genomics-based studies no single set of bacterial genes has been identified that 
consistently correlates with the survival or lethality of ExPEC strains within the 
bloodstream of the human host [10, 20-25]. These findings indicate that, as a 
group, ExPEC strains may utilize a diverse array of functionally redundant genes 
to deal with host defenses and other challenges during systemic infections. 
An ExPEC isolate will typically possess about 5,000 genes, but specific 
gene content between individual ExPEC strains can differ by as much as 30% 
[26]. ExPEC genomes are mosaic assemblies of individual genes, operons, and 
genomic islands acquired from other microbes by horizontal gene transfer. The 
total number of genes that may be shared among all ExPEC isolates and related 
E. coli strains in nature is referred to as the pan-genome and is currently 
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estimated to total more than 16,000 [20, 26, 27]. Most of these genes are at 
present functionally undefined, making it often difficult to correlate bacterial 
virulence properties with gene function. The mosaic nature of ExPEC genomes 
helps explain previous observations showing that the lethality of even closely 
related isolates can vary markedly in animal models [23, 28, 29]. It is likewise 
feasible that phylogenetically dissimilar ExPEC isolates can be equally lethal, but 
have differential effects on host signaling pathways and inflammatory responses.  
Here, I set out to define how different ExPEC isolates impact host 
responses during sepsis. I present a novel model for studying sepsis, showing 
that the inoculation of a limited number of ExPEC strains into the bloodstream of 
zebrafish embryos elicits many of the pathophysiological and transcriptional 
responses seen during human sepsis. Importantly, I find that even similarly lethal 
bacterial isolates can trigger notably divergent host responses, an unappreciated 
phenomenon that could in part account for the variability in physiological features 
observed in human septic patients. 
 
Results 
Few E. coli strains cause death following entry  
into the bloodstream 
To investigate the potential of different ExPEC isolates to induce variable 
host responses during systemic infections, a panel of E. coli strains from various 
sources were injected into the bloodstream of 48-hours postfertilization (hpf) 
zebrafish embryos. At this developmental stage, the zebrafish immune system 
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consists solely of innate defenses, including macrophages, neutrophils, 
complement, Toll-like receptors (TLRs), antimicrobial peptides, and cytokines 
similar to those encoded by humans [30, 31]. Using an inoculation dose of 
approximately 700-1500 colony forming units (CFU) per embryo, I found that the 
K12 strain MG1655 and the human gut isolate HS caused no death at 24 hours 
postinoculation (hpi), whereas the sequenced ExPEC reference strains F11 and 
CFT073 were both highly lethal within the same time frame (Figure 2.1A). Two 
other, mostly uncharacterized ExPEC isolates (BEC7 and NMEC1) were similarly 
lethal. The remaining ExPEC strains tested were for the most part nonfatal, with 
the exception of the pyelonephritis isolate 536, which killed about 40% of the fish. 
In total, of all the E. coli strains tested, only about 26% killed more than 30% of 
the zebrafish following injection into the bloodstream.  
In zebrafish, the lethality of an E. coli strain generally correlates with its 
ability to survive and multiply within the host [28]. This trend holds true here. I 
found that titers of the nonlethal strains MG1655 and HS were greatly reduced 
within 12 hpi, while numbers of the nonlethal ExPEC isolate UTI89 remained 
relatively stable during the same time frame (Figure 2.1B). In contrast, the lethal 
reference ExPEC strains F11 and CFT073 not only persisted within the zebrafish 
host, but also multiplied on average more than 1,000-fold by 12 hpi. Of note, all 
of the E. coli strains used here grew at similar rates in broth culture at 28.5°C, the 
temperature at which the zebrafish embryos are maintained (Figure 2.2A), and 
37°C (Figure 2.2B). Taken together, these results highlight the strain-dependent 
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lethality of E. coli following inoculation into the zebrafish bloodstream, and are in 
line with previous observations indicating that the bloodstream is a highly 
restrictive environment for many bacteria [13, 28, 32]. 
 
Differential pathophysiological effects of similarly lethal 
but phylogenetically distant ExPEC isolates  
F11 and CFT073 are phylogenetically distinct strains as determined by 
multilocus sequence typing (MLST) and, although they both encode the same K2 
capsular and O6 surface antigens, they possess distinct flagellar antigens, 
different genomic islands, and only partially overlapping sets of recognized 
virulence factors [27, 28, 33]. Gene content between F11 and CFT073 are about 
73% identical at the protein coding level. Though these two strains are similarly 
lethal and grow at comparable rates within the zebrafish host, embryos infected 
with F11 appeared qualitatively more debilitated than embryos infected with 
CFT073. Infection with both strains led to overt signs of illness, including 
pericardial edema, ulceration of the skin, and erosion of the tail fin when 
compared to PBS-injected control fish (Figure 2.3A-B). However, these 
phenotypes were markedly more pronounced and common in fish infected with 
F11.  
Infection with F11 also resulted in the development of prominent tissue 
protrusions on the trunk or tail of the embryo (Figure 2.3C). These protrusions 
were found on up to 50% of fish infected with F11, but were not seen with 
CFT073-infected embryos. Infection with F11 carrying a plasmid encoding 
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destabilized green fluorescent protein (F11/pGEN-GFP(LVA)) revealed that the 
protrusions themselves did not contain bacteria, but within the tissues and 
vessels adjacent to the protrusions small bacterial clusters were often detected 
(Figure 2.3D). The protrusions stained strongly with the fluorescent cationic dye 
acridine orange, which accumulates within the nucleus and cytoplasm of 
apoptotic cells, but not necrotic or viable cells (Figure 2.3E) [34]. Additional 
experiments using the fluorescently labeled transgenic zebrafish lines 
Tg(krt8:GFP) [35] and Tg(fli1a:EGFP) [36] showed that the F11-induced 
protrusions were comprised largely of epithelial cells (Figure 2.3F) and devoid of 
leukocytes and endothelial cells (Figure 2.3G). Staining with phalloiden to detect 
F-actin demonstrated that the actin cytoskeleton is significantly perturbed in 
these lesions and contain activated caspase-3 positive cells (Figure 2.4). These 
epithelial protrusions presumably arise in response to an as-yet undefined toxin 
or other factor(s) that is expressed by F11, but missing in CFT073.  
 
Ciprofloxacin administration is only effective for a short  
window of time that varies dependent on the  
infecting strain 
The survival of septic patients is often dependent upon rapid diagnosis 
and the timely delivery of appropriate antibiotics—for every hour that antibiotic 
treatment is delayed there is a 6-7% increased chance of patient death [37]. 
Even with adequate antimicrobial therapies that curtail bacterial growth, 
complications such as edema, immunosuppression, and coagulation defects are 
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frequent [38-40]. To determine how septic zebrafish respond to antibiotic 
treatment, I administered ciprofloxacin at various time points postinoculation with 
CFT073 or F11. Ciprofloxacin was chosen because it is of use clinically for the 
treatment of Gram-negative sepsis, particularly for sepsis arising from the 
gastrointestinal or urinary tract [41, 42]. Additionally, ciprofloxacin is very cell 
permeable, making it easy to administer by placing infected zebrafish embryos in 
water containing the antibiotic. When F11-infected embryos were treated with 50 
μg/ml ciprofloxacin at 6 hpi, the antibiotic was able to rescue all embryos from 
lethal infection with no apparent complications (Figure 2.5A). When given at 12 
hpi, ciprofloxacin was only slightly less effective, but a delay of just another 3 
hours resulted in greatly increased mortality rates.  
 In sharp contrast to results obtained with the F11-infected embryos, the 
complete rescue of all CFT073-infected zebrafish required that I administer 
ciprofloxacin at a much earlier time point (3 hpi, Figure 2.5B). The addition of 
ciprofloxacin to CFT073-infected fish at 9 hpi decreased the survival rate to less 
than 30%, while waiting just another 3 hours was almost entirely ineffective 
(Figure 2.5B). Of note, CFT073 and F11 are similarly susceptible to ciprofloxacin 
as measured by both disc diffusion antibiotic sensitivity assay at 28.5°C and 
37°C (Figure 2.5C and D). Furthermore, within zebrafish embryos the growth of 
both pathogens is effectively inhibited by addition of the antibiotic (Figure 2.5E-
F). Taken together, these results demonstrate that, as with human sepsis 
patients, the early administration of antibiotic therapy is crucial for host survival 
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and that even small delays in treatment can drastically increase mortality rates. 
In addition, these data show that ExPEC isolates that are similarly sensitive to an 
antibiotic can have drastically different effects on disease outcome when 
exposed to the same antibiotic within the host environment. 
 
Infected embryos often develop profound edema  
following rescue with ciprofloxacin 
In our studies with ciprofloxacin given to F11-infected zebrafish at 12 hpi, I 
noticed that the surviving animals often displayed marked pericardial edema at 
24 hpi (Figure 2.6A). By 48 hpi, approximately 50% of the surviving embryos 
developed profound widespread edema (Figure 2.6B and C). These embryos 
were not retained beyond 96 hpi, but it is unlikely that they would have 
successfully survived to adulthood. I also observed similarly severe edema in 
many of the surviving CFT073-infected fish that were dosed with ciprofloxacin at 
6 or 9 hpi. These results indicate that complications like subcutaneous and body-
cavity edema, which are not uncommon in human sepsis patients [38, 39, 43], 
can also develop in zebrafish despite effective inhibition of pathogen growth.  
 
Lethal ExPEC isolates can trigger divergent  
host transcriptional responses 
The differential pathophysiological effects that F11 and CFT073 have on 
the zebrafish host were examined more closely by transcriptional profiling. Using 
a previously described Agilent microarray that is enriched with probes specific for 
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zebrafish homologs of mammalian immunity genes [44-46], the host response to 
each ExPEC strain was surveyed at 6 and 12 hpi. The 6-hour time point 
represents the more acute phase of infection, while the 12-hour time point 
reflects a later stage where the two strains have established a solid foothold and 
replicated to high titers within the zebrafish host (see Figure 2.1B). For these 
experiments, groups of 18-20 embryos were injected with CFT073, F11, or a 
similar volume of sterile PBS as a control. RNA was then isolated from each pool 
of embryos at 6 and 12 hpi and processed for analysis using two-color 44k 
microarrays. Each experiment was repeated in biological quadruplicate. Gating 
on probes that were differentially expressed at least 2-fold up or down when 
compared to PBS-injected fish and with a p-value of ≤ 0.05, I found that infection 
with F11 altered mRNA levels for nearly a third more genes than CFT073 at both 
6 and 12 hpi (Fig 2.7A and B, see also Tables 2.4-2.7). While infection with both 
strains changed the expression of a large number of overlapping host genes, F11 
infection also induced an almost equal sized cohort of additional host genes that 
was not seen in CFT073-infected fish. 
The biological attributes of the host genes that are differentially expressed 
in response to F11 and CFT073 at 6 and 12 hpi were assessed by gene ontology 
(GO) and KEGG pathway enrichment analysis using DAVID bioinformatics 
resources [47]. GO categories that were enriched at both time points with both 
ExPEC isolates included those dealing with host response to oxidative stress 
(e.g., peroxidases), immune and defense responses (e.g., cytokine expression 
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and complement components), proteolysis (e.g., caspases and matrix 
metalloproteinases), and aminoglycan metabolism (e.g., peptidoglycan 
recognition protein 5) (Figure 2.7C). In contrast, the numbers of genes within the 
GO category for regulators of transcription were significantly elevated only at 6 
hpi, whereas GO categories linked with oxidation reduction (redox) reactions and 
blood coagulation were not enriched until 12 hpi. The latter group includes 
upregulated genes that encode coagulation factor IIIb (f3b) and the α, β, and γ 
chains of fibrinogen. These gene products are functionally well conserved among 
vertebrates as mediators of thrombosis and have been implicated in DIC during 
sepsis [40, 48-50].   
In many cases, the numbers of differentially expressed genes within each 
enriched GO category were greater for the F11-infected fish (Figure 2.7C). This 
trend was also observed by KEGG pathway analysis (Figure 2.8). Common 
pathways affected by F11 and CFT073 at both 6 and 12 hpi include those 
involved in apoptosis, proteasome activities, arachidonic acid metabolism, and 
TLR, MAP kinase, and cytokine signaling. Pathways associated with primary bile 
acid metabolism were also significantly altered by both pathogens, though 
CFT073 was slower to induce the changes. Other host metabolic pathways, 
including those connected with the metabolism of select sugars and amino acids, 
were differentially affected by F11 and CFT073 only at 12 hpi. At this time point 
F11 also caused significant transcriptional changes in several genes that encode 
proteins within the p53 pathway, which has a central role as a regulator of host 
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cell cycle arrest and apoptosis in response to stress [51]. Altered levels of factors 
like Cyclin B1, GADD45 homologues, and Sestrin-2 within the p53 pathway may 
enable host cells to better sense and deal with oxygen radicals and other 
genotoxic stresses generated during the infection process [52-55], but could also 
conceivably help promote the formation of the apoptotic epithelial protrusions 
seen in many F11-infected embryos. 
 
Zebrafish embryos infected with lethal ExPEC isolates 
have transcriptional responses and pathologies like 
those seen in human sepsis  
In humans with sepsis or related syndromes like endotoxemia, there is 
often a large amount of variation in the gene expression datasets obtained from 
different studies [56]. However, general trends in these datasets are discernable 
and are reiterated, in large part, in our zebrafish infection model (Table 2.1). 
These include the upregulation of Pattern Recognition Receptors like TLR5 as 
well as components of the NFκB, MAP kinase, and Jak-STAT signaling 
pathways. Activation of these pathways can stimulate the expression of multiple 
cytokines, chemokines, and other immunomodulatory factors. The high level 
expression of numerous cytokines and other inflammatory mediators induced in 
zebrafish by both F11 and CFT073 is reminiscent of the cytokine storms seen in 
human patients during sepsis. Major inflammatory cytokines that are substantially 
elevated both in our assays and in human patients with sepsis-like syndromes 
include TNFα, TNFβ, IL-1β, IL-6, IL-8, IL-12, and IL-17 [48, 57-62]. During human 
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sepsis, as in many inflammatory diseases, there is imbalance among pro- and 
anti-inflammatory mediators [62]. We observe a similar situation in our zebrafish 
model, as evidenced by the simultaneous upregulation of multiple pro-
inflammatory signals along with several key anti-inflammatory factors, including 
IL-10, SOCS1 and 3, IRAK3, and galectin-1 (Table 2.1).  
 Clinically, sepsis is diagnosed when there is a documented source of 
infection as well as at least two of the following signs: fever (temperature above 
38°C) or hypothermia (temperature below 35.5°C), tachypnea (more than 20 
breaths per minute), hypocapnia (PaCO2 of less than 32 torr), tachycardia (more 
than 90 beats per minute), and leukocytosis (more than 12,000/mm3) or 
leukopenia (less than 4,000/mm3) [37]. Additional pathologies commonly seen 
during sepsis include endothelial dysfunction and consequent loss of barrier 
function leading to progressive subcutaneous edema and clotting abnormalities, 
including DIC. Considering these criteria, I set out to determine if zebrafish 
embryos infected with ExPEC display any overt signs of sepsis like those seen 
clinically in human patients.   
 Given that changes in body temperature are less applicable in ectothermic 
organisms such as zebrafish, I did not evaluate fever or hypothermia in ExPEC-
infected embryos. ExPEC-induced leukopenia in zebrafish is suggested by 
previous work from our group in which we note that F11- or CFT073-infected 
zebrafish have notably diminished numbers of phagocytes by 12 hpi, relative to 
MG1655-infected controls [28]. As a measurement of vascular leakage, I injected 
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fluorescent dextran (70 kDa) into the bloodstream of embryos and quantified its 
movement from the vasculature into host tissues (myotomes) after 15 min (Figure 
2.9A). In comparison with control embryos that were injected with nonpathogenic 
MG1655 or PBS, embryos that were infected with F11 had significantly higher 
amounts of vascular leakage by 9 hpi (Figure 2.9B). Disruption of endothelial 
barriers may be driven in part by heightened cytokine levels and the abundant 
expression of MMP9 and other metalloproteinases in response to ExPEC. These 
events may also contribute to the edema that becomes manifest within the 
pericardial cavity and at other sites within ExPEC-infected embryos at later time 
points (see Figures 2.2A, 2.6A, and 2.6C). Heart rate measurements showed that 
ExPEC can also induce tachycardia during systemic infections at 6 hpi (Figure 
2.9C), though heart rates eventually decline as the embryos succumb to the 
infection. Interestingly, our microarray analysis indicates that at 12 hpi both 
CFT073 and F11 induce expression of UCP2, a mitochondrial uncoupling protein 
that is linked with stress hyperglycemia and heart failure in human sepsis 
patients [63, 64]. In total, these observations demonstrate that ExPEC-infected 
zebrafish have altered gene expression patterns and develop overt pathologies 
on par with those that are often observed in humans with sepsis.  
 
F11 and CFT073 have differential effects on host TLR 
signaling and associated inflammatory responses 
 Our KEGG analysis indicated that F11 and CFT073 have especially 
sizeable effects on TLR signaling pathways. A map that illustrates how F11 and 
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CFT073 influence the transcription of specific TLR genes, associated signaling 
factors, and various downstream targets is presented in Figure 2.10. Both 
pathogens alter the expression of several key components within canonical 
MyD88-dependent and MyD88-independent TLR signaling cascades, as well as 
intersecting and overlapping MAP kinase, Jak-STAT, Interferon (IFN), and Tumor 
Necrosis Factor (TNF) signaling pathways. Although F11 and CFT073 have 
similar effects on expression of many of the inflammatory mediators depicted in 
Figure 2.10, our array data indicate that the pathogens can also elicit 
conspicuously divergent inflammatory responses. Examples of this phenomenon 
are seen with two conserved cytokines—the macrophage-activating cytokine 
IFN-γ2 (ifng1-2), which is induced by F11 but repressed by CFT073, and the anti-
inflammatory factor IL-10, which is markedly upregulated by CFT073 but less so 
by F11. 
qRT-PCR was used to validate a subset of our microarray results and to 
explore the host transcriptional responses to additional E. coli strains (Figures 
2.11 and 2.12). In agreement with our microarray data, qRT-PCR indicated that 
CFT073 induced significantly higher levels of IL-10 than did F11 at both 6 and 12 
hpi (Figure 2.11A). Following a spike at 6 hpi, IL-10 transcript levels in CFT073-
infected fish were reduced by 12 hpi to levels seen in embryos injected with 
either the gut isolate HS or the nonlethal ExPEC strain UTI89. Interestingly, the 
IL-10 mRNA levels induced by HS and UTI89 at 12 hpi were still significantly 
greater than those observed in F11-infected fish and in control animals that were 
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inoculated with either PBS or the K12 strain MG1655. The situation was quite 
different when transcript levels for the pro-inflammatory cytokines Il-1β and IL-8 
were quantified.  Relative to the nonlethal strains, CFT073 and F11 enhanced the 
expression of IL-1β and IL-8 similarly at 6 hpi, but by 12 hpi the transcript levels 
for these cytokines in F11-infected embryos were markedly higher than those in 
fish infected with CFT073 (Figure 2.11B-C). Similar trends with somewhat less 
pronounced differences between F11- and CFT073-infected fish were observed 
with the pro-inflammatory cytokines TNFα, Interferon-1 (IFN-1), and IL-6 (Figure 
2.11D-E, and Figure 2.13E). In contrast, F11 and CFT073 had comparable 
effects on the expression of another pro-inflammatory cytokine, IL-17c, which 
was strikingly elevated at both 6 and 12 hpi only in response to the two lethal 
pathogens (Figure 2.11F).  
The differing effects of F11 and CFT073 on cytokines like IL-1β and IL-8 
were in part recapitulated when I used qRT-PCR to survey expression levels of 
three other host defense genes—saa1, hamp1, and mmp9. Transcription of the 
gene encoding serum amyloid A1 (SAA1), which is an acute phase protein with 
antimicrobial activity [65-68], was significantly induced by all tested E. coli 
strains, relative to PBS-injected controls (Figure 2.12A). However, F11 caused a 
more rapid and higher level of induction than any of the other strains, including 
CFT073. Transcript levels for hepcidin (HAMP1), which is an antibacterial peptide 
that also functions as a key regulator of iron homeostasis [69], were significantly 
elevated at 6 hpi in response to all strains except MG1655 (Figure 2.12B). By 12 
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hpi, hamp1 expression was notably higher in the F11-infected embryos than in all 
other samples, including the CFT073-infected fish. A comparable expression 
pattern was seen with the matrix metalloproteinase MMP9, a secreted protease 
that facilitates the migration of leukocytes to sites of infection (Figure 2.12C) [70]. 
Of note, serum levels of SAA1, hepcidin, and MMP9 are elevated during human 
sepsis and have been investigated as prognostic biomarkers [71-73]. 
Overall, these qRT-PCR results are in close agreement with our 
microarray data, demonstrating that similarly lethal ExPEC isolates like F11 and 
CFT073 can elicit distinctive, though overlapping, inflammatory responses during 
systemic infections. This phenomenon was mirrored in a mouse model of sepsis 
in which I focused on IL-6 expression. IL-6 is a marker of sepsis severity, with 
elevated levels of this cytokine during early sepsis correlating with increased 
mortality rates in both humans and mice [74-76]. Following subcutaneous 
inoculation of adult outbred Swiss Webster mice with 108 CFU of either CFT073 
or F11, both pathogens disseminate systemically and kill 90-100% of the host 
animals within 24 hours. At 6 and 12 hpi, I detected no significant differences in 
the titers of the two ExPEC isolates within the kidneys, liver, or spleen (Figure 
2.13A-C). Relative to PBS-injected controls, both pathogens induce production of 
IL-6, but by 12 hpi the levels of IL-6 in the sera of F11-infected mice were 
significantly higher than those in CFT073-infected animals (Figure 2.13D). This 
pattern of IL-6 expression was also seen, though with less statistical significance, 
in F11- and CFT073-infected zebrafish embryos (Figure 2.13E), paralleling our 
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findings with other pro-inflammatory cytokines. 
 
Discussion 
Septic patients often present with wide-ranging disease symptoms, and 
are notoriously difficult to manage because they do not respond homogenously to 
treatment [56]. In septic individuals, the infecting microbes are commonly viewed 
as generic inducers of inflammation while the host background is considered the 
primary variable affecting disease progression and outcome. Here, using a model 
system in which bacteria are injected into the bloodstream of zebrafish embryos, 
I found that only a limited subset of ExPEC isolates is able to cause overt sepsis-
like disease. Most strikingly, this work demonstrates that similarly lethal bacterial 
isolates belonging to the same species can affect the development of sepsis in 
markedly different ways irrespective of host background characteristics. 
Our results support previous observations indicating that the bloodstream 
is a restrictive niche for most E. coli strains [13, 28]. The survival and growth of 
ExPEC during systemic infections are likely limited by nutrient and iron 
availability and the presence of various antimicrobial factors such as circulating 
phagocytes, complement, and antimicrobial peptides. Recent functional genetic 
screens from our group and others show that numerous bacterial genes can 
promote the fitness of ExPEC strains within the bloodstream [13-15, 32]. 
However, many of the genetic loci implicated in ExPEC survival during systemic 
infections remain functionally indeterminate. Rather than always relying on 
specific sets of homologous genes, it appears that ExPEC strains, as a group, 
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may instead employ multiple nonorthologous, but functionally redundant, factors 
to deal with the myriad challenges encountered within the bloodstream. The 
capacity of ExPEC isolates to evolve and utilize distinct solutions to challenges 
presented by the host likely contributes to the ability of ExPEC strains to 
differentially affect host responses during sepsis.  
In our assays, F11 altered the transcription of nearly a third more host 
genes than CFT073 at 6 and 12 hpi, while simultaneously inducing higher-level 
expression of many pro-inflammatory cytokines and other immunomodulatory 
factors. This trend was also observed with serum IL-6 levels in a mouse sepsis 
model. In comparison with CFT073-infected zebrafish, those infected with F11 
often appeared qualitatively more ill and frequently developed apoptotic 
epidermal protrusions. These may be manifestations of the cutaneous lesions 
seen in some human patients with bacteremia or sepsis [77], but the factors that 
promote their formation are not yet defined. Overall, CFT073 was less 
inflammatory than F11 and is arguably a stealthier pathogen, stimulating the 
expression of more anti-inflammatory factors like IL-10 and producing fewer overt 
signs of illness during the initial stages of infection. From these results, I posit 
that the ability of different ExPEC isolates to elicit dissimilar host inflammatory 
responses in human patients contributes to the heterogeneity of symptoms 
experienced by septic individuals.  
Though F11 and CFT073 encode many of the same fitness and virulence 
determinants, including the same capsular K2 and LPS O6 surface antigens, they 
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each have a distinct repertoire of known virulence genes. For example, each 
pathogen expresses the repeat-in-toxin (RTX) family member α-hemolysin 
(HlyA), but only CFT073 encodes the RTX protein TosA (a.k.a. UpxA). In 
zebrafish, HlyA acts to disable phagocytes while TosA functions as an adhesin 
that can promote bacterial survival during systemic infections [16, 28]. Both F11 
and CFT073 also carry homologues of the serine protease autotransporter toxins 
Tsh and Vat, but only CFT073 expresses a related toxin known as Sat. Of note, 
in a recent large-scale sequencing study of 312 ExPEC strains, sat and tosA 
genes were enriched among isolates from bacteremic patients [20]. Yet results 
presented here with F11 show that these genes are not strictly required for 
ExPEC survival and growth within the bloodstream. The fitness of F11 during 
systemic infections is, however, increased by another secreted protein known as 
cytotoxic necrotizing factor (CNF1). This toxin, which is absent in CFT073, 
causes the constitutive activation and eventual degradation of host Rho GTPases 
[78]. The deletion of cnf1 significantly diminishes the growth and virulence of F11 
within the zebrafish host (Figure 2.14). Altered expression of IL-1β (Figure 2.15A) 
and MMP9 (Figure 2.15C) were seen in the cnf1 mutant compared to F11 at 12 
hpi, but these data are somewhat difficult to interpret given the significant 
difference in bacterial titers at this time point (Figure 2.14B). Furthermore, the 
mutant bacteria can still trigger the formation of epidermal protrusions.  
A number of ExPEC-associated proteins that can be described as 
immunomodulators may also account for the differential effects of F11 and 
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CFT073 on the transcription of host pro- and anti-inflammatory mediators. Both 
CFT073 and F11 have genes for the TIR domain-containing protein TcpC, which 
can antagonize host TLR signaling [79]. A major TLR affected in our zebrafish 
model, as well as in some human patients with sepsis-like syndromes, is the 
flagellin receptor TLR5 [59, 61]. CFT073 and F11 produce distinct flagellar 
antigens (H1 and H31, respectively), which could potentially impact how these 
two pathogens engage TLR5 and influence downstream signaling cascades. 
CFT073, but not F11, may further affect host inflammatory pathways via 
expression of the inflammation repressors SisA/B and the neutrophil migration 
suppressor YbcL [80, 81].  
The diversity of host responses elicited by F11, CFT073, and other ExPEC 
isolates in our zebrafish model reflects many of those seen in human patients 
with bacteremia or sepsis. Overt pathophysiological changes observed within the 
infected zebrafish and in human septic patients include tachycardia, vascular 
leakage, edema, and signs of leukopenia. In addition, though we did not assess 
clotting abnormalities directly, our microarray results show that the ExPEC strains 
do have significant effects on host coagulation factors at 12 hpi, suggesting that 
the pathogens may cause disregulation of clotting cascades that could lead to 
problems like DIC.  
Since 2000, hospitalization rates for sepsis have doubled and associated 
costs have skyrocketed in the USA to greater than $20 billion annually [82]. In the 
clinic, the effective treatment of sepsis typically requires early diagnosis and the 
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timely delivery of fluids to maintain blood pressure plus broad-spectrum 
antibiotics to control the infecting bacteria [37, 83]. Results presented here 
reiterate the importance of timely antibiotic delivery for survival of the septic host 
(see Figure 2.9). Furthermore, our data show that the window during which 
antibiotic therapy can effectively rescue the host can vary greatly, even when 
comparing ExPEC strains that are equally sensitive to the drug in vitro. Adding to 
the complexity of factors that can confound the assessment and treatment of 
septic patients is the ongoing rise of Multidrug Resistant (MDR) pathogens, 
including MDR ExPEC strains [84, 85].  
Zebrafish embryos are amenable to high-throughput pharmacological and 
genetic screens, and work from our group has already demonstrated the utility of 
zebrafish as a tool for identifying and functionally defining ExPEC-associated 
factors that are of importance in mammalian hosts [13, 14, 16, 28, 86]. 
Considering the tractability of the zebrafish infection model and its ability to 
recapitulate important aspects of human disease, as shown here, I expect that it 
will provide a useful platform for the examination of cellular processes during 
sepsis and the much needed discovery of improved therapies for sepsis and 
associated sequelae.  
 
Materials and Methods 
Ethics statement 
Animals used in this study were handled in accordance with University of 
Utah and IACUC-approved protocols following standard guidelines described at 
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The bacterial strains used in this study are listed in Table 2.2. Bacteria 
used for infecting zebrafish and mice were grown statically at 37°C for 24 h in 12 
ml modified M9 minimal medium (6 g/l Na2HPO4, 3 g/l KH2PO4, 1 g/l NH4Cl, 0.5 
g/l NaCL, 1 mM MgSO4, 0.1 mM CaCl2, 0.1% glucose, 0.0025% nicotinic acid, 
0.2% casein amino acids, and 16.5 μl thiamine in H2O, pH 7.2). F11 carrying 
pGEN-GFP(LVA) was grown in medium containing ampicillin (50 µg/ml). 
Targeted deletion of cnf1 in F11 was generated using lambda Red-based 
recombination and the primers noted in Table 2.3, as described previously [87]. 
 
Zebrafish embryos 
Wild type AB zebrafish and the transgenic lines Tg(krt8:GFP) and 
Tg(fli1a:EGFP) were maintained as breeding colonies on a 14-h/10-h light/dark 
cycle. The Tg(krt8:GFP) fish express GFP in the outermost layer of epithelial 
cells while the Tg(flia1:EGFP) fish have EGFP-labeled endothelial cells and 
leukocytes [35, 36]. Embryos were collected as mixed egg clutches and raised at 
28.5°C in E3 medium (5 mM NaCl, 0.27 mM KCl, 0.4 mM CaCl2, 0.16 mM 





Infection of zebrafish embryos 
48 hpf embryos were manually dechorianated, briefly anesthetized with 
0.77 mM ethyl 3-aminobenzoate methanesulfonate salt (tricaine) (Sigma-Aldrich), 
and embedded in 0.8% low melt agarose (MO BIO Laboratories) without tricaine. 
After the agarose solidified, embryos were immersed in E3 media lacking 
methylene blue. Prior to injection, 1 ml of bacterial culture was pelleted, washed 
with 1 ml sterile PBS, and resuspended in PBS to obtain ~1X109 CFU/ml PBS. 
One nl of this bacterial suspension was microinjected into the bloodstream via 
the circulation valley using an Olympus SZ61 or SZX10 stereomicroscope 
together with a YOU-1 micromanipulator (Narishige), a Narishige IM-200 
microinjector, and a JUN-AIR model 3-compressor. For each experiment, the 
average CFU per injection was determined by adding 10 1-nl drops to 1 ml of 
0.7% NaCl, which was then serial diluted and plated on Luria-Bertani (LB) agar 
plates. Mock-infected controls were inoculated with 1 nl sterile PBS.  Following 
injection, embryos were removed from agar and placed individually into wells of a 
48-well plate (Nunc) containing E3 medium and incubated at 28.5°C. For lethality 
assays, death was defined by absence of heart contraction and blood flow.  
 
Enumeration of bacterial numbers in zebrafish embryos 
Embryos were homogenized at the indicated time points in 500 μl of PBS 
containing 0.5% Triton X-100 using a mechanical PRO 250 homogenizer (PRO 
Scientific). Homogenates were serially diluted and plated on LB agar plates, 
which were then incubated overnight at 37°C. 
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Growth curves 
Bacteria were grown from frozen stocks at 37°C with shaking overnight in 
5 ml of LB broth or modified M9 minimal medium (6 g/liter Na2HPO4, 3 g/liter 
KH2PO4, 1 g/liter NH4Cl, 0.5 g/liter NaCl, 1 mM MgSO4, 0.1 mM CaCl2, 0.1% 
glucose, 0.0025% nicotinic acid, 16.5 μg/ml thiamine, and 0.2% casein amino 
acids). Cultures were then diluted 1:100 into the indicated medium, and the 
growth of quadruplicate 200-μl samples in shaking 100-well honeycomb plates at 
37°C was assessed using a Bioscreen C instrument (Growth Curves USA).  
 
Mouse sepsis model 
Outbred female Swiss Webster mice (Charles River) that were 5-6 weeks 
old were briefly anesthetized using isofluorane inhalation and injected 
subcutaneously with 108 CFU of bacteria in 200 μl warm, sterile PBS. After 6 or 
12 h, mice were euthanized and the kidneys, livers, and spleens were collected 
and weighed. Excised tissues were homogenized in PBS containing 0.5% Triton 
X-100 using a Bullet Blender Storm 24 (Next Advance) in tubes containing 3.2 
mm stainless steel beads. These beads disrupt host tissues, but do not affect 
bacterial viability. Homogenates were serially diluted and plated on LB agar 
plates for determination of bacterial titers. 
 
Quantification of mouse serum IL-6 levels 
Blood was obtained from mice by cardiac puncture at the time of 
euthanasia. IL-6 concentrations in sera collected from the blood samples were 
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determined by sandwich ELISA using clone MP5-20F3 as a capture antibody and 
clone MP5-2C11 as a detection antibody. Recombinant IL-6 was used as a 
standard. Antibodies for these assays were purchased from BD Pharmingen. 
 
RNA isolation from zebrafish embryos 
Pools of 15-20 embryos were manually homogenized in 1 ml QIAzol Lysis 
Reagent (Qiagen) and total RNA extracted using the Qiagen RNeasy Plus 
Universal Kit according to the manufacturer’s instructions. Genomic DNA was 
removed by the gDNA Eliminator Solution (Qiagen). Samples used for microarray 
and qRT-PCR had a minimum RNA integrity number score of 9.  
 
Microarray design, labeling, and hybridization 
Microarray analysis was performed with biological quadruplicate samples 
using custom-designed 44k Agilent chips [44-46]. Fluorescently labeled cRNA 
was synthesized using the Two-Color Low RNA Input Linear Amplification Kit 
(Agilent). Fluorescently labeled cRNA (825 ng) was then fragmented, combined 
with Hi-RPM Hybridization Buffer (Agilent), and hybridized using a SureHyb 
Hybridization chamber (Agilent). Slides were scanned in a G2505C Microarray 
Scanner (Agilent). Labeling, hybridizing, and scanning were performed by the 
Microarray and Genomic Analysis Core at the University of Utah.  
 
Microarray data analysis 
TIFF files of the scanned microarrays were processed using Feature 
Extraction Software version 10.5 (Agilent). Array data was then log2 transformed, 
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Lowess-normalized, and median-centered.  Fold changes were calculated by 
comparing infected samples to mock-infected (PBS-injected) controls from the 
same clutch of embryos. Significance cutoffs were defined as an average of ≥ 2.0 
fold change across all 4 arrays and p ≤ 0.05. In order to restrict the false 
discovery rate, all p-values were adjusted using the Benjamini and Hochberg 
method [88]. GO and KEGG analyses were performed using Database for 
Annotation, Visualization, and Integrated Discovery (DAVID) 
(http://david.abcc.ncifcrf.gov/) as described [47].  
 
cDNA synthesis and qRT-PCR 
cDNA was synthesized from 2 μg of RNA using the SuperScript III First-
Strand Synthesis System (Invitrogen) in a 20 μl reaction volume. Following 
assembly of the master mix according to manufacturer instructions, samples 
were incubated at 25°C for 5 min, 55°C for 45 min, and 70°C for 15 min. 
Complimentary RNA was then removed by addition of RNase H (Invitrogen) for 
15 min at 37°C. 
 qRT-PCR was performed on a LightCyler 480 instrument (Roche) 
following manufacturer recommendations. Cycling parameters were 95°C for 8 
min to activate the polymerase followed by 40 cycles of 95°C for 4 sec, 60°C for 
6 sec, and 72°C for 6 sec. Fluorescence measurements were taken at the end of 
each cycle. Melt curve analysis was performed to ensure that no primer dimers 
were amplified. All reactions were performed in technical duplicate. Sequences 
for the forward and reverse primers are listed in Table 2.3. Results were 
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normalized to transcript levels of the housekeeping gene ef1α (elongation factor 
1-alpha) using ΔΔCt analysis.  
 
Zebrafish staining 
To assess host cell viability, 12 hpi wild type zebrafish embryos were 
incubated for 30 min at 28.5°C in E3 medium with 10 µg/ml acridine orange. 
Samples were then washed several times with E3 medium and embedded in low 
melt agar for imaging. To further investigate the cell biology of the tissue 
protrusions, embryos were fixed in 4% paraformaldehyde with 0.2% Triton X-100, 
blocked in PBS containing 10% heat inactivated goat serum and 0.5% Triton X-
100, and stained with active caspase-3 (Abcam) and Alexa Fluor 594-phalloidin 
(Abcam) overnight with three washes in 0.5% Triton X-100 in PBS between each 




Embryos were imaged using a fluorescent Olympus SZX10 
stereomicroscope equipped with an Olympus DP72 camera or on a Nikon 
Eclipse TE300 inverted microscope fitted with spinning disc confocal system 
(Andor Technologies) and images captured using a Micromax charge-coupled 





Heart rate measurements in zebrafish embryos 
Infected and PBS-injected control zebrafish embryos were briefly 
anesthetized with 0.77 tricaine (Sigma-Aldrich), embedded in low melt agarose 
(MO BIO Laboratories) without tricaine, and immersed in E3 media lacking 
methylene blue. After 1 h, embryos were filmed for ~1 min using an Olympus 
SZX10 stereomicroscope and an Olympus DP72 camera recording at 15 
frames/sec. Heart rates (beats/min) were calculated from review of the footage.  
 
Quantifying endothelial leakage in zebrafish embryos 
Embryos were injected intravenously with 1 nl of tetramethylrhodamine-
conjugated, lysine-fixable 70 kDa dextran (25 µg/ml; Life Technologies). After 15 
min, embryos were fixed overnight at 4°C in PBS containing 4% 
paraformaldehyde. Samples were then washed 3X with PBS and taken through a 
series of washes with 30%, 50%, and 80% glycerol before mounting on slides 
using FluorSave Reagent (Calbiochem). Embryos were imaged using a 
fluorescent Olympus SZX10 stereomicroscope and an Olympus DP72 camera, 
ensuring equal exposure times for each sample. Using ImageJ [89], the mean 
fluorescent intensity for 3 specific myotomes, as well the lumen of the caudal 
artery, was measured (see Figure 9A). Endothelial leakage was defined as the 
ratio of the mean fluorescent intensity in a myotome to the mean fluorescent 
intensity in the lumen of the caudal artery below that myotome. This method 
accounts for variability in the amount of dextran injected.  
 
 47 
Zebrafish ciprofloxacin assays 
At the indicated time points, infected zebrafish embryos were transferred 
from E3 medium into E3 medium containing 50 μg/ml ciprofloxacin (pH 7.4). For 
enumeration of bacterial titers within ciprofloxacin-treated embryos, the fish were 
washed with E3 medium twice to remove ciprofloxacin and then homogenized 
and plated as described above. 
 
Statistical analysis 
Except where indicated, p values were calculated by two-tailed Student’s 
t-tests, Mann-Whitney U tests, or log-rank tests using Prism 6.0e software 
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Table 2.2. Bacterial strains and plasmids used in Chapter 2. 
 
E. coli Strain Description Source or Reference 
F11 Cystitis isolate (O6:K2:H31) [33] 
CFT073 Urosepsis isolate (O6:K2:H1) [95] 
UTI89 Cystitis isolate (O18:K1:H7) [96] 
536 Pyelonephritis isolate (O6:K15:H31) [97] 
RS218 Neonatal meningitis isolate (O18ac:K1:H7) [96, 98] 
EC958 UTI isolate (O25b:H4) [99] 
HS Commensal gut isolate (O9:H4) [100] 
MG1655 K12 lab strain [101] 
NMEC1 Neonatal meningitis isolate ARUP 
NMEC2 Neonatal meningitis isolate ARUP 
BEC1 Blood isolate ARUP 
BEC2 Blood isolate ARUP 
BEC3 Blood isolate Weyrich lab 
BEC4 Blood isolate Weyrich lab 
BEC5 Blood isolate H. Crandall 
BEC6 Blood isolate H. Crandall 
BEC7 Blood isolate H. Crandall 
BEC8 Blood isolate H. Crandall 
BEC9 Blood isolate H. Crandall 
F11/pGEN-
GFP(LVA) 
Encodes destabilized GFP (half life ≈ 40 
min) under control of the em7 promoter, 
AmpR 
[28] 
F11/pKM208 Encodes IPTG inducible lambda Red 
recombinase, AmpR 
[87] 





Table 2.3. Oligonucleotides used in Chapter 2. 
 
Primer Sequence (5’-3’) 
zEF1α  
 Forward TGAGCGTGGTATCACCATTG 
 Reverse CAACACCACCAGCAACAATC 
zIL1β  
 Forward TGGACTTCGCAGCACAAAATG 
 Reverse CACTTCACGCTCTTGGATGA 
zTNFα  
 Forward AAGGAGAGTTGCCTTTACCG 
 Reverse ATTGCCCTGGGTCTTATGG 
zSAA1  
 Forward GGAACTATGAAGCTGCACAGCGG 
 Reverse CCTCTGCGAATGAGACCTTG 
zHAMP  
 Forward TGCAGGAGAACCAACATCTG 
 Reverse AGCAGTATCCGCAGCCTTTA 
zMMP9  
 Forward CATTAAAGATGCCCTGATGTATCCC 
 Reverse AGTGGTGGTCCGTGGTTGAG 
zIL10  
 Forward TCACGTCATGAACGAGATCC 
 Reverse CCTCTTGCATTTCACCATATCC 
zIFN1  
 Forward TCTGCGTCTACTTGCGAATG 
 Reverse GGCTTGGAAATGGTGTCTCC 
zIL8  
 Forward TGTGTTATTGTTTTCCTGGCATTTC 
 Reverse GCGACAGCGTGGATCTACAG 
zIL17c  
 Forward GTCGGAGAGCAAAGTGGAAG 
 Reverse GCAGCCATCACACAAACACT 
zIL6  
 Forward TCCTCAAACCTTCAGACCGC 
 Reverse TCAGGACGCTGTAGATTCGC 






 Forward CTCTCGCCCAGTGATTAGGT 















































































































Figure 2.1. Few E. coli strains can proliferate and cause death in the 
bloodstream. 
(A) Lethality of nonpathogenic reference strains, pathogenic reference
strains, and uncharacterized clinical isolates in the zebrafish embryo
bloodstream at 24 hpi. Bars show percentage (± SEM) of fish that were
killed by ≈1000 CFU of each strain at 24 hpi following inoculation into
the bloodstream. n = 30-60 embryos pooled from 2-4 experiments.
(B) Bacterial burden in infected embryos at 0, 6, and 12 hpi. Each circle
represents an individual embryo with data pooled from two independent
experiments. Lines mark median values. CFT073 and F11 did not show




Figure 2.2. Similar growth rates of E. coli strains in broth culture.
(A-B) Representative data showing that all strains tested share similar growth 
kinetics in LB broth at 28.5°C (A) and 37°C (B). Each graph is representative of 




















































Figure 2.3. Distinct pathologies associated with different, but equally lethal 
ExPEC isolates. 
(A) An F11-infected embryo displaying characteristic pericardial edema 
(arrowhead) at 12 hpi. This is not seen following injection of controls with PBS (left).
(B) A CFT073-infected embyro at 12 hpi showing fin erosion and 
ulceration commonly seen during infection with either CFT073 or F11.
(C) F11-infected embryos often develop protrusions 
(arrowhead) on the trunk or tail regions by 12 hpi. 
(D) Merged bright field and fluorescent images of an F11/pGEN-
GFP(LVA)-infected embryo at 12 hpi showing bacteria at the 
base of a protrusion (inset), but not within the main structure. 
(E) Bright field and matched fluorescent images of F11-infected embryos 
stained with acridine orange (green) at 12 hpi. The dye accumulates 
within protrusions on the trunk (left, chevron) and tail (right, arrows). 
(F) Bright field (top) or fluorescent (bottom) images of Tg(krt8:GFP) 
embryos 12 hpi with F11. Epithelial cells within this transgenic 
line express GFP. Arrowhead marks an F11-induced protrusion.
(G) Merged bright field and fluorescent images of Tg(fli1a:GFP) 
embryos at 12 hpi with F11. Endothelial cells and leukocytes in this 
transgenic line express GFP. Protrusions are indicated with arrowheads. 
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Keratin8 Actin Activated Caspase-3
Control
F11
Figure 2.4. Perturbed actin architecture and activated caspase-3 present in 
tissue lesions.
Fluorescent images of Tg(krt8:GFP) embryos infected with F11 at 12 
hpi and stained with Phalloidin (middle) and anti-active Caspase-3 
(right). Epithelial cells within this transgenic line express GFP (left). 
 65 









































































Figure 2.5. Survival of ExPEC-infected embryos varies with ciprofloxacin 
treatment
(A-B) Kaplan-Meier survival curves of zebrafish embryos injected systemically via 
the circulation valley with (A) F11 or (B) CFT073 and then treated with ciprofloxacin 
at the indicated times; n=15-20 embryos. Black lines shows untreated controls
(C-D) Representative images of ciprofloxacin disc diffusion assays on LB 
plates incubated overnight at 28.5°C (C) and 37°C (D).Each disc contains 5 μg 
ciprofloxacin. 
(E-F) Bacterial titers recovered from (E) F11- and (F) CFT073-infected embryos 
before and after treatment with ciprofloxacin at 12 or 3 hpi, as indicated. Bars 




Figure 2.6. Infected embryos develop profound edema following rescue 
with ciprofloxacin.
(A and C) Images show uninfected control and F11-infected embryos 
at (A) 24 and (C) 72 hpi. Both control and F11-infected zebrafish were 
treated with ciprofloxacin beginning at 12 hpi. Arrowhead in (A) indicates 
the presence of pericardial edema in a surviving F11-infected embryo.
(B) Percent of surviving embryos with overt signs of edema at 48 and 72 hpi 
of the bloodstream with F11. Ciprofloxacin was administered at 12 hpi. Bars 
represent mean data ± SEM from 2 independent experiments; n=30-40 fish total.
A
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Figure 2.7. Equally lethal ExPEC isolates trigger distinct host responses.
(A-B) Venn diagrams indicating the numbers of host genes that are differen-
tially expressed in zebrafish embryos at (A) 6 hpi or (B) 12 hpi with CFT073 
versus F11, as determined by microarray analysis. The number of differ-
entially expressed transcripts was calculated for each dataset by gating on 
probes with ≥2-fold changes relative to mock-infected controls and P≤0.05. 
Results from multiple probes that mapped to the same gene were com-
bined to generate non-redundant lists of the differentially expressed genes.
(C) The number of differentially expressed host genes in a se-
lected list of enriched GO terms, as determined by DAVID.
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Figure 2.8. CFT073 and F11 have differential effects on specific host 
pathways.
Quantification of differentially expressed genes (fold change ≥2, P≤ 0.05) 
within KEGG pathways that are affected in response to systemic infections 















































Figure 2.9. ExPEC induces tachycardia and vascular leakage in zebrafish 
embryos.
(A) Image shows the tail region of an embryo following intravenous injection of 
fluorescent 70-kDa dextran. Using ImageJ, the mean fluorescent intensities of 3 
specific myotomes (red outlines) and the sections of caudal artery below each 
myotome (blue outlines) were measured. Dextran leakage was quantified by cal-
culating the ratio of fluorescent intensity within the myotomes to the underlying 
vasculature. 
(B) Endothelial leakage in infected and control PBS-injected embryos at 9 hpi. 
Data indicate mean values ± SEM from 2 independent experiments; n=9-15 em-
bryos with 3 measurement sites used per fish.
(C) Heart rate (beats/min) in infected and PBS-injected control zebrafish embryos 
at 6 hpi. Each bar represents mean values ± SEM from 2 independent experi-
ments; n=10-12 embryos. The indicated P values were determined by unpaired 










































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.11. Variable expression of cytokines in response to lethal and 
nonlethal E. coli strains.
(A-G) qRT-PCR analysis of the specified cytokine transcripts at 6 and 12 hpi 
with PBS or ~1,000 CFU of the indicated E. coli strains. Each bar represents 
mean results ± SEM from 3-4 pools of ≥16-20 embryos. qRT-PCR for 
each pool was carried out using technical duplicates. *P≤0.05, **P≤0.01, 
***P≤0.001 versus PBS-injected controls, as determined by Student’s t 

























































































































































































































































































Figure 2.12. Variable expression of host defense genes in response to lethal 
and nonlethal E. coli strains.
(A-C) qRT-PCR analysis of the specified cytokine transcripts at 6 and 12 hpi 
with PBS or ~1,000 CFU of the indicated E. coli strains. Each bar represents 
mean results ± SEM from 3-4 pools of ≥16-20 embryos. qRT-PCR for 
each pool was carried out using technical duplicates. *P≤0.05, **P≤0.01, 
***P≤0.001 versus PBS-injected controls, as determined by Student’s t 











































































































































6 hpi 12 hpi
A B C
D E
Figure 2.13. ExPEC strain differences observed in the zebrafish are 
recapitulated in a mouse model of sepsis.
(A-C) Bacterial titers per gram organ in the kidney (A), liver (B), and spleen (C) 
of CFT073- and F11-infected mice at 6 and 12 hpi. Each circle represents an 
individual mouse with data pooled from two independent experiments (n = 10 mice 
total for each time point). Lines mark median values. CFT073 and F11 did not 
show significantly different titers in any organ at any time point as measured by 
student’s t-test. 
(D) Serum IL-6 levels during sepsis. Each bar represents the mean ± SEM with 5 
mice per group and time point. Gray line is the limit of quantification.  P = *≤0.05, 
**≤0.01, ***≤0.001, **** ≤0.0001 when compared to PBS-injected controls. 
(E) IL-6 transcript levels of fish injected with ≈1000 CFU CFT073 or F11, or a 
similar volume of sterile PBS as a control. Each bar represents the mean (± SEM) 




Figure 2.14. CNF1 is an important virulence determinant in the zebrafish 
bloodstream.
(A) Kaplan-Meier survival curves of zebrafish embryos injected via the circulation 
valley with 1000-1800 CFU of F11 or F11Δcnf1; n≥51 embryos pooled from two 
independent experiments. Curves are significantly different (p=0.0018) by Mantel-
Cox log-rank test.
(B) Bacterial titers recovered from F11- or F11Δcnf1-infected embryos. Bars 
denote median values; n≥11 embryos pooled from two independent experiments. 
**p≤0.01, as determined by Mann-Whitney U tests.
















































































































































































































































































Figure 2.15. Variable cytokine expression in response to CFT073, F11, and 
F11Δflic.
(A-G) qRT-PCR analysis of the specified cytokine transcripts at 6 and 12 hpi with 
PBS or ~1,000 CFU of the indicated E. coli strains. Each bar represents mean 
results ± SEM from 3-4 pools of ≥16-20 embryos. qRT-PCR for each pool was 
carried out using technical duplicates. *P≤0.05, **P≤0.01, ***P≤0.001 versus PBS-
















































BACTERIAL FLAGELLIN IS A KEY MODULATOR OF 








Sepsis is the systemic and life-threatening activation of the immune 
system in response to invading microorganisms. Escherichia coli, the most 
common cause of bloodstream infections and second leading cause of sepsis, is 
of great concern clinically given the increasing incidence of multidrug resistant 
strains. Previous work has established that genetically distinct E. coli isolates 
CFT073 and F11 induce divergent host responses during sepsis, independent of 
baseline host attributes, offering a partial explanation for the variability in disease 
progression and response to treatment seen in septic individuals. Using a 
zebrafish model of sepsis, I show that these disparate host responses are the 
result of differences in the levels of bacterial flagellin expressed by CFT073 and 
F11 during sepsis, as well as in the genetically distinct flagellin variants produced 
by each strain differentially activate TLR5. I also present a novel system in which 
recombinant flagellin is produced by mammalian cells in culture, in the absence 
of any other bacterial products, to define the contributions of candidate residues 
and domains within flagellin to TLR5 activation. 
 
Introduction 
Sepsis is an acute systemic inflammatory condition marked by high 
mortality rates ranging from 17-49%. Compounding the problem of sepsis is its 
high degree of patient heterogeneity, making it notoriously difficult to diagnose 
and manage effectively [1, 2]. The incidence of sepsis is also on the rise, with 
hospitalization rates doubling since 2000 and associated costs reaching greater 
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than $20 billion annually, putting a significant financial burden on the healthcare 
system [3]. E. coli are the principal cause of bacteremia and a leading cause of 
sepsis, second only to Group B Streptococcus in neonates and Staphylococcus 
aureus in adults [4-8]. Sepsis caused by E. coli is more likely to cause death 
compared to these Gram-positive pathogens [9, 10]. The rate of multidrug-
resistant E. coli has increased in recent years, greatly limiting the effectiveness of 
current antibiotic therapies [6, 11, 12]. 
Much of the variability in disease progression in septic patients has been 
attributed to differences in the genetic background and immune status of 
individual hosts [13-15]. However I demonstrate in Chapter 2 that lethal but 
genetically distinct E. coli strains are also capable of contributing to differences in 
host responses, particularly in TLR signaling pathway genes, independent of host 
background. However, the underlying bacterial cause of these divergent host 
responses remains unknown.  
Flagella are best known as the locomotor organelles involved in bacterial 
motility and chemotaxis [16]. However flagellin, the ligand of TLR5 and the 
principal component of bacterial flagella, is also a potent inducer of inflammation 
and well-established virulence factor for E. coli and other pathogens [16-21]. 
Flagellin protein is composed of highly conserved N- and C- termini and a 
hypervariable center domain. TLR5 binding and signaling are mediated through 
the conserved regions, while the hypervariable domain is canonically dispensable 
for TLR5 activation but responsible for generating serotype diversity [22-24]. The 
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contributions of serotype variability to pathogenesis have historically only been 
studied in the context of its importance for antibody-mediate immune evasion. 
However there is emerging evidence that flagellin (FliC) variants can differentially 
modulate TLR5 activation and cytokine production [25-30]. There are currently 56 
characterized H (flagellar) antigens in E. coli [31], but the contributions of these 
different variants to TLR5 activation and downstream cytokine production remain 
largely unknown. 
In this chapter I establish that for two lethal ExPEC strains, CFT073 and 
F11, the observed differences in host response during sepsis are the result of 
variable flagellin expression as well as how genetically distinct flagellin molecules 
differentially activate TLR5, unappreciated phenomenon that could account for 
the variability in symptoms observed in human septic patients. I also present a 
novel system in which recombinant flagellin protein is produced by mammalian 
cells in culture in the absence of any other bacterial products.  
 
Results 
Flagellin from CFT073 and F11 differentially modulate 
inflammatory responses during sepsis 
CFT073 and F11 cause different host responses (Figures 2.7-2.8, 2.10-
2.13). However the cause is unknown. CFT073 and F11 share the same type 2 
(K2) capsule and O6 LPS antigens, but possess distinct flagellar serotypes (H1 
vs. H31, respectively). The flagellin proteins from CFT073 and F11 are only 
67.3% similar at the protein coding level, with each being comprised of well-
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conserved N- and C-terminal domains separated by a variable middle domain 
that is responsible for generating serotype diversity (Figure 3.1). This domain 
architecture is common among bacterial flagellin proteins and provides the basis 
for flagellin recognition by TLR5 [16, 22, 24]. Regions within the conserved 
termini of FliC that are predicted to be bound by TLR5 are nearly identical in the 
CFT073 and F11 sequences, with the exception of a single conservative 
isoleucine to valine change. 
Considering the stimulatory effects of both CFT073 and F11 on the 
transcription of TLR5 and associated signaling factors (see Figures 2.8, 2.10, and 
2.11), I wished to define the contributions of the FliC variants to the infection 
process and host responses. Deletion of fliC in either CFT073 or F11 rendered 
both pathogens immobile on swim agar plates (Figure 3.2), but had no effect on 
bacterial titers recovered from the zebrafish host at 12 hpi (Figure 3.3A). At this 
time point CFT073ΔfliC induced similar levels of the pro-inflammatory cytokines 
IL-1β and IL-8 as its wild type counterpart, whereas F11ΔfliC was markedly less 
inflammatory than the wild type F11 strain (Figure 3.3B and C).  
The levels of flagellin expression by CFT073 and F11 during infection of 
the zebrafish host were examined using a low-copy reporter construct in which 
the luxCDABE gene cluster encoding bacterial luciferase is transcriptionally fused 
with the conserved fliC promoter (pfliC-lux) [18]. Titers of the recombinant strains 
present at 12 hpi were comparable, though marginally fewer F11/pfliC-lux were 
recovered (Figure 3.4A). Despite this discrepancy, significantly higher levels of 
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fliC expression were detected in zebrafish infected with F11/pfliC-lux versus 
CFT073/pfliC-lux (Figure 3.4B). Disparity in the observed host responses to F11 
and CFT073 correlates with variations in the levels of flagellar expression by 
these two ExPEC isolates.  
In addition, using a TLR5 reporter cell line (HEK-Blue mTLR5 cells), I 
found that semipurified preparations of flagella from F11 were significantly more 
stimulatory than preparations from CFT073 (Figure 3.4C), despite the presence 
of similar amounts of FliC (as verified by immunoblot, Figure 3.4D). In these 
assays, HEK-Blue mTLR5 cells treated with preparations from CFT073ΔfliC or 
F11ΔfliC showed no significant activation above baseline. Further confirming the 
specificity of the measured responses, I found that the addition of anti-TLR5 
neutralizing antibody, but not an isotype control, significantly inhibited stimulation 
of the TLR5 reporter cells by flagella from both CFT073 and F11 (Figure 3.4E). In 
total, these data indicate that the divergent inflammatory responses seen in F11- 
and CFT073-infected zebrafish are in part attributable to differences in the levels 
of FliC expression by these two pathogens as well as contrasting stimulatory 
effects of the two FliC variants on TLR5 signaling.  
 
Knockdown of TLR5 increases bacterial burden during  
sepsis, but does not alter cytokine levels  
To directly examine the contributions of TLR5 to host response and 
disease outcome during sepsis, I used morpholinos (antisense oligonucelotides) 
against tlr5a and tlr5b to reduce levels of these genes in the zebrafish. 
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Knockdown of zTLR5a/b did not significantly alter the survival rate of infection 
with CFT073 or F11 when compared to larvae injected with a control morpholino 
(Figure 3.5A). However, TLR5 morphants showed a significantly increased 
bacterial burden at 12 hpi during infection with CFT073 and F11 compared to 
control morphants (Figure 3.5B). Despite the increased bacterial load, the 
abrogation of TLR5 did not significantly alter levels of downstream inflammatory 
mediators as similar amounts of il1β (Figure 3.5C) or il8 (Figure 3.4D) were found 
between control and TLR5 morphants at 12 hpi during infection with CFT073 and 
F11. 
 
Bacterial-free protein expression system for the identification 
of residues and domains that contribute to  
differential stimulation of TLR5 
The predicted canonical TLR5-binding sites within the FliC variants from 
CFT073 and F11 are nearly identical, save for one residue (isoleucine 528 in 
CFT073 and valine 488 in F11) that sits on the backside of the C-terminal α-helix 
that interfaces with TLR5 [22, 24]. This change, as well as multiple synonymous 
SNPs present within coding sequences for the conserved termini of the FliC 
variants could potentially affect signaling via TLR5. Though the center 
hypervariable domain of FliC does not make direct contact with TLR5, previous 
studies indicate that this domain may also modulate cytokine responses [27, 32]. 
To determine the contributions of candidate residues and domains to TLR5 
signaling by FliC variants from CFT073 and F11, I created constructs encoding 
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the full length version of each variant (pBF16 and pBF12 for CFT073 FliC and 
F11 FliC, respectively), the hypervariable domain alone from each variant [pAB1 
for CFT073 FliC(176-497) and pAB2 for F11 FliC(176-466)], and mutant FliC 
variants where the nonidentical residue in the predicted C-terminal TLR5 binding 
domain is modified to the residue present in the other variant [pBF16(I528V) and 
pBF16(V488I)] (Figure 3.6A). With the aim of creating recombinant protein free 
from contamination of other bacterial products, each of these constructs was 
cloned into a mammalian expression vector in between an insulin secretory 
signal and C-terminal 6xhis tag (Figure 3.6B). Following transfection of HEK293T 
cells, media containing recombinant flagellin was collected and added to a TLR5 
reporter cell line. Media from pBF12- and pBF16-transfected cells induced robust 
activation of TLR5, while no significant activation was seen following treatment 
with PBS or media from empty vector control cells (Figure 3.6C). Subsequent 
immunoblot of media from transfected cells indicated that there was substantially 
more recombinant flagellin in the pBF16-transfected media than the pB12-
transfected media, explaining the differential levels of TLR5 stimulation seen 
between these samples and indicating that activation by recombinant flagellin 
was dose dependent (Figure 3.6D). 
 
Discussion 
Septic patients often present with wide-ranging disease signs and 
pathophysiological manifestations, which makes diagnosis difficult, and are 
notoriously difficult to manage because they do not respond homogenously to 
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treatment [33]. During sepsis, the host background is often considered the 
primary variable affecting disease progression and outcome, while microbes are 
commonly viewed as generic inducers of inflammation. In Chapter 2 I 
demonstrated that E. coli isolates belonging to the same species can markedly 
affect the host response during sepsis, irrespective of host background 
characteristics. Continuing on this work, here I establish variable expression of 
bacterial flagellin during sepsis and differential stimulation of the host receptor 
TLR5 as key factors contributing to differences in host response during sepsis. 
The involvement of flagellin as a regulator of host responses during sepsis 
has precedence. Flagellin can be detected in the plasma of septic patients at 
concentrations ranging from 2 to 20 ng/mL, with higher levels being associated 
with longer duration of septic shock [34]. In mouse burn wound models of sepsis, 
the administration of flagellin can enhance the antibacterial activities of 
neutrophils and the delivery of antiflagellin antibodies can promote host survival 
[35, 36]. In both our zebrafish model and in human patients with sepsis-like 
syndromes, the flagellin receptor TLR5 is among the most highly induced pattern 
recognition receptors [37-39]. Allelic variants of TLR5 may predispose infants to 
sepsis, and high-level expression of TLR5 in septic individuals is positively linked 
with more severe disease [39-41].  
The failure of morpholinos targeting tlr5a/b to alter cytokine levels in the 
zebrafish sepsis model may be attributable to technical limitations, rather than 
TLR5 not being involved in the host response during sepsis. For our experiments, 
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we used previously published oligonucleotide sequences against TLR5a/b [42, 
43], but found significant toxic side effects at the published dose required for 
knockdown. Some of these effects were also seen in embryos injected with a 
comparable dose of the standard control morpholino, indicating that they are non-
specific. Additionally, targeted knockdown by morpholinos frequently fails to 
recapitulate mutant phenotypes [44] so to truly determine the contributions of 
TLR5 to sepsis in our system a genomic knockout of TLR5a/b would be needed. 
Finally, interpreting data regarding cytokine levels can be somewhat ambiguous 
in cases where there is an accompanying change in bacterial burden (Figure 
3.4C-D). 
The capacity of distinct flagellar serotypes to differentially activate TLR5, 
as demonstrated in this study, indicates an unanticipated mechanism by which 
different ExPEC isolates may elicit variable inflammatory responses in septic 
individuals. The predicted canonical TLR5-binding sites within the FliC variants 
from CFT073 and F11 are nearly identical, save for one residue (isoleucine in 
CFT073 and valine in F11) that sits on the backside of the C-terminal α-helix that 
interfaces with TLR5 [22, 24]. This change, as well as multiple synonymous 
SNPs present within coding sequences for the conserved termini of the FliC 
variants could potentially affect signaling via TLR5. Though the hypervariable 
middle domain of FliC does not make direct contact with TLR5, previous studies 
indicate that this domain may also modulate cytokine responses [27, 32]. The 
ability of different versions of FliC to elicit contrasting host responses suggests 
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that some bacteria may utilize flagella as immunomodulators, expanding their 
function beyond motility.  
The ability to purify recombinant proteins in a system free of contamination 
from bacterial products that stimulate host pathogen recognition receptors is a 
valuable implement. There have been many instances where LPS contamination 
is the actual cause of a phenotype, rather than the recombinant molecule being 
tested [discussed in 45]. The protein purification strategy discussed in this 
chapter is particularly advantageous for the generation of recombinant eukaryotic 
protein, which can be inactive when produced in bacteria due to differing or 
missing post-translational modifications [46]. Conversely, recombinant bacterial 
proteins generated in our system are likely to have eukaryotic post-translational 
marks, such as N- or O-linked glycosylations, which would not be present if they 
were synthesized under native bacterial conditions. Not surprisingly, flagellin 
generated from HEK293T cells runs larger than flagellin isolated from bacteria on 
SDS-PAGE, likely as a result of modifications that are not present under native 
conditions. However, mammalian cell-generated flagellin is still very stimulatory 
to TLR5, indicating that functionality of the protein is retained. I did not have a 
chance to test the constructs created to determine the residues and domains that 
contribute to differential stimulation of TLR5 by the FliC variants from CFT073 
and F11 (Figure 3.6A), but elucidating the underlying mechanism would form a 
foundation by which specific FliC variants could be engineered as regulators of 
host inflammatory responses with possible therapeutic value. 
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Materials and Methods 
Ethics statement 
Animals used in this study were handled in accordance with University of 
Utah and IACUC-approved protocols following standard guidelines described at 




The bacterial strains used in this study are listed in Table 3.1. Bacteria 
used for infecting zebrafish and mice were grown statically at 37°C for 24 h in 12 
ml modified M9 minimal medium (6 g/l Na2HPO4, 3 g/l KH2PO4, 1 g/l NH4Cl, 0.5 
g/l NaCL, 1 mM MgSO4, 0.1 mM CaCl2, 0.1% glucose, 0.0025% nicotinic acid, 
0.2% casein amino acids, and 16.5 μl thiamine in H2O, pH 7.2). F11 carrying 
pGEN-GFP(LVA) was grown in medium containing ampicillin (50 µg/ml). 
Targeted deletion of fliC in F11 and CFT073 were generated using lambda Red-
based recombination as described previously [47]. Expression constructs pBF14 
and pBF15 were made using the low-copy-number plasmid pGEN-MCS and 
standard molecular biology techniques as in [18]. Primers for the generation and 








Wild type AB zebrafish were maintained as breeding colonies on a 14-
h/10-h light/dark cycle. Embryos were collected as mixed egg clutches and raised 
at 28.5°C in E3 medium (5 mM NaCl, 0.27 mM KCl, 0.4 mM CaCl2, 0.16 mM 
MgSO4; pH 7.4) containing 0.000016% methylene blue as an antifungal agent.  
 
Infection of zebrafish embryos 
48 hpf embryos were manually dechorianated, briefly anesthetized with 
0.77 mM ethyl 3-aminobenzoate methanesulfonate salt (tricaine) (Sigma-Aldrich), 
and embedded in 0.8% low melt agarose (MO BIO Laboratories) without tricaine. 
After the agarose solidified, embryos were immersed in E3 media lacking 
methylene blue. Prior to injection, 1 ml of bacterial culture was pelleted, washed 
with 1 ml sterile PBS, and resuspended in PBS to obtain ~1X109 CFU/ml PBS. 
One nl of this bacterial suspension was microinjected into the bloodstream via 
the circulation valley using an Olympus SZ61 or SZX10 stereomicroscope 
together with a YOU-1 micromanipulator (Narishige), a Narishige IM-200 
microinjector, and a JUN-AIR model 3-compressor. For each experiment, the 
average CFU per injection was determined by adding 10 1-nl drops to 1 ml of 
0.7% NaCl, which was then serially diluted and plated on Luria-Bertani (LB) agar 
plates. Mock-infected controls were inoculated with 1 nl sterile PBS.  Following 
injection, embryos were removed from agar and placed individually into wells of a 
48-well plate (Nunc) containing E3 medium and incubated at 28.5°C. For lethality 
assays, death was defined by absence of heart contraction and blood flow.  
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Enumeration of bacterial numbers in zebrafish embryos 
Embryos were homogenized at the indicated time points in 500 μl of PBS 
containing 0.5% Triton X-100 using a mechanical PRO 250 homogenizer (PRO 
Scientific). Homogenates were serially diluted and plated on LB agar plates, 
which were then incubated overnight at 37°C. 
 
RNA isolation from zebrafish embryos 
Pools of 15-20 embryos were manually homogenized in 1 ml QIAzol Lysis 
Reagent (Qiagen) and total RNA extracted using the Qiagen RNeasy Plus 
Universal Kit according to the manufacturer’s instructions. Genomic DNA was 
removed by the gDNA Eliminator Solution (Qiagen). 
 
cDNA synthesis and qRT-PCR 
cDNA was synthesized from 2 μg of RNA using the SuperScript III First-
Strand Synthesis System (Invitrogen) in a 20 μl reaction volume. Following 
assembly of the master mix according to manufacturer instructions, samples 
were incubated at 25°C for 5 min, 55°C for 45 min, and 70°C for 15 min. 
Complimentary RNA was then removed by addition of RNase H (Invitrogen) for 
15 min at 37°C. 
 qRT-PCR was performed on a LightCyler 480 instrument (Roche) 
following manufacturer recommendations. Cycling parameters were 95°C for 8 
min to activate the polymerase followed by 40 cycles of 95°C for 4 sec, 60°C for 
6 sec, and 72°C for 6 sec. Fluorescence measurements were taken at the end of 
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each cycle. Melt curve analysis was performed to ensure that no primer dimers 
were amplified. All reactions were performed in technical duplicate. Sequences 
for the forward and reverse primers are listed in Table 3.2. Results were 
normalized to transcript levels of the housekeeping gene ef1α (elongation factor 
1-alpha) using ΔΔCt analysis.  
 
Semipurified bacterial flagellin preparation 
Overnight bacterial cultures were back diluted 1:100 into 20 ml of tryptone 
broth and grown shaking (180 rpm) at 30°C to midlog. Motility was verified by 
microscopy prior to proceeding. Cultures were spun down at 6000g for 10 min at 
4°C and resuspended in 3 mL sterile PBS. Suspensions were then passed 
between two syringes connected with 0.28mm I.D. polyethylene tubing (Becton 
Dickson) to shear flagella. Following shearing, samples were spun down at 
6000g for 10 min at 4°C and supernatant containing flagella collected. Equal 
loading of flagellar protein for TLR reporter assays was verified by 
immunoblotting for fliC (Abcam anti-Flagellin; 1:10,000) following standard 
Western blotting protocols. 
 
Quantification of flagella expression in infected embryos 
Embryos were infected with approximately 2000-2500 CFU CFT073/pfliC-
lux and F11/fliC-lux as described above. Following infection, embryos were 
individually placed into wells of a white-walled 96 well plate containing E3 
medium and incubated at 28.5°C. Luminescence was measured at each time 
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point using a BioTek Synergy H1 plate reader. 
 
Quantification of TLR5 activation 
TLR5 stimulation was assayed using HEK-Blue mTLR5 cells (Invivogen), 
a SEAP reporter line expressing mouse TLR5. Briefly, cells were suspended at a 
concentration of 140,000 cells/mL in HEK-Blue detection media and 180 μl 
(25,000 cells/well) placed into wells of a 96 well plate. Cells were then stimulated 
with 20 μl semipurified flagella or PBS as a control. After 15 hours, absorbance 
(640 nm) was measured using a BioTek Synergy H1 reader. For neutralizing 
antibody experiments, 1 μg/ml anti-mTLR5 or control IgG2a antibody were added 
to cells and allowed to incubate for 1 hour prior to the addition of flagella.  
 
TLR5a/b morpholino experiments 
Morpholino oligonucleotides (Gene Tools) were used to block translation 
of tlr5a and tlr5b. Using previously published oligonucleotide sequences [42, 43] 
0.85 ng (0.1 mM) tlr5a morpholino and 4.2 ng (0.5 mM) tlr5b morpholino were 
injected into one-cell stage zebrafish embryos. To control for nonspecific 
morpholino effects, 0.6 mM of a standard control morpholino was injected into 
one-cell stage embryos. Sequences for morpholino oligonucleotides can be found 
in Table 3.2. 
 
Generation of vectors for recombinant protein purificiation 
pBF12, pBF16, pAB1, and pAB2 were generated by subcloning the coding 
sequences of CFT073 FliC, CFT073 FliC176-497, F11 FliC, and F11 FliC176-
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466 sans stop codon, respectively, into parent vector pSF-CMV-NH2-InsulinSP1-
NcoI (Oxford Genetics). A 6xHis tag was added to the C terminal end of each 
coding sequence for recombinant protein purification. The parent vector uses the 
mammalian CMV promoter to drive strong gene expression and adds a secretory 
signal peptide to the N-terminus. This signal causes the translocation of the 
nascent protein to the endoplasmic reticulum, where the signal peptide is cleaved 
off and the peptide is secreted into the medium by bulk flow exocytosis. 
pBF12(V488I) and pBF16(I528V) were generated using the QuikChange II Site-
Directed Mutagenesis Kit (Agilent) following the manufacturer instructions. Primer 
sequences for the generation these constructs are provided in Table 3.2. 
 
Recombinant protein generation by 293T cells 
293T cells were maintained in DMEM containing 10% heat-inactivated 
FBS, 2 mM L-glutamine and 1% Penicillin/Streptomycin in a humidified incubator 
with 5% CO2. For transfection, 293T cells were seeded at 30% confluency with 
the goal of being 60% confluent at the time of transfection. pBF12, pBF16, and 
the control vector pSF-CMV-NH2-InsulinSP1-Nco1 were transiently transfected 
using calcium phosphate to mediate transfection and media containing 
recombinant protein was collected at 72 hours post-transfection. Levels of 
recombinant protein were determined by SDS-PAGE and immunoblot against 






Except where indicated, p values were calculated by two-tailed Student’s 
t-tests, Mann-Whitney U tests, or log-rank tests using Prism 6.0e software 
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Table 3.1. Bacterial strains and plasmids used in Chapter 3. 
 
E. coli Strain Description Source or Reference 
F11 Cystitis isolate (O6:K2:H31) [49] 
CFT073 Urosepsis isolate (O6:K2:H1) [50] 
pfliC-lux Encodes fliC driven luciferase reporter, 
AmpR 
[18] 
pKM208 Encodes IPTG inducible lambda Red 
recombinase, AmpR 
[47] 
CFT073ΔfliC CFT073 fliC::kan This study 
F11ΔfliC F11 fliC::kan This study 
pBF14 Encodes FliC from F11 This study 
pBF15 Encodes FliC from CFT073 This study 
pBF12 Encodes CMV driven F11_FliC with a N-
terminal insulin secretion sequence and 
C-terminal 6xHis tag, KanR 
This study 
pBF16 Encodes CMV driven CFT073_FliC with a 
N-terminal insulin secretion sequence and 
C-terminal 6xHis tag, KanR 
This study 
pAB1 Encodes CMV driven CFT073_FliC(176-
497) with a N-terminal insulin secretion 
sequence and C-terminal 6xHis tag, KanR 
This study 
pAB2 Encodes CMV driven F11_FliC(176-466) 
with a N-terminal insulin secretion 
sequence and C-terminal 6xHis tag, KanR 
This study 
pBF12(V488I) Amino acid substitution of isoleucine for 
valine at reside 488 in pBF12 
This study 
pBF16(I528V) Amino acid substitute of valine for 




Table 3.2. Oligonucleotides used in Chapter 3. 
 
Primer Sequence (5’-3’) 






 Forward CGACAGACGATAACAGGGTTG 
 Reverse ATCCGGCCTACAAAAATGTG 






 Forward CGACAGACGATAACAGGGTTG 
 Reverse CTTACCCGGCCTACAAAATG 
zEF1α 
 Forward TGAGCGTGGTATCACCATTG 
 Reverse CAACACCACCAGCAACAATC 
zIL1β 
 Forward TGGACTTCGCAGCACAAAATG 
 Reverse CACTTCACGCTCTTGGATGA 
zIL8 
 Forward TGTGTTATTGTTTTCCTGGCATTTC 
 Reverse GCGACAGCGTGGATCTACAG 
zTLR5a Morpholino 
  AAAGTGTATGTAGCTGCCATTCTGG 
zTLR5b Morpholino 
  TGAATGTATATCCCATTCTGTGAGC 
Control Morpholino 
  CCTCCTACCTCAGTTACAATTTATA 
pBF12 
 Forward GGCTGAGGTCGCCATGGGTATGGCACAAGTCATTAATAC 
 Reverse GATAACTCGAGTTAGTGGTGGTGGTGGTGGTGTCC 
ACCCTGCAGCAGAGACAGAA 
pBF16 
 Forward GGCTGAGGTCGCCATGGGTATGCTGAATGGTTTTAACGTGAA 
 Reverse ATAACTCGAGTTAGTGGTGGTGGTGGTGGTGTCC ATCTTTTGTTACTGTGCCTTC 
pBF14/pBF15 
  GATCGAAGCTTGTTATCGGCCTGAATTGCGC 
  GATTGCCATTGGTTAACCCTGCAGCAGAGACAG 
pAB1 








 Forward TTTCGCTCCTCCTTGGGTGCGATACAAAACCGTCTGGATTCTGCGG 
 Reverse CCGCAGAATCCAGACGGTTTTGTATCGCACCCAAGGAGGAGCGAAA 
pBF16(I528V) 
 Forward ATTCCGTTCATCCCTGGGGGCTGTCCAAAACCGTTTGGA 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.2. Functional verification and complementation of fliC mutants.
(A-B) Deletion of flic in F11(A)  and CFT073 (B) renders  both pathogens 
immobile on 0.1% LB agar plates. Wild type strains are also pictured as controls.
(C) Complementation of F11ΔfliC with pBF14 restores motility on 0.1% LB agar 
plates, while the mutant carrying the pGEN empty vector remains immobile.
(D) Complementation of CFT073ΔfliC with pBF15 restores motility on 0.1% LB 











































































































Figure 3.3. Flagellin contributes to the inflammatory response of F11, but 
not CFT073 during sepsis.
(A) Bacterial burden in infected embryos at 12 hpi with ~1,000 CFU. Data were 
pooled from two independent experiments. Bars denote median values; n = 10 
embryos. No significant differences were detected between wild type and fliC 
mutant strains, as determined by Mann-Whitney U tests.
(B-C) qRT-PCR analysis of the specified cytokine transcripts at 12 hpi with PBS 
or ~1,000 CFU of the indicated E. coli strains. Bars indicate mean results ± SEM 
from 3 pools of ≥ 18-20 embryos. qRT-PCR for each pool was carried out using 
technical duplicates. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 versus PBS-injected 
controls, as determined by Student’s t tests. P values for wild type vs. fliC mutant 


































































































































































Figure 3.4. Differences in inflammation between CFT073 and F11 result from 
variable flagellin expression and differential stimulation of TLR5.
(A) Bacterial burden in infected embryos at 12 hpi following innoculation with ~5000
CFU. Data were pooled from two independent experiments. Lines mark median
values; n = 10 embryos. ****PDVFDOFXODWHGE\0DQQ:KLWQH\8WHVW
(B) fliC expression in infected embryos at 9 and 12 hpi. Lines mark
PHGLDQ YDOXHV Q    HPEU\RV SRROHG IURP WZR LQGHSHQGHQW
experiments. P YDOXHV FDOFXODWHG E\ 0DQQ:KLWQH\ 8 WHVWV
(C ,PPXQREORW RI VHPLSXULÀHG ÁDJHOOD IURP &)7 &)7ΔfliC ) DQG 
)ΔfliC.
(D-E 7/5 VWLPXODWLRQ E\ VHPLSXULILHG IODJHOOD DV PHDVXUHG XVLQJ 
+(.%OXH P7/5 UHSRUWHU FHOOV %DUV UHSUHVHQW PHDQ UHVXOWV  
CI from two independent experiments with three replicates. ****P 









































































































































Figure 3.5. Knockdown of TLR5 increases bacterial burden during sepsis, 
but does not affect cytokine levels.
(A) Representative Kaplan-Meier survival curve of control or TLR5 
morphant zebrafish embryos infected with CFT073 (solid and dotted 
orange lines) or F11 (solid and dotted maroon lines); n=12-18 embryos. 
(B) Bacterial burden in infected embryos at 12 hpi with ~1,000 CFU. Data 
were pooled from three independent experiments. Bars denote median values; 
n = 14 embryos. *P ≤ 0.05, **P ≤ 0.01 as determined by Mann-Whitney U test.
(C-D) qRT-PCR analysis of IL-1β (B) and IL-8 (C) at 12 hpi with ~1,000 CFU 
of the indicated E. coli strains. Bars indicate mean results ± SEM from 4 pools 
of ≥ 18-20 embryos. qRT-PCR for each pool was carried out using technical 
duplicates. No significant differences were detected between TLR5 morphants 
and control morphants for either CFT073 or F11 using Student’s t tests.
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Figure 3.6. Recombinant flagellin production by 293T cells.
(A) Illustration of constructs created to determine the molecular basis for differential 
stimulation of TLR5 by FliC variants from CFT073 and F11.
(B). Each construct from (A) was cloned into parent vector pSF-CMV-InsulinSP1-
Nco1 which features CMV-driven expression of the recombinant coding sequence 
and a 3’ his tag. Recombinant protein is secreted into the medium of transfected 
cells as a result of the 5’ insulin signal peptide.
(C) TLR5 stimulation by recombinant flagellin, as measured using HEK-Blue 
mTLR5 reporter cells. Bars represent mean results ± SD from three replicates.
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GENERATION OF NOVEL ZEBRAFISH LINES FOR THE  






The immune response to pathogens or tissue damage involves the rapid 
activation of immune cells and generation of pro-inflammatory cytokines (e.g., IL-
β, IL-6, TNFα). However, excess inflammation can be destructive and detrimental 
to the host so the immune system has evolved parallel anti-inflammatory 
molecules (e.g., IL-10) and pathways to regulate and curb production of 
inflammatory molecules and prevent damage to the host. The zebrafish is an 
attractive, emerging model for the study of host-microbe interactions and 
inflammation (see Chapter 1), but is currently hampered by the limited availability 
of tools in these disciplines such as knock out lines in immune-associated genes 
and transgenic reporter lines for immune cell types and mediators. Within this 
chapter I will discuss the generation of an IL-10 deficient zebrafish and 
transgenic lines placing IL-1β and IL-10 under inducible control to better 




Interleukin-10: the prototypical anti-inflammatory cytokine 
 IL-10 is part of a greater family of cytokines (including IL-10, IL-19, IL-20, 
IL-22, IL-24, and IL-26) based upon similarities in their genomic architecture, 
protein structures, and the receptor complexes used [1]. IL-10 itself is a small 20 
kDa protein whose secondary structure forms a compact, bundle-like shape 
comprised of 6 α-helices creating a hydrophobic core stabilized by 2 disulfide 
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bridges essential for maintaining the structure and biological activity of the 
cytokine. Functioning as a homodimer, the main in vivo source of IL-10 is 
monocytes, macrophages, and T-cell subsets. However it is also synthesized by 
other immune cells such as dendritic cells, B cells, natural killer cells, neutrophils, 
and other granulocytic immune cells [2]. The receptor for IL-10 is comprised of 
two IL-10R1 and two IL-10R2 molecules and is expressed predominantly on 
macrophages and monocytes, making them the main cellular targets for IL-10. IL-
10-receptor binding induces JAK/STAT signaling, including the downstream 
activation of Suppressor of cytokine signaling 3 (SOCS3) to mediate its 
downstream effects. 
 IL-10 is one of the most important anti-inflammatory and 
immunosuppressive cytokines and is produced by immune cells following their 
activation. It functions largely to suppress the key functions of macrophages, 
including downregulating the release of pro-inflammatory mediators IL-1β and 
TNFα, inhibiting antigen presentation, and altering phagocytosis and microbial 
killing [2]. Additionally, it inhibits the expression of MHC class II and associated 
co-stimulatory molecules and inhibits the synthesis of Prostaglandin-
endoperoxide synthase 2.  
 IL-10 is implicated in the pathogenesis of myriad infections and 
inflammatory conditions. The absence of IL-10 in mice either by disruption of the 
il10 gene or antibody blockade of the receptor leads to improved clearance of 
many bacterial, fungal, and viral pathogens [reviewed in 2, 3]. Occasionally this is 
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not accompanied by an increase in immunopathology [4, 5]. However more often 
the absence of IL-10 leads to severe immunopathology [6-10]. Given that the 
absence of IL-10 improves pathogen clearance, it is not surprising that many 
infectious microbes such as Mycobacterium tuberculosis and Trypanosoma cruzi 
have evolved mechanisms to selectively upregulate IL-10 during infection [8, 10]. 
Some viruses (e.g., Herpesviridae and Poxviridae) take a more direct approach 
and encode IL-10 homologs within their genomes to create a more favorable 
niche for themselves [11].  
The role of IL-10 during sepsis is complex given its pleotropic 
immunosuppressive properties. On one hand, IL-10 deficient mice show 
enhanced mortality and increased organ damage in an E. coli model of sepsis on 
account of increased levels of inflammatory cytokines such as TNFα [7]. 
However, exogenous administration of IL-10 during sepsis has produced 
heterogeneous results [discussed in 12] and there are additional concerns 
regarding IL-10’s suppression of T cell responses during recovery from sepsis.  
Interestingly, IL-10 secreted by monocytes keeps neural stem cells in an 
undifferentiated state, blocking neurogenesis and partially explaining why 
regenerative neurogenesis does not take place following injury of the adult brain 
[13, 14]. IL-10 plays a key modulatory role in tolerizing the immune system to 
resident enteric bacteria as IL-10 deficient mice spontaneously develop 
inflammatory colitis [15], a phenomenon that does not happen in mice maintained 
under germ free conditions [16]. IL-10 deficiency and the associated rise in 
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inflammation have also been linked with the development and pathogenesis of 
psoriasis, rheumatoid arthritis, inflammatory bowel disease, and systemic lupus 
erythematosus [17, 18]. While recombinant IL-10 has been investigated as 
therapy for many of these conditions, the results have been heterogeneous and 
overall, not particularly effective during clinical trials [19]. 
Zebrafish IL-10 (zIL-10) is highly similar to mammalian IL-10, sharing the 
same genomic architecture of five exons and four introns and secondary 
structure comprised of six α-helices [20]. The four cysteine residues essential for 
biological function in mammalian IL-10 are also conserved in zIL-10. Despite 
these similarities, there are currently no transgenic lines or characterized mutants 
for the study of this key anti-inflammatory mediator in zebrafish. Within this 
chapter I will describe the generation of an IL-10 deficient zebrafish as well as a 
transgenic line placing IL-10 under inducible control. 
 
Interleukin-1β: a key inflammatory mediator 
IL-1β is a master inflammatory cytokine of local and systemic 
inflammation. As such, the levels of IL-1β are tightly regulated. IL-1β mRNA is not 
constitutively expressed and most of the IL-1β transcripts produced are degraded 
and never translated. Blood monocytes, tissue macrophages, and dendritic cells 
are the primary sources of IL-1β, but it can also produced by B cells, NK cells, 
and platelets. IL-1β is unique among cytokines in that it is produced as a pro-
peptide that requires processing by Caspase-1 for activity. Caspase-1 itself 
requires activation by the inflammasome, a multiprotein complex, to initiate the 
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inflammatory cascade. While activation of IL-1β occurs predominantly via 
Caspase-1, Proteinase-3 or Elastase can also activate IL-1β [21]. Following IL-1β 
binding to its cognate receptor, Interleukin-1 receptor (IL1R), the cytoplasmic 
domain of IL1R recruits adapter protein MyD88 and downstream inflammatory 
programs are initiated by NFκB and AP-1. Nearly all microbial products induce 
the production of IL-1β via TLR signaling, as do activated complement 
components and other cytokines (i.e., TNFα). IL-1β can also induce itself, 
forming a positive inflammatory feedback loop and leading to autoinflammation 
[22]. The systemic symptoms of IL-1β expression include fever, inflammatory 
pain hypersensitivity, vasodilation, and hypotension. Patients treated with a low 
dose of IL-1β also exhibit a loss in appetite, muscle and joint pain, fatigue, as well 
as sleep and gastrointestinal disturbances [23]. 
While IL-1β deficient mice exhibit no overt phenotypes during 
development, homeostasis, or resistance to endogenous microbial flora, IL-1β 
has myriad indirect effects on immune cells [24, 25]. The presence of IL-1β 
increases the expression of cellular adhesion molecules, thus promoting the 
infiltration of inflammatory cells into tissue from the circulation. Exposure to IL-1β 
induces the differentiation of bone marrow stem cells into myeloid progenitors, 
prolongs the lifespan and effector function of neutrophils, and increases the 
number of circulating neutrophils. It is also essential for the generation of Th17 
responses and plays a role in antibody production. In models of local or systemic 
inflammation, IL-1β deficiency typically results in increased susceptibility to 
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infections, but reduced disease severity [24]. Importantly, infants born with a loss 
of function in IL-1 receptor agonist (IL-1RA), a natural inhibitor of IL-1β, die early 
in life due to overwhelming inflammation of the skin and joints with large amounts 
of infiltrating neutrophils and high IL-17 levels.  
 IL-1β plays a significant role in the pathogenesis of many inflammatory 
disorders including rheumatoid arthritis, gout, systemic juvenile idiopathic 
disease, type ii diabetes, and Behcet’s disease. IL-1β is also a key participant in 
familial autoinflammatory diseases such as cryopyrin-associated periodic 
syndrome and familial Mediterranean fever that are marked by increased 
inflammation mediated by cytokines of the innate immune system, without the 
presence of autoantibodies or self-reactive T cells. Surprisingly, a crucial role for 
IL-1β during cancer metastasis has been established. In IL-1β deficient mice, 
vascular endothelial growth factor cannot stimulate the formation of blood 
vessels, so malignant melanoma cells do not spread and mice rarely develop 
tumors. The tumors that do form develop significantly slower and are marked by 
their absence of leukocyte infiltration [26].  
 Considering the significant contributions that IL-1β makes to a multitude of 
diseases, it is not surprising that it is an emerging therapeutic target. There are 
three currently approved therapeutics for reducing IL-1β activity and numerous 
others in clinical trials [discussed in 27]. In addition to being a valuable 
therapeutic for the chronic inflammatory diseases mentioned above, targeting IL1 
has also proved beneficial in cases of acute ischemic inflammation following 
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myocardial infarction, stroke, and acute lung injury. Blocking IL1 also has utility in 
the treatment of chronic inflammatory conditions that are refractory to 
glucocorticoids and TNF blockers. IL-1 blockade was investigated as a sepsis 
therapeutic given the sharp increase in IL-1β levels during sepsis [28-31]. 
Though initially promising, reducing IL-1β did not significantly affect patient 
mortality, which was thought to be due to the heterogeneity in patients with 
sepsis. 
 Zebrafish IL-1β (zIL-1β) is conserved compared to its mammalian 
ortholog, including structural conservation of the critical βtrefoil fold and it is 
transcriptionally upregulated during infection and following inflammatory stimuli 
[Figure 2.11, 32, 33-35]. Additionally, zebrafish possess two Caspase 1 orthologs 
(Caspase A and Caspase B) that are both capable of processing zIL-1β [36]. In 
this chapter I will discuss the creation of a novel zebrafish line placing IL-1β 




Use of TALENs to induce somatic mutations in zIL-10 
Reverse genetics to elucidate the function of specific genes in zebrafish 
has been problematic up until recent years. One previous approach was to 
attenuate gene function in embryos using antisense morpholino oligonucleotides. 
However, morpholinos could only be used to transiently reduce gene expression 
and were limited to embryos. Additionally, morpholinos frequently had detrimental 
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off-target effects [37] and, more alarmingly, often failed to phenocopy genomic 
mutants for the same gene target [38]. Another approach for perturbing selected 
gene function was the use of zinc finger nucleases to specifically induce somatic 
mutations in the zebrafish by targeting a nuclease to a desired location. While 
initially promising, the rules of zinc finger protein binding to DNA are incompletely 
understood and zinc finger nucleases did not have the ability to target any 
desired genomic locus [39, 40].  
As a solution, Transcription Activator-Like Effector (TALE) proteins have 
been developed to specifically target genomic regions of interest. TALEs were 
originally identified as injected effectors of the pathogenic plant bacteria 
Xanthomonas. These effectors bind to the promoters of anti-inflammatory genes 
with high affinity and specificity, causing upregulation of these transcripts and 
allowing the bacteria to initiate a productive infection [41]. DNA binding of TALE 
molecules is mediated by a collection of 33-34 amino acid DNA recognition 
binding motifs, where an individual motif recognizes and binds a single nucleotide 
[42, 43]. TALENs, which are the fusion of TALE proteins with the sequence 
independent nuclease FokI, function as obligate heterodimer endonucleases 
where a “left” and “right” TALE protein each recognizes a unique DNA site 
separated by a spacer region [44, 45]. Targeted DNA cleavage by FokI is only 
achieved when both molecules are bound with the correct spacing and 
orientation and are effective in inducing genomic mutations in zebrafish and other 
systems [46, 47]. TALENs induce DNA double strand breaks in the target site 
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that are repaired by host machinery in a process called nonhomologous end 
joining. This process is error prone and often produces small (2-20 base pair) 
genomic insertions or deletions (indels) that, when occuring in coding regions, 
disrupt the coding sequence and can cause premature stops, leading to null 
mutations. 
The il10 locus of zebrafish is on chromosome 12 and consists of 5 coding 
exons. To generate targeted mutations of il10, we used TALENs directed against 
the start of exon 3 (Figure 4.1A). This site was chosen with the guidance of the 
University of Utah Mutation and Detection Core who also designed and 
synthesized the plasmids encoding the left and right TALEN monomers. To 
induce mutation in il10, we synthesized and injected equal amounts of mRNA 
encoding each TALEN monomer into one-cell zebrafish embryos (Figure 4.1B). 
TALEN activity and the presence of mutations were confirmed in our G0 
population using high resolution melt analysis (HRMA) on a portion of the 
injected embryos at 24 hpf. HRMA consists of amplifying small (50-75) bp DNA 
fragments in the presence of a saturating dye such as LCGreen that binds to 
DNA, but is fluorescent only when bound to double-stranded DNA. After the 
amplification, the sample is heated until the two strands fall apart, quenching 
fluorescence. Any changes in DNA sequence result in detectable differences in 
the melt curve. 
 We found that 90% of TALEN-injected embryos showed evidence of 
mutation by HRMA (Figure 4.2A). When our G0 population reached sexual 
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maturity, we outcrossed them to wild type fish to determine if mutations reached 
the germ line and found that 81% of our G0 adults showed evidence of germ line 
mutation transmission. In line with published observations, most G0 founders 
were capable of transmitting multiple mutant alleles. On average, 31% of G1 
progeny had mutation in il10 (range 0-75%). 
 To identify null mutants, we prescreened for il10+/Δ G1 adults with HRMA 
as above and then PCR amplified and Sanger sequenced the TALEN-targeted 
region of il10. Since the individual fish being genotyped were heterozygous for a 
mutant allele, the resulting sequence file starts with a series of single peaks, but 
then turns to multiple peaks at the site of the indel (Fig 4.2B). Using the web-
based Poly Peak Parser software developed by the Yost lab at the University of 
Utah (http://yosttools.genetics.utah.edu/PolyPeakParser/) which separates wild 
type and mutant sequences from each other, we identified G1 individuals with 5 
bp (il10Δ5) and 13 bp (il10Δ13) deletions in the start of exon 3 of il10 (Fig 4.2C). 
 
Use of unlabeled probe melting analysis for  
genotyping of il10 mutant zebrafish 
While the il10 Δ/Δ fish were viable, we decided to maintain our breeding 
adults as heterozygotes to avoid potential complications that the Il10 knockout 
mouse is known to suffer from such as spontaneous colitis [48]. This strategy has 
the additional benefit of providing wild type siblings as controls. However, we 
sought to develop a more robust genotyping protocol because most of our 
experiments would be on 2 dpf embryos and thus impossible to genotype 
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beforehand. As a solution, we developed a genotyping assay using asymmetrical 
PCR combined with unlabeled probe melt analysis (Figure 4.3). Targeting the 
same short amplicon as above, asymmetrical PCR containing an excess of 
forward primer and a limited amount of reverse primer on the opposite strand 
were performed in the presence of LCGreen and a 3’ phosphorylated 
oligonucleotide probe. This results in a major product that is complementary to 
the excess primer. A 30 bp probe that is complimentary to the TALEN-targeted 
region of the major product, but cannot participate in the PCR reaction due to the 
3’ modification which serves as a binding partner during melt analysis. The probe 
either forms a perfect match, in the case of a wild type allele, or a mismatch 
duplex, which can be readily distinguished on the melt curve. 
 We attempted to use TALENs to induce somatic locations in il1β by 
targeting the beginning of exon 3 following the same TALEN procedures as 
above. HRMA of G0 embryos indicated that 88% possessed mutations in the 
TALEN-targeted region. However, when individuals from the G0 population were 
outcrossed to wild type fish, we observed that only 13% of G1 individuals showed 
evidence of mutant allele transmission via the germline. As a result of this low 
germline transmission rate, we were unable to isolate a frame shifting indel in the 




Use of the Tol2kit to generate heat-inducible IL-1β  
and IL-10 transgenic zebrafish lines 
To generate zebrafish lines where expression levels of IL-1β and IL-10 
can be modulated, we used the Tol2kit developed in Kwan et al. (2007). The 
Tol2kit allows for easy vector construction and through the To2 transposon 
features a high efficiency of transgenesis and integration into the germline. 
Vector construction was completed using the three-insert multisite Gateway 
system (Thermo Fisher Scientific), where site-specific att sites from lambda 
phage make it possible to directionally combine multiple fragments or entry 
clones into a destination vector. To mediate inducible gene expression, 1.5 kb of 
the zebrafish hsp70l promoter was combined with a Kozak sequence, the mRNA 
sequence of il1β or il10, and a polyA tail. To be able to visualize the intensity and 
location of transgene expression, we added mCherry connected by a 2A peptide 
self-cleaving peptide, which allows for multiple gene products from a single 
vector to the 3’ end of the expression construct. The hsp70:IL1β-2A-mCherry and 
hsp70:IL10-2A-mCherry expression constructs were recombined into the 
pDestTol2CG2, which features flanking Tol2 transposon ends and an additional 
cmcl2:EGFP-pA cassette which drives EGFP expression in the developing heart 
and functions as a transgene marker (Figure 4.4A). 
To generate the transgenic lines, plasmid DNA for 
pDestTol2CG2(hsp70:IL1β-2A-mCherry) and pDestTol2CG2(hsp70:IL10-2A-
mCherry) was injected into the cell of one-cell stage embryos along with 
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transposase RNA to catalyze transgene insertion. Embryos were visually 
screened for the presence of EGFP expression in the heart at 48 hpf and those 
displaying green hearts were raised to adulthood. The G0 adults were then 
outcrossed to wild type fish to confirm germline transmission. 
 
Validation of Tg(hsp70:IL1β-2A-mCherry) and  
Tg(hsp70:IL10-2A-mCherry) lines 
 Zebrafish are typically maintained at 28.5°C. To functionally confirm our 
Tg(hsp70: IL1β-2A-mCherry) and Tg(hsp70:IL10-2A-mCherry) lines, we placed 2 
dpf G0 embryos at 40°C for 30 minutes to stimulate heat-inducible gene 
expression. After two 30-minute heat shocks in an 8-hour period, we could see 
significant mCherry expression in Tg(hsp70: IL1β-2A-mCherry) (Figure 4.4B) and 
Tg(hsp70:IL10-2A-mCherry) fish (data not shown) at 1 hour following the second 
heat shock. We also demonstrated an increase in il1β transcript levels 1 hour 
post-heat shock in Tg(hsp70:IL1β-2A-mCherry) embryos using qRT-PCR (Figure 
4.4C). Notably, at 12 hours after heat shock il1β levels had returned to a basal 
level, indicating that heat-induced expression was transient.  
 Subsequent generations of the Tg(hsp70:IL10-2A-mCherry) fish displayed 
mosaic cmcl2:EGFP expression and significantly reduced mCherry expression, 
suggesting silencing of the Tol2 insertion site. Despite mCherry expression being 
difficult to discern by eye in 2 dpf embryos following a 6-hour heat shock at 37°C, 
immunoblotting indicated that levels of IL-10 protein were increased 1.85-fold 
(Figure 4.4D). Notably, when wild type embryos were heat shocked under 
 121 
identical conditions, we saw a 50% reduction in IL-10 levels (Figure 4.4D), 
indicating that heat shock alone causes a reduction in IL-10 levels and offering 
an explanation for the lower than expected levels of IL-10 and mCherry 
expression in Tg(hsp70:IL10-2A-mCherry) fish.  
 
Discussion 
 In this chapter, I described the generation of novel zebrafish lines to study 
the biology of IL-1β and IL-10 during infection, inflammation, and other biological 
processes. Using TALENs, I created two mutant lines carrying null mutations in 
IL-10 and subsequently developed a robust and sensitive protocol for genotyping 
these lines using asymmetrical PCR combined with HRMA using a 3’-blocked 
unlabeled probe. Using the Tol2kit, I generated two transgenic lines that place IL-
1β and IL-10 under inducible control and provide a mCherry marker for their 
expression.  
The IL-10 deficient fish will be a valuable tool for the growing community of 
researchers using zebrafish as a model of inflammation and host-microbe 
interactions. Within my own research field, I think these fish will prove informative 
in understanding the complicated role of IL-10 during sepsis. Additionally, given 
the absence of an adaptive immune system in zebrafish embryos, these fish can 
help parse IL-10’s role on the innate immune system from its effects on the 
adaptive immune system. Considering that genetically distinct E. coli strains 
induce divergent levels of il10 (Figure 2.11A), examining these infections in an IL-
10 deficient background and exploring how this affects the behavior of both the 
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host and the pathogen will also be interesting. IL-10 is important for the resolution 
phase of acute inflammation, but also impairs regeneration following injury [13, 
50]. The zebrafish has a unique ability to regenerate many of its tissues 
compared to other vertebrates [51, 52], so the IL-10 deficient fish is well suited 
for determining the specific contexts and cues by which IL-10 impairs 
regeneration. Finally, considering the ease of generating and maintaining 
gnotobiotic zebrafish [53] and the established role of IL-10 in educating the 
immune system to the resident enteric microbiota, the IL-10 deficient fish will be a 
valuable tool for studying the establishment and maintence of gut microbial 
communities, as well as the host immune response to these communities.  
Considering that exogenous IL-10 is being explored as therapy for many 
inflammatory-associated conditions [19], the generation of a zebrafish line where 
IL-10 is placed under inducible control is a valuable tool. Heat induction was 
selected as it is commonly used for gene expression in zebrafish and other 
systems [54]. However, at the time I constructed the lines, I did not appreciate 
that the use of heat induction in the context of infection and inflammation is 
problematic.  Fever is an evolutionarily conserved response and in ectothermic 
organisms such as fish, where body temperature is dependent on external 
sources, a behavioral fever or acute preference for warmer temperatures is often 
present following infection [54]. Behavioral fever also has a functional benefit 
following infection. Carassius auratus (goldfish) maintained at an increased 
temperature have a higher survival rate following infection with Aeromonas 
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hydrophila. Behavioral fever also specifically affects the immune response, as 
demonstrated in Oncorhynchus mykiss (rainbow trout). Following injection with 
LPS, fish show an increased preference for warmer temperatures and notably, 
possess higher levels of IL-1β at the increased in temperature compared to fish 
maintained at the homeostatic temperature [55-59]. There is even evidence of 
heat shock affecting the immune response in zebrafish, where increased 
neutrophil mobilization but decreased neutrophil recruitment to the site of 
Streptococcus iniae infection or tail injury is seen following heat shock [59]. 
These muddling effects of heat shock on the immune response, combined with 
the suboptimal induction of IL-1β and IL-10 requiring extended and repeated heat 
shocks, have led to limited utility for the Tg(hsp70:IL1β-2A-mCherry) and the 
Tg(hsp70:IL10-2A-mCherry) lines. 
 
Materials and Methods 
Ethics statement 
Animals used in this study were handled in accordance with University of 
Utah and IACUC-approved protocols following standard guidelines described at 
www.zfin.org and in the Guide for the Care and Use of Laboratory Animals, 8th 
Edition. 
 
Zebrafish stock and embryo maintenance 
Zebrafish were maintained as breeding colonies on a 14-h/10-h light/dark 
cycle. Embryos were collected as mixed egg clutches and raised at 28.5°C in E3 
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medium (5 mM NaCl, 0.27 mM KCl, 0.4 mM CaCl2, 0.16 mM MgSO4; pH 7.4) 
containing 0.000016% methylene blue as an antifungal agent.  
 
TALEN target site and assembly 
The exon sequence for IL10 was scanned for potential TALEN target sites 
as described in [47]. Once a target site was identified, pCS2TAL3-IL10-TALEN-
DD and pCS2TAL3-IL10-TALEN-RR encoding the left and right TALEN, 
respectively, were constructed by the University of Utah Mutation and Detection 
Core using a modified TALEN Golden Gate assembly system as in [60]. 
 
Injection of TALEN-encoding RNA into zebrafish embryos 
5’-capped mRNA encoding the left and right TALEN was generated from 
NotI-linerized pCS2TAL3-IL10-TALEN-DD and pCS2TAL3-IL10-TALEN-RR by in 
vitro transcription (mMessage mMachine SP6 kit; Invitrogen).  mRNA was diluted 
to 50 ng/µl and 1 nl of this solution injected into one-cell stage embryos. 
 
Genomic DNA extraction 
Genomic DNA was extracted from embryos and the fins of adult fish by 
boiling for 20 min at 95°C in 50 mM NaOH followed by neutralization in 1M Tris-
HCl (pH 8.0). Samples obtained from adult fins were then centrifuged at 12,000 





HRMA was used to detect TALEN-induced mutations. A 92 bp amplicon 
surrounding the target site was PCR-amplified in a 10 µl reaction using LCGreen-
containing LightScanner Master Mix (Biofire) according to the manufacturer’s 
directions. Melt data were collected on a LightCycler480 (Roche) or LightScanner 
(Biofire). 
 
Unlabeled 3’-blocked HRMA 
Asymmetrical PCR targeting the same genomic region as above and using 
LightScanner Master Mix was performed using 5 pmol forward primer, 1 pmol 
reverse primer, and 4 pmol unlabeled probe. Melt data were collected on a 
LightCycler480 (Roche). 
 
Construction of pME(IL1β) and pME(IL10) 
pME entry clones were generated as described in the Invitrogen MultiSite 
Three-Fragment Gateway manual. Briefly, att sites were added to the mRNA 
sequence of IL-1β (NM_212844.1) or IL-10 (NM_001020785.2) via PCR with 
Phusion High Fidelity Taq (NEB Biosciences). PCR products were then gel 
purified and 100 fmoles added to a BP recombination reaction with 150 ng 
pDONR221. Completed reactions were transformed into DH5alpha cells and 
resulting colonies prepped and sequence verified using the M13 primer site built 




Construction of pDestTol2CG2(hsp70:IL1β-2A-mCherry) and 
pDestTol2CG2(hsp70:IL10-2A-mCherry) 
Expression constructs were generated following the protocols described in 
the Invitrogen MultiSite Three-Fragment Gateway manual. 20 fmol of either 
p5E(hsp70v3), pME(il1β), and p3E(2A-mCherry) or p5E(hsp70v3), pME(il10), 
and p3E(2A-mCherry) were combined into an LR recombination reaction with 20 
fmol pDestTol2CG2. Completed reactions were transformed into OneShot 
Chemically Competent Top10 and verified by restriction digest. 
 
Injection of pDestTol2CG2(hsp70:IL1β-2A-mCherry) and 
pDestTol2CG2(hsp70:IL10-2A-mCherry)  
into zebrafish embryos 
5’-capped transposase RNA was generated from pCS2FA-transposase by 
in vitro transcription (Invitrogen mMessage mMachine SP6 kit). 25 pg 
transposase RNA and 25 pg plasmid DNA for each expression construct were 
co-injected into the cell of one-cell stage embryos.  
 
RNA isolation from zebrafish embryos 
Pools of 15-20 embryos were manually homogenized in 1 ml QIAzol Lysis 
Reagent (Qiagen) and total RNA extracted using the Qiagen RNeasy Plus 
Universal Kit according to the manufacturer’s instructions. Genomic DNA was 




cDNA synthesis and qRT-PCR 
cDNA was synthesized from 2 μg of RNA using the SuperScript III First-
Strand Synthesis System (Invitrogen) in a 20 μl reaction volume. Following 
assembly of the master mix according to manufacturer instructions, samples 
were incubated at 25°C for 5 min, 55°C for 45 min, and 70°C for 15 min. 
Complimentary RNA was then removed by addition of RNase H (Invitrogen) for 
15 min at 37°C. 
 qRT-PCR was performed on a LightCycler 480 instrument (Roche) 
following manufacturer recommendations. Cycling parameters were 95°C for 8 
min to activate the polymerase followed by 40 cycles of 95°C for 4 sec, 60°C for 
6 sec, and 72°C for 6 sec. Fluorescence measurements were taken at the end of 
each cycle. Melt curve analysis was performed to ensure that no primer dimers 
were amplified. All reactions were performed in technical duplicate. Sequences 
for the forward and reverse primers are listed in Table 2.3. Results were 
normalized to transcript levels of the housekeeping gene ef1α (elongation factor 
1-alpha) using ΔΔCt analysis.  
 
Detection of IL-10 protein in zebrafish embryos 
Zebrafish embryos were homogenized in PBS using a Bullet Blender 
Storm 24 (Next Advance). Following BCA to determine protein concentration, 
samples were diluted accordingly in 5X sample buffer and boiled for 5 min at 
95°C. Samples were then immunoblotted against IL-10 (Abbiotec; 1:200) or β-
actin (Abcam; 1:1000) as in [47]. 
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Imaging zebrafish embryos 
Zebrafish embryos were imaged using a fluorescent Olympus SZX10 
stereomicroscope equipped with an Olympus DP72 camera.  
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Table 4.1. Oligonucleotides used in Chapter 4. 
 
Primer Sequence (5’-3’) 
zIL10 HRMA  
 Forward TCTTGTGTGTATTATCAACAGAGTCC 




zIL10 Sequencing  
 Forward TGGGTGTCTGAAACAGCAGA 
 Reverse CACCATATCCCGCTTGAGTT 
pME(IL1β)  
 Forward (attB1) GGGGACAAGTTTGTACAAAAAAGCAGGCTCCACCA
TGGCATGCGGGCAATATGAAGT 
 Reverse (attB2) GGGGACCACTTTGTACAAGAAAGCTGGGTCGATGC
GCACTTTATCCTGCAGCTC 
pME(IL10)  
 Forward (attB1) GGGGACAAGTTTGTACAAAAAAGCAGGCTCCACCA
TGATTTTCTCTGGAGTCATCCTT 
 Reverse (attB2) GGGGACCACTTTGTACAAGAAAGCTGGGTCGTGCT
TAACCCTCTTTGAGGCT 
zIL1β  
 Forward TGGACTTCGCAGCACAAAATG 
 Reverse CACTTCACGCTCTTGGATGA 
zEF1α  
 Forward TGAGCGTGGTATCACCATTG 



























































































































































































































































































































































































































Figure 4.2. Identification of il10Δ5 and il10Δ13 alleles.
(A) HRMA from G0 embryos showing differences between the melt curves of 
TALEN-injected and uninjected siblings, indicating mutations in the targeted region 
of il10.
(B) Sanger sequencing chromatogram from a G1 il10+/Δ fish. Multiple peaks appear 
at the mutation site (arrow) due to the presence of a wild type and mutant allele. 
The Poly Peak Parser is able to separate this into two separate sequences and 
identify unknown indels.
(C) Sequence alignment of wild type il10, il10Δ5 and il10Δ13.


























Figure 4.3. Unlabeled probe melt analysis for genotyping of IL10 mutant 
]HEUDÀVK
Asymetrical PCR containing 5x forward primer, 1x reverse primer, and 4X 
Xnlabeled 3’-blocked probe LV perIorPed Ln WKe preVence oI /&*reen TKe e[ceVV 
oI IorZard prLPer enVXre WKaW WKe PaMor prodXcW ZLll be coPplePenWar\ Wo WKe 
probe ZKLcK cannoW parWLcLpaWe Ln WKe reacWLon dXe Wo WKe 3’ PodLÀcaWLon 'XrLnJ 
PelW anal\VLV ZLld W\pe alleleV ZKLcK IorP a perIecW dXple[ ZLWK WKe probe can 
be readLl\ dLVWLnJXLVKed IroP PXWanW alleleV ZKLcK ZLll IorP a PLVPaWcK dXple[ 
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Figure 4.4. Use of the Tol2kit to generate heat-inducible IL-1β and IL-10 
transgenic zebrafish lines.
(A) Diagram of completed Tg(hsp70:IL1β-2A-mCherry) and Tg(hsp70:IL10-2A-
mCherry) expression constructs.
(B) Representative fluorescent image of a Tg(hsp70:IL1β-2A-mCherry) embryo
before and after two 30 min heat shocks at 40°C within an 8-hour period. Images
taken shortly after second heat shock.
(C) qRT-PCR analysis of il1β levels in wild type and Tg(hsp70:IL1β-2A-mCherry)
embryos. Each bar represents mean results ± SEM from 2 pools of ≥16-20
embryos. qRT-PCR for each pool was carried out using technical duplicates.
(D) Immunoblot of IL-10 in wild type and Tg(hsp70:IL10-2A-mCherry) embryos
following a 6-hour heat shock at 37°C. β-actin blot is provided as a control to show
equal protein loading.
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Sepsis is a life-threatening systemic inflammatory condition. Compounding 
the burden of sepsis is its high degree of patient heterogeneity, making it 
notoriously difficult to effectively diagnose and manage. Much of this variability in 
disease progression has been attributed to differences in host background and 
immune status. Research presented within this dissertation challenges this belief 
by demonstrating in a novel zebrafish model of sepsis that genetically distinct E. 
coli strains can trigger divergent host responses, including markedly different 
levels of inflammatory mediators. These variances correlate with the amount of 
bacterial flagellin expression during sepsis, as well as differential activation of 
TLR5 by discrete flagellar serotypes (Figure 5.1). Altogether my doctoral 
research establishes zebrafish as a relevant model for key aspects of human 
sepsis and highlights a previously unappreciated ability of genetically distinct E. 
coli strains to induce divergent host responses independent of baseline host 
attributes, and implicates bacterial flagellin as a key mediator of inflammation 
during sepsis. 
In Chapter 2, I presented the zebrafish as a relevant model for the study of 
sepsis by demonstrating that infected embryos display signs and pathologies of 
sepsis, including tachycardia, endothelial leakage, progressive subcutaneous 
edema, and cutaneous lesions. Embryos also show transcriptional profiles that 
are equivalent to those seen in human patients, including marked upregulation of 
pattern recognition receptors, immune signaling cascades, and downstream 
inflammatory mediators. Reiterating what is seen clinically, timely administration 
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of antibiotics that curtail bacterial growth within the zebrafish is critical, but only 
helpful to a point and delays in antibiotic delivery lead to significantly enhanced 
mortality. My doctoral research also adds new insight to the field’s understanding 
of sepsis, demonstrating that distinct pathologies and divergent host 
transcriptional responses are seen in response to genetically distinct ExPEC 
strains. Specifically, I found marked differences in the levels of pro-inflammatory 
cytokines including IL-1β and IL-8, the antimicrobial peptides Serum amyloid A1 
and Hepciden, and also in anti-inflammatory mediators such as IL-10 during 
infection with these strains. Chapter 2 also presented novel observations 
regarding the fact that despite similar in vitro drug sensitivities, the window during 
which antibiotic therapy can effectively rescue fish from a lethal infection can vary 
greatly. Together these findings help explain the problematic variability seen 
during sepsis and why patients frequently do not present or respond to treatment 
homogenously.  
ExPEC strains often vary by up to 30% of their gene content and have 
almost unlimited access to new genetic material due to repeated horizontal gene 
transfer [1-3]. Given this extensive genomic diversity, the results presented here 
are likely just the tip of the iceberg in terms of how ExPEC strains differentially 
and uniquely influence the host response during sepsis. For example, the 
mechanism by which F11 induces the formation of tissue protrusions not 
observed during infection with CFT073 remains unresolved. Though a number of 
immunomodulatory genes (e.g., TcpC which antagonizes host TLR signaling and 
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YbcL which suppresses neutrophil migration [4, 5]) have been characterized in 
ExPEC strains, there are assuredly myriad other factors that influence the host 
response within the plastic E. coli pan-genome. Given the tractability of zebrafish 
to forward bacterial genetic screens [6-8], the zebrafish sepsis model has utility in 
identifying novel ExPEC virulence factors required for survival in the bloodstream 
during sepsis as well as those that modulate host response(s). 
Exploration into the mechanism by which two ExPEC reference strains, 
CFT073 and F11, trigger distinct host responses in Chapter 3 implicated bacterial 
flagellin as a key modulator of inflammation during sepsis. This is mediated via 
variable levels of flagellin expression during infection and the unique observation 
that distinct flagellar serotypes can differentially activate TLR5. The realization 
that different versions of flagellin elicit varying host responses suggests that 
some bacteria may utilize flagella as immunomodulators, expanding their function 
beyond motility. There are currently 56 characterized H (flagellar) antigens in E. 
coli [9], but the contributions of these different variants to TLR5 activation and 
downstream host responses remain largely unknown. Additionally, the specific 
residue or domains that mediate the ability of these flagellin variants to 
differentially stimulate TLR5 is an interesting and relevant question worth 
following up on and may open the door to engineered flagellin variants with 
therapeutic value in regulating host inflammatory responses.  
Observations regarding variable levels of IL-1β and IL-10 recorded during 
sepsis in our model and human patients [10-15] and the lack of available tools to 
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study these molecules in zebrafish led to the creation of three novel lines. 
TALENs were used to induce mutations in il10 and two mutant alleles, il10Δ5 and 
il10Δ13, were identified to produce an IL-10 deficient zebrafish. Though these 
lines have not yet been tested phenotypically, I see their utility in further 
understanding the complicated role of IL-10 during sepsis as well as further 
delineating the impact of IL-10 on regeneration, colitis, and the microbiota. 
Despite unsuccessful efforts to generate an IL-1β	 deficient fish, I still think the 
creation of this line would be useful given the role of this cytokine	 in many 
inflammatory disorders and metastasis. 
The findings from my doctoral research (summarized in Figure 5.1) can be 
applied in the future to better diagnosis and treatment of sepsis. The incidence of 
sepsis is increasing rapidly and hospitalization rates for sepsis have more than 
doubled since 2000 [16]. One of the key issues concerning sepsis is the 
heterogeneity seen in the patient population. Understanding that infections 
caused by the same bacterial species may present with different pathologies and 
induce variable host responses will hopefully aid in the earlier diagnosis of 
sepsis, one of main goals of the “Survive Sepsis Campaign” [17]. Earlier 
detection of sepsis will help to lower the unacceptably high mortality rate 
associated with the disease. It will also relieve some of the financial burden 
placed on the healthcare system by sepsis, where the average sepsis admission 
costs more than $20,000 and adds up to over $20 billion dollars per year in the 
US alone [18]. The variability seen in sepsis has resulted in a lack of satisfactory 
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biomarkers for its diagnosis. Further study on how different microbes contribute 
to differences in host response during sepsis may lead to the identification of 
novel panels of biomarkers that are tailored to specific infecting microbes or even 
subgroups within a single microbial species. The conclusions of my dissertation 
can also potentially be applied more directly to the treatment of sepsis, where 
determining the flagellar serotype present during E. coli sepsis or assessing 
levels of flagellin in blood could prove to be a useful tool for informing treatment 
choices. Finally, the introduction of the zebrafish model for sepsis will also 
provide a useful platform for the examination of cellular processes during sepsis 
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Figure 5.1. Model and summary.
During sepsis, extraintestinal pathogenic Escherichia coli strain F11 produces 
high levels of a very immunostimulatory flagella, leading to a robust transcriptional 
response and a higher level of inflammatory mediators compared to other E. coli 
strains. Infection with this strain also induced the formation of tissue protrusions 
and was more responsive to treatment with ciprofloxacin. In contrast, strain 
CFT03 produces lower levels of a less immunogenic flagella, resulting in a smaller 
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Acute cystitis is one of the most commonly encountered bacterial infections and is responsible for substantial
morbidity and high medical costs in the United States and across the globe. Though generally considered to be
self-limiting and easily treated with antibiotics, urinary tract infections (UTIs) are often incompletely resolved
by antibiotic therapy and frequently recur. This is in part due to the ability of uropathogenic bacteria to
invade, replicate, and persist within host epithelial cells. The biological complexity of these infections combined
with a dramatic rise in antibiotic-resistant pathogens highlight the need for alternative therapies. In this review
we examine current management strategies for UTIs, as well as emerging treatments, including novel com-
pounds that block bacterial interactions with the urothelium and vaccines focused on preventing both acute
and recurrent infections.
Keywords. UPEC; antibiotic resistance; vaccine; cystitis; recurrent UTI.
A urinary tract infection (UTI) is deﬁned as microbial
inﬁltration of the otherwise sterile urinary tract and is
one of the most common bacterial infections world-
wide. UTIs encompass infections of the urethra (ure-
thritis), bladder (cystitis), ureters (ureteritis), and
kidney (pyelonephritis). There is an estimated annual
occurrence of well over 8 million UTIs in the United
States, many of which result in a visit to a physician [1].
Nearly all patients with UTI are prescribed a regimen
of antibiotics, with roughly 1% of patients requiring
hospitalization. The annual cost of UTI treatment in
the United States is estimated at $2.14 billion [2], a
value compounded by the frequency of recurrent infec-
tions. In this review we discuss the epidemiology of
acute and recurrent UTIs, detail current management
strategies, and explore emerging therapeutics.
EPIDEMIOLOGYOF UTIs
UTIs are the most frequent bacterial infection seen in
the outpatient setting: 1 in 3 women will develop a UTI
requiring antibiotic treatment by age 24, and 50% expe-
rience at least 1 UTI during their lifetime [1]. The inci-
dence of cystitis is signiﬁcantly higher in women than
men, likely the result of anatomic differences. Speciﬁ-
cally, the shorter female urethra can facilitate bacterial
transit from the urethral opening to the bladder. Colo-
nization of the vaginal introitus by gastrointestinal
pathogens can also increase the likelihood of urinary
tract inﬁltration [3, 4]. Other factors, including urinary
tract obstruction, incomplete voiding, and aberrant
structural anatomy also predispose individuals to UTIs.
Additional risk factors include prior history of UTIs,
vaginal intercourse within the past 2 weeks, use of con-
traception with spermicide, low vaginal estrogen lev-
els [1, 5], and individual genetic background (extensively
reviewed in [6]). While a number of comorbidities in-
crease susceptibility to UTI, the majority of UTIs occur
in otherwise healthy women.
The most common bacterial cause of uncomplicated
community-acquired UTI is uropathogenic Escherichia
coli (UPEC), representing >80% of infections [1]. These
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 bacteria inhabit the lower intestinal tract of warm-blooded ver-
tebrates where they lead a seemingly innocuous existence until
they gain access to a niche, such as the urinary tract, where they
can cause disease. Other pathogens commonly associated with
uncomplicated UTI include Staphylococcus saprophyticus, Kleb-
siella species, Proteus mirabilis, and Enterococcus faecalis [7].
One of the more ominous issues on the horizon for bacterial
infections, with UTIs being no exception, is the rise of antibiot-
ic-resistant organisms. One especially troubling example is the
heightened incidence of sequence type 131 (ST131) strains of
UPEC around the world. These strains often exhibit high levels
of resistance to multiple antibiotics and have undergone rap-
id intercontinental dispersal over the last decade [8]. ST131
strains are an increasingly common cause of community-acquired
UTIs, spurring efforts to better identify and treat these resilient
pathogens [8, 9]. Factors driving the global spread of ST131
strains are incompletely understood, but likely include the ac-
quisition of antibiotic resistance genes, such as those encoding
extended-spectrum β-lactamases (ESBLs), and the capacity to
effectively utilize a broad range of metabolites [8, 10]. These
characteristics may give ST131 strains a competitive advantage
within host environments, increasing the likelihood of their
dissemination within and between individuals.
RECURRENT UTIs AND INTRACELLULAR
BACTERIAL RESERVOIRS
The burden of UTIs is compounded by their high rate of recur-
rence. Recurrent UTI (rUTI)—deﬁned as 2 uncomplicated
infections in a 6-month time period or 3 infections within a
year—cause a tremendous amount of morbidity and are frustrat-
ing to patients and physicians alike [1]. Despite administration
of antibiotics that seemingly clear the infection (determined by
negative urine cultures), the probability that a patient will
develop a second UTI within 6 months is 25%, with the chance
of recurrence over a 12-month period increasing to 46%. The
historical view of rUTI pathogenesis is that each recurrence
represents an independent inoculation of the urinary tract.
However, this model does not satisfactorily explain many
(>50%, by some estimates) rUTI episodes in which the bacterial
strains responsible for both the initial infection and the recur-
rence are genetically identical [11]. An alternative mechanism
for recurrence involves the establishment of protected, intracel-
lular bacterial reservoirs within the bladder mucosa (Figure 1).
UPEC can invade host epithelial cells, including the termi-
nally differentiated superﬁcial umbrella cells that line the
lumen of the bladder, as well as the underlying, immature
Figure 1. Events that promote the establishment and recurrence of urinary tract infection (UTI). (1) During a UTI, uropathogenic Escherichia coli (UPEC;
green) can replicate within the lumen of the bladder or (2) attach to and invade bladder epithelial cells. (3) Following invasion, UPEC is either shuttled back
out to the lumen or trafﬁcked into late endosome-like compartments. (4) Disruption of these compartments and subsequent entry of UPEC into the host
cytosol allows for rapid intracellular bacterial growth and the development of intracellular bacterial community. During these events, UPEC can acquire al-
ternate morphologies, including the formation of long, ﬁlamentous cells that are resistant to host defenses such as neutrophils. (5) Infection can trigger the
exfoliation of bladder cells, a process that aids in the elimination of adherent and internalized bacteria. The efﬂux of UPEC from host bladder cells, includ-
ing those undergoing exfoliation, facilitates pathogen dissemination within and between hosts. (6) UPEC that remains bound within late endosome-like
compartments in the urothelium can establish long-lived intracellular quiescent reservoirs that are often enmeshed within actin ﬁlaments (red) and ex-
tremely difﬁcult to eradicate with antibiotic treatments. The resurgence of UPEC from these reservoirs can initiate recrudescent infections. Abbreviation:
IBC, intracellular bacterial community.




intermediate and basal cells [12]. Within superﬁcial bladder
cells, UPEC can enter the host cytosol and rapidly multiply,
forming a bioﬁlm-like assembly known as an intracellular bac-
terial community (IBC) [12, 13]. The development of IBCs can
enhance the ability of UPEC to establish itself within the
urinary tract, building up large numbers of bacteria while se-
questered away from the ﬂow of urine and the inﬂux of inﬂam-
matory cells and antibacterial molecules. IBCs, however, are
not long-lived and will eventually disperse or be shed along
with the infected host cells [14]. Indeed, the remnants of IBC-
containing host cells can be detected in urine samples isolated
from women seeking treatment for UTIs [3]. The efﬂux of
UPEC from within IBCs, as well as the eventual exfoliation of
the infected superﬁcial cells, may potentiate the dissemination
of UPEC both within the urinary tract and between hosts.
Rather than forming an IBC, UPEC can enter a dormant
state within host epithelial cells after trafﬁcking into mem-
brane–bound compartments that become enmeshed within
host actin ﬁlaments [12]. The quiescent nature and intracellular
localization of these bacteria renders them resistant to most an-
tibiotics and inaccessible to inﬁltrating neutrophils and other
host defenses [13, 14]. Experimental models indicate that these
quiescent intracellular UPEC reservoirs can persist for long
periods in the absence of any overt clinical symptoms, even
with the use of antibiotic treatments that effectively sterilize the
urine [14]. Environmental signals, such as the reorganization of
actin ﬁlaments that occurs as bladder cells undergo terminal
differentiation, can trigger the resurgent growth of UPEC,
prompting the development and dispersal of IBCs and the rein-
itiation of clinical symptoms. According to this model, rUTIs
may in many instances be more accurately deﬁned as recrudes-
cent infections. These issues highlight the need for therapeutic
strategies that effectively target both active and dormant stages
of UTI.
CURRENTMANAGEMENTOF UTIs
Initial diagnosis of acute uncomplicated cystitis is typically
based on patient medical history, taking into account past indi-
vidual and family health issues, sexual activity, and current
symptoms. Common indicators of acute cystitis include urinary
urgency and frequency, pain when voiding (dysuria), lower ab-
dominal discomfort, and cloudy or dark urine. The diagnosis
of patients presenting with these classic symptoms may be con-
ﬁrmed by urinalysis showing the presence of red blood cells,
high nitrite levels, and leukocyte esterase in the urine.
Although medical history and urinalysis are sufﬁcient for the
diagnosis of most uncomplicated UTIs, the gold standard for
diagnosis of acute cystitis includes a bacteriological urine
culture with identiﬁcation of the causative agent and antimicro-
bial susceptibility testing. Using fresh, midstream urine, clinical
conﬁrmation of an uncomplicated UTI is classically deﬁned as
≥105 colony-forming units (CFU)/mL of urine. However, this
deﬁnition has recently been modiﬁed based on observations
that many uropathogens are capable of eliciting clinical pathol-
ogy in the urinary tract even with low levels of bacteriuria [1].
Consequently, as little as 103 CFU/mL urine, in the presence of
overt UTI symptoms, is now considered sufﬁcient for diagnosis
of acute cystitis [15]. Current recommended treatments for
acute uncomplicated cystitis are described in Table 1 [1, 16].
Treatment of rUTI
For women who suffer from rUTI, low-dose antibiotic prophy-
laxis such as nitrofurantoin (100 mg per day), cephalexin (250
mg daily) or trimethoprim-sulfamethoxazole (40 mg/200 mg
daily) can provide symptomatic relief and protection against
subsequent infections [17]. For women whose UTIs are coinci-
dent with sexual activity, a single, postcoital prophylactic antibi-
otic can be effective in preventing infections [18]. Self-initiated
antibiotics are also useful for women with frequent recurrent
infections. After diagnosing themselves based on symptoms
and/or a urine dipstick, they can initiate a 3-day regimen
without needing to visit a physician [18].
The increasing prevalence of antibiotic-resistant uropatho-
gens is likely to limit the effectiveness of our current antibiotic
arsenal. For example, individuals who suffer from serious re-
current or chronic UTIs due to ESBL-producing ST131 strains
may beneﬁt greatly from carbapenems such as ertapenem [9],
but these antibiotics are considered one of our last lines of
defense and so should be used cautiously. The ongoing emer-
gence of antibiotic-resistant strains, in conjunction with the
high frequency of rUTIs, highlights the need for a better under-
standing of these infections and the development of new thera-
peutic strategies.
EMERGING THERAPIES
As noted above, many rUTIs are thought to arise from the
ability of bacteria to attach to and invade the bladder mucosa,
where they can form intracellular reservoirs protected from an-
tibiotics and host defenses. As such, many emerging treatments
for UTIs are aimed at blocking adhesion of bacteria to the
urothelium and thereby preventing the establishment of trou-
blesome reservoirs. Type 1 pili (or ﬁmbriae), which are multi-
protein ﬁlamentous adhesive structures encoded by virtually all
UPEC isolates, are generally indispensible for colonization of
the urinary tract [11]. The adhesin protein FimH, which is lo-
calized at the distal tip of each type 1 pilus, binds mannose resi-
dues on host glycoprotein receptors and allows UPEC to
adhere to and invade host bladder cells [19]. Type 1 pili also
promote bioﬁlm formation and the development of IBCs [20].
Because type 1 pili are important colonization factors, the




therapeutic potential of inhibiting the assembly or function of
these adhesive organelles has received considerable attention.
Pilicides and Mannosides
The assembly of type 1 pili occurs through the chaperone-
usher pathway, relying on the periplasmic chaperone FimC for
the stabilization, folding, transport, and assembly of pilus sub-
units [21]. Small synthetic molecules known as pilicides, which
are designed to target periplasmic chaperones and consequent-
ly interfere with pilus assembly, provide an attractive approach
for blocking bacterial adhesion and subsequent reservoir for-
mation. In vitro, pilicides effectively inhibit pilus biogenesis, re-
ducing UPEC adherence to bladder epithelial cells as well as
type 1 pili–dependent bioﬁlm formation [22, 23]. The efﬁcacy
of pilicides in animal infection models has not been reported.
Researchers have also speciﬁcally targeted the FimH adhesin
by use of soluble receptor analogues, or mannosides, that act as
antiadhesives. These molecules bind FimH and prevent it from
interacting with host receptors [24]. Recently, orally available
mannoside derivatives have been developed that show great
promise as therapeutics [25, 26]. In a murine UTI model, these
agents work prophylactically, preventing bacterial invasion into
bladder tissue [26]. They can also be used to treat established
and catheter-associated infections, acting synergistically with
standard antibiotic treatments to reduce UPEC titers within the
urinary tract of infected mice [27].
Both mannosides and pilicides have exciting potential as
future therapies for the treatment of uncomplicated cystitis and
rUTI, and both types of reagents may help circumvent the
rising tide of antibiotic-resistant organisms. However, one po-
tential concern with the systemic administration of either man-
nosides or pilicides is potential adverse effects on commensal
E. coli strains and other members of the intestinal microbiota,
many of which also express type 1 pili [28]. Current thinking
by many in the ﬁeld is that use of pilicides and mannosides will
likely be less disruptive than current antibiotic treatment proto-
cols, but this supposition requires additional investigation.
Vaccinology
An alternate strategy for the prevention of recurrent and
chronic UTIs is the development of systemic or mucosal vac-
cines. Over the past 20 years, several vaccination approaches
have been explored, including the use of heat-killed whole bac-
teria, bacterial cell extracts, and puriﬁed UPEC-associated viru-
lence factors as antigens. Vaccination of women using a vaginal
suppository containing 10 heat-killed strains of uropathogenic
bacteria showed much promise in recent years [29, 30]. This
multivalent vaccine formulation, known as Solco Urovac, in-
cluded 6 E. coli strains plus 1 strain each of P. mirabilis,
Morganella morganii, Klebsiella pneumoniae, and E. faecalis.
Urovac passed phase 2 clinical trials and was shown to reduce
the incidence of UTI caused by E. coli in sexually active women
Table 1. Common Treatment Options for Uncomplicated Cystitis
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400 mg, once daily for 3–7 d Low resistance rates and risk
of adverse side effects. Not
available in North America
The choice of antibiotics should be made after considering patient allergy and compliance history, local resistance rates, drug availability, and cost.
Fluoroquinolones such as ciprofloxacin are highly effective and can be given if none of the recommended antimicrobials can be used. However, resistance rates to
these drugs are on the rise and it is recommended that they be reserved for conditions other than acute cystitis. β-lactam antibiotics, such as amoxicillin, cefdinir,
cefaclor, or cefpodoximine, in 3- to 7-day treatment regimens can be given when other recommended agents cannot be used. However, β-lactam antibiotics have
inferior efficacy and a higher rate of resistance, particularly in ST131 strains. Ampicillin should not be used because it displays relatively poor efficacy in the
treatment of urinary tract infections and resistance rates to ampicillin are typically high.




between 20 and 50 years of age with histories of rUTI [29].
Although some individual patients in the study showed increas-
es in anti–E. coli antibody levels, no statistically signiﬁcant dif-
ferences between vaccinated and placebo control groups were
detected, possibly accounting for the lack of any follow-up
phase 3 trials.
Speciﬁc bacterial factors that have been targeted as vaccine
candidates for UTI include the type 1 pilus–associated adhesin
FimH and UPEC-associated iron acquisition systems. Like pili-
cides and mannosides, antibodies directed against FimH can
interfere with the functionality of type 1 pili, disrupting the
ability of UPEC to colonize the urinary tract. Vaccination with
puriﬁed FimH coupled to its periplasmic chaperone FimC
offered protection against UPEC when administered systemi-
cally in both murine and primate models of cystitis [31–33]. A
similar vaccine containing a truncated version of FimH protect-
ed mice from experimentally induced cystitis when given by
either intramuscular or intranasal (mucosal) inoculation, using
CpG oligonucleotides as adjuvant [34].
Most bacteria require iron for survival, and while there is
ample iron in the human body, it is sequestered and generally
inaccessible to bacteria. Consequently, UPEC and many other
pathogenic bacteria rely upon iron-chelating molecules and re-
ceptors that enable them to scavenge essential iron from the
host [35]. Use of puriﬁed bacterial iron receptor proteins for
vaccination against UPEC has had mixed results. Of 7 UPEC-
associated iron receptors tested as vaccines in mice, 2 (IreA and
LutA) provided signiﬁcant protection against experimentally
induced cystitis [36]. Vaccination with another iron receptor,
Hma, protected against kidney infection, but not cystitis. For
this analysis, the puriﬁed iron receptors were delivered intrana-
sally after being conjugated to cholera toxin to increase antige-
nicity.
In total, these studies highlight both FimH and iron recep-
tors as potentially valuable vaccine candidates that merit
further investigation. However, as with mannosides and pili-
cides, the use of puriﬁed iron receptors, FimH, or other UPEC-
associated factors as vaccines may have inadvertent effects on
members of the endogenous microbiota that should be consid-
ered. In addition, the route of vaccine delivery and the types of
adjuvants utilized need to be optimized for maximal efﬁcacy
in humans. While individuals prone to recurrent or chronic
UTIs may beneﬁt greatly from the development of anti-UPEC
vaccines, the costs and risks of this strategy require further
evaluation.
Despite these hurdles, initial success in the development of
anti-UPEC vaccines has spurred the search for additional
vaccine antigens. Candidate approaches, in which known viru-
lence factors such as ﬂagellin are targeted, continue to generate
promising results [37], but less biased methods that are not nec-
essarily reliant on our limited understanding of UTI
pathogenesis may prove more fruitful. Along these lines, re-
searchers have developed in silico approaches, known collec-
tively as reverse vaccinology, to probe the increasingly large
number of sequenced bacterial genomes for pathogen-speciﬁc,
surface-localized antigens [38, 39]. These traits in a vaccine
antigen should increase the efﬁcacy of antibody responses
while limiting cross-reactivity with nonpathogenic bacteria.
This approach to vaccine design is encapsulated in a publicly
available, Web-based system known as Vaxign (http://www.
violinet.org/vaxign/). By screening for outer membrane pro-
teins with amino acid sequences that are conserved among
UPEC isolates, but absent from nonpathogenic E. coli strains as
well as humans and mice, Vaxign identiﬁed 22 putative UPEC-
speciﬁc vaccine targets [40]. Several of these are functionally
undeﬁned, and a few are known to be expressed by UPEC
during UTI, but to date none have been shown to protect
against cystitis. The reﬁnement of reverse vaccinology, coupled
with gene expression proﬁling, proteomic analyses, and emerg-
ing high-throughput genetic screens, promises to greatly
enhance our ability to identify useful vaccine targets.
CONCLUSIONS
Although UTIs are often considered to be easily managed in-
fections, they remain a huge burden for millions of individuals
and our healthcare system. The increasing prevalence of antibi-
otic resistance among uropathogens presents a major challenge
to the clinical management of UTIs. Recurrent infections, in-
cluding those caused by antibiotic-sensitive pathogens, are ex-
ceptionally common and are likely attributable in part to the
establishment of recalcitrant intracellular bacterial reservoirs
within the bladder mucosa. Eradication of these clinically rele-
vant reservoirs will require a better understanding of the under-
lying molecular mechanisms that allow for their persistence.
The ongoing development of new antimicrobial approaches,
such as the use of pilicides and mannosides in conjunction
with antibiotics, will provide new treatment options, while the
identiﬁcation of new vaccine candidates and optimized vacci-
nation protocols promises relief to individuals who suffer from
recurrent or chronic UTI.
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SUMMARY
Urinary tract infections (UTIs) are some of the most common
bacterial infections worldwide and are a source of substantial
morbidity among otherwise healthy women. UTIs can be caused
by a variety of microbes, but the predominant etiologic agent of
these infections is uropathogenic Escherichia coli (UPEC). An es-
pecially troubling feature of UPEC-associated UTIs is their high
rate of recurrence. This problem is compounded by the drastic
increase in the global incidence of antibiotic-resistant UPEC
strains over the past 15 years. The need for more effective treat-
ments for UTIs is driving research aimed at bettering our under-
standing of the virulencemechanisms and host-pathogen interac-
tions that occur during the course of these infections. Surrogate
models of human infection, including cell culture systems and the
use of murine, porcine, avian, teleost (zebrafish), and nematode
hosts, are being employed to define host and bacterial factors that
modulate the pathogenesis of UTIs. These model systems are re-
vealing how UPEC strains can avoid or overcome host defenses
and acquire scarce nutrients while also providing insight into the
virulence mechanisms used by UPEC within compromised indi-
viduals, such as catheterized patients. Here, we summarize our
current understanding of UTI pathogenesis while also giving an
overview of the model systems used to study the initiation, persis-
tence, and recurrence of UTIs and life-threatening sequelae like
urosepsis. Although we focus on UPEC, the experimental systems
described here can also provide valuable insight into the disease
processes associated with other bacterial pathogens both within
the urinary tract and elsewhere within the host.
INTRODUCTION
Urinary tract infections (UTIs) occur when pathogenic mi-crobes colonize typically sterile niches within the urethra
(urethritis), bladder (cystitis), ureters (ureteritis), or kidneys (py-
elonephritis). These infections are among the most common in-
fections experienced by humans, affecting more than 8 million
people annually in the United States with associated costs exceed-
ing $2 billion (1–4). UTIs affect individuals of all age groups and
both sexes, although they occur most frequently in otherwise
healthy women. It is estimated that one in three womenwill suffer
from a UTI by the age of 24 years, with 50% of women experienc-
ing a UTI at least once during their lifetime (1, 5). Compounding
the burden of these infections is their high rate of recurrence. For
an individual with a UTI, there is a 25% chance that the infection
will recur within 6 months, regardless of antibiotic intervention
(2, 5). The probability of recurrence over a 12-month period in-
creases to 46%. Individuals with anatomical abnormalities of the
urinary tract and patients with urinary catheters are exceptionally
prone to UTIs and may develop complicated chronic infections
that can be extremely difficult to eradicate.
Cystitis, which is by far the most common type of UTI, is as-
sociated with increased urinary frequency and urgency, pain dur-
ing urination, cloudy or bloody urine, urine with a strong or foul
odor, and discomfort in the pelvic region. A low-grade fever can
coincide with cystitis but is more frequently associated with pye-
lonephritis. A patient suffering from pyelonephritis can have any
or all symptoms associated with cystitis in addition to costoverte-
bral flank pain, nausea, and vomiting. Pyelonephritis can also lead
to renal scarring and diminished kidney function, particularly in
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young children (6, 7). Episodes in which bacteria disseminate
from the kidneys into the bloodstream can be especially serious,
resulting in bacteremia and life-threatening sepsis (urosepsis) (4,
8, 9).
Most uncomplicated UTIs are easily treated by using standard
prescribed antibiotic regimens, including single-dose treatments
with antibiotics like fosfomycin or 3- to 7-day treatments with
drugs like nitrofurantoin, trimethoprim-sulfamethoxazole, or
pivmecillinam (10, 11). Prophylactic low-dose administration of
antibiotics can provide relief and protection for individuals prone
to recurrent UTIs (12). However, the effectiveness of nearly all
antibiotics used to treatUTIs is declining at an alarming rate as the
incidence of antibiotic-resistant bacteria is rapidly increasing
across the globe (13–15). To counter the rise of antibiotic-resis-
tant uropathogens, there is a pressing need to better understand
the host and bacterial factors that contribute to the establishment,
persistence, recurrence, and spread of UTIs.
ETIOLOGY OF UTIs
Strains of uropathogenic Escherichia coli (UPEC) are the primary
cause of UTIs, being responsible for !80% of uncomplicated
community-acquired cystitis andpyelonephritis cases (2, 16). Less
common, although still highly problematic, are UTIs caused by
Staphylococcus saprophyticus, Klebsiella spp., Proteus mirabilis,
Pseudomonas spp., and Enterococcus faecalis (16, 17). In cases of
complicatedUTI, occurring in people with anatomical abnormal-
ities or in catheterized patients, the microbial etiology is more
diverse. UPEC strains are still the prominent pathogens, but these
individuals have a higher prevalence of infections caused by Pro-
teus mirabilis, Pseudomonas aeruginosa, Serratia marcescens, and
group B streptococci and an increased susceptibility to fungal in-
fections byCandida species. Due to its high prevalence, UPEC has
been the focus of most research on UTIs and is discussed in detail
here.
UPEC and other E. coli isolates comprise a highly heterogenic
group of Gram-negative bacteria (18, 19). Commensal E. coli
strains are commonly found in association with the gastrointesti-
nal tract of warm-blooded vertebrates, where the bacteria can es-
tablish mutually beneficial relationships with their hosts, provid-
ing necessary vitamins (e.g., vitamin K and B-complex vitamins),
promoting gastrointestinal homeostasis, and protecting the gut
from pathogens (20–23). Pathogenic E. coli variants can cause a
wide range of diseases bothwithin and outside the gastrointestinal
tract. Diarrheagenic strains, like enterohemorrhagic E. coli (best
known for the O157:H7 serotypes found in contaminated food)
and enteropathogenic E. coli, can cause gastroenteritis but do not
typically cause disease outside the gastrointestinal tract (24). In
contrast, UPEC strains appear to rarely cause problems within the
gut but can elicit disease when given access to alternative niches
such as the urinary tract or bloodstream.UPEC strains originating
from the gut are likely the primary cause of UTIs (25), but the
factors that promote UPEC fitness within the intestinal tract are
just beginning to come to light (26–28).
The ease with which UPEC isolates acquire resistance to com-
monly used antibiotics contributes to the widespread success of
these pathogens.Of deep concern is the recent and rapid intercon-
tinental dissemination of multidrug-resistant UPEC strains, in-
cluding many so-called ST131 isolates (29–31). In less than a de-
cade, ST131 isolates have become a major cause of UTIs in many
parts of the world, includingNorth America (32, 33). The increas-
ing prevalence of multidrug-resistant UPEC strains within the
global community is driving the search for more effective ap-
proaches to prevent and treat UTIs, which in turn necessitates the
development and use of model systems with which we can discern
and mechanistically define bacterial and host factors that impact
the infection process.
THE LIFE CYCLE OF UPEC
UPEC typically initiates a UTI by traversing the urethra to reach
the bladder (25, 34). The gender bias observed in UTI epidemiol-
ogy is thought to be in large part attributable to anatomical differ-
ences in the male and female genitourinary tracts (2). Specifically,
women possess a significantly shorter urethra than men, which
greatly reduces the distance that infectious microbes must travel
from the urethral opening in order to establish an infectionwithin
the bladder. In addition, women can harbor UPEC within the
vaginal introitus, which may become contaminated with uro-
pathogens through contact with fecal matter or, in some cases, via
sexual interactions (34–36).
Each step leading up to bacterial entry into the urinary tract can
be problematic for would-be pathogens. For instance, the natural
microbial communities (the microbiota) that persist as commen-
sals within the gastrointestinal tract and vagina can competitively
interfere with UPEC survival by limiting space and nutrient avail-
ability and by altering host immunity (21, 37, 38). It is probable
that phages and toxic products such as colicins produced by com-
mensal organisms also restrict the growth and dissemination of
UPEC. Within the vagina, for example, the production of lactic
acid and other factors by commensal lactobacilli can damage
UPEC strains that are in transit between the intestinal and urinary
tracts (39–41). Consequently, a healthy vaginal microbiome can
help protect women against ascending UTIs. Interestingly, recent
research employingmassively parallel sequencing techniques sug-
gests that the urinary tract itself may also be home to a protective
microbiota (42).
Once within the urinary tract, UPEC faces a barrage of host
defenses and other challenges to its survival (43, 44). Among the
most formidable of these is the bulk flow of urine. Shearing forces
associated with the release of urine during micturition can dis-
lodge nonadherent and weakly adherent microbes, rinsing bacte-
ria from the body before they have a chance to elicit disease. In-
complete voiding of the bladder greatly increases the risks of
bacteriuria and UTI, and these complicated infections are espe-
cially problematic for individualswhohave anatomical abnormal-
ities or neurogenic bladder due to spinal cord injuries, spina bi-
fida, or other medical conditions (45). Catheterization of these
patients is common and can inadvertently facilitate the introduc-
tion of uropathogens into the bladder.
In uncomplicated UTIs, uropathogens can resist expulsion
from the urinary tract via elaboration of adhesive molecules (ad-
hesins) that mediate bacterial attachment to host cells and extra-
cellular matrix components. Mathematical modeling suggests
that bacterial attachment to host tissues within the urinary tract is
potentially unnecessary, since small numbers of unbound residual
bacteria that remain following micturition should be able to mul-
tiply fast enough in urine to continually repopulate the bladder
lumen as it repeatedly empties and fills (46). Indeed, some ABU
isolates seemingly lack the ability to bind host bladder cells, and
yet, they can still persist for extended periods at high levels within
Barber et al.




the urinary tract (47). However, most UPEC isolates appear to
require adhesins to effectively colonize the urinary tract.
UPEC isolates encode dozens of adhesins that vary in their
receptor specificity andwhether or not they are assembled into pili
(also known as fimbriae) (34, 48–50) (Fig. 1). One of the most
frequently studied adhesins, which is expressed by nearly all UPEC
isolates, is the type 1 pilus-associated protein FimH. This adhesin
can bind a variety of mannose-containing host membrane glyco-
proteins as well as components of the extracellular matrix (51).
Upon entering the bladder, UPEC encounters a thin glycosamin-
oglycan-rich glycocalyx that is in loose association with the termi-
nally differentiated superficial umbrella cells that comprise the
outer layer of the urothelium (52–54). The apical surface of each
umbrella cell is highly enriched for a group of integral membrane
glycoproteins known as uroplakins, which are assembled into
quasicrystalline arrays of hexagonal complexes (55, 56). To-
gether with underlying layers of less-differentiated epithelial
cells, the uroplakin-coated umbrella cells create an exception-
ally strong permeability barrier. FimH can mediate bacterial
interactions with one of the uroplakins, UP1a, as well as with
several other host receptors thatmay be situated on andwithin the
urothelium (57–62). Although UP1a is doubtlessly the most
abundant receptor available to type 1 piliated UPEC on the
urothelial surface, other receptors and other adhesins likely come
into play as UPEC encounters changing environments and host
cell types during the course of infection.
In addition to promoting bacterial attachment to host cells and
tissues, several of the adhesins encoded by UPEC isolates can also
stimulate the development of biofilm communities. Biofilms con-
sist of bacterial cells encasedwithin a complex extracellularmatrix
that can include proteins, nucleic acids, and polysaccharides like
cellulose. UPEC-associated adhesins that have been implicated in
the formation of biofilms include type 1 pili, F1Cpili, S pili, and F9
fimbriae as well as the adhesive autotransporter proteins Ag43,
UpaG, UpaB, and UpaH (63–70). Flagella and thin aggregative
amyloid fibers known as curli can also promote biofilm formation
by UPEC (63, 64, 67, 70). The development of biofilms within
urinary catheters and in association with host tissues can render
UPEC less sensitive to antibiotics and host defenses like neutro-
phils (70, 71).
The establishment, persistence, and dissemination of UPEC
strains within the urinary tract are aided further by the ability of
FIG 1 UPEC-associated fitness and virulence determinants. Shown is a sampling of the many different factors that can promote the survival and virulence of
UPEC strains within the host. (Left) These factors include iron acquisition systems like enterobactin and salmochelin. Enterobactin is a broadly conserved,
high-affinity siderophore that can be inhibited by the host protein lipocalin. To sidestep this host factor, someUPEC isolates produce salmochelin, a glucosylated
version of enterobactin that is not recognized by lipocalin. (Right) UPEC strains can secrete a variety of toxins that can disrupt normal host proteolytic cascades,
membrane trafficking, cytoskeletal rearrangements, inflammatory responses, and survival pathways. Indicated here are some of the effects of host cell intoxica-
tion by alpha-hemolysin (HlyA), secreted autotransporter toxin (Sat), and cytotoxic necrotizing factor 1 (CNF-1). (Bottom)UPEC can bind host cells and tissues
via multiple adhesins. These include Afa/Dr adhesins (which bind integrins, collagens, or CD55), S pili (which bind !-sialyl-2,3-" galactoside-containing
receptors), F1C pili (which bind lactosylceramide-containing receptors), type 1 pili (T1) (which bind numerous factors, including!3"1 integrins andUP1a), and
P pili [which bind Gal!(1-4)Gal"moieties of glycosphingolipids].
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these pathogens to invade host epithelial cells (Fig. 2). Among the
dozens of adhesins that are encoded by UPEC, type 1 pili and
Dr/Afa fimbriae have been implicated most often as mediators of
host cell invasion (51). The type 1 pilus adhesin FimH promotes
UPEC entry into bladder cells by stimulating actin cytoskeletal
rearrangements that cause the host cell membrane to zipper
around and envelop adherent bacteria (72). Host receptors for
FimH and other UPEC-associated factors that have been impli-
cated as mediators of host cell invasion include integrins (58, 73,
74), the complement regulatory protein CD46 (75, 76), the com-
plement decay-accelerating factor CD55 (77–79), and the flagellin
sensor Toll-like receptor 5 (Tlr5) (80, 81). Following entry into
host bladder cells, most UPEC cells face one of three fates: (i) they
can be quickly returned back to the extracellular environment (82,
83), (ii) they can enter into a nonreplicating quiescent state (83–
85), or (iii) they can multiply, forming large intracellular bac-
terial communities (IBCs) (83, 86, 87). The superficial um-
brella cells of the bladder are the initial targets of host cell
invasion by UPEC, but the exfoliation of these cells and the
influx of neutrophils during the course of a UTI can provide
UPEC with access to deeper layers of immature host cells
within the urothelium (83, 88, 89).
Within both mature and immature bladder epithelial cells, in-
ternalized bacteria that are not immediately expelled are trafficked
intomembrane-bound compartments that have characteristics of
late endosomes and early lysosomes (84, 85, 90). Specifically, these
UPEC-containing vacuoles incorporate the host proteins CD63
and LAMP-1 and the lipid lysobisphosphatidic acid (LBPA) but
lack the protease cathepsin-D. It is within these compartments,
enmeshed within host actin filaments, that UPECmay persist in a
nonreplicating state for indeterminate periods that can last for
several hours to weeks and perhaps longer (83, 84, 91). Ongoing
research indicates that these quiescent intracellular bacteria may
serve as reservoirs for the recurrent, or relapsing, UTIs that plague
many individuals despite the use of antibiotics (89). Intracellular
pathogens are protected from antibiotics due to the permeability
barrier function of the urothelium and the inability of many an-
tibiotics to effectively cross host membranes (92). The quiescent
bacteria within bladder epithelial cells are also likelymore tolerant
of antibiotics since most antibiotics affect only replicating mi-
crobes.
Changes in both host cholesterol levels and the actin cytoskel-
eton can stimulate the transition of internalized UPEC from a
quiescent state to a rapidly dividing pool of microbes within blad-
der cells, forming IBCs that can contain several thousand bacterial
cells (84, 93). Bacteria present within IBCs are protected from
infiltrating phagocytes and are possibly less sensitive to antibiotic
treatments (87). During IBC development, many of the normally
rod-shaped bacteria transiently assume a filamentous morphol-
ogy, with some attaining lengths of well over 150 !m (83, 94).
These filamentous bacteria are resistant to phagocytosis by infil-
trating neutrophils and can extend for long distances within, and
even between, host cells. IBCs likely do not serve as long-lived
reservoirs for UPECwithin the urinary tract, as host cells contain-
ing IBCs will eventually rupture or are shed and cleared with the
flow of urine (83, 87, 95). The release of UPEC from IBCs as
filaments or as single rods can promote pathogen spread both
within the urinary tract and, potentially, between hosts. Cycles in
which host cell invasion by UPEC is followed by stages of IBC
formation, bacterial quiescence, and resurgence may help drive
the development of chronic and recurrent UTIs.
In addition to adhesins, UPEC survival within the urinary tract
is also facilitated by the expression of various toxins, chelators,
and other factors that allow the bacteria to sequester nutrients and
essential metals away from the host, modulate host immune re-
sponses, and disrupt tissue barriers (a few examples are shown in
Fig. 1) (96–99). However, no single set of virulence factors that is
required by all UPEC isolates to cause disease has been identified.
Rather, UPEC strains appear to rely upon an assorted array of
factors that may act redundantly, dependent upon the niche oc-
cupied and the specific environmental stresses present. Although
the life cycle of UPEC is not fully understood, it almost certainly
involves bacterial exposure to various environmental stresses as
the pathogens traverse niches both within and between human
FIG 2 Multiple fates for UPEC in association with the urothelium. Interactions between the type 1 pilus-associated adhesin FimH and the sugar side chains of
receptors like UP1a or "3/#1 integrins can stimulate actin cytoskeletal rearrangements leading to the internalization of UPEC. Bacteria are then either trafficked
back out of host cells or taken intomembrane-bound compartments that are similar to late endosomes or early lysosomes.Within bladder cells, UPECcan remain
in a nonreplicating state, forming quiescent reservoirs that are protected from host defenses and antibiotics. Intravacuolar growth of UPEC is restricted in part
by the host actin cytoskeleton, which is dense within the immature epithelial cells of the bladder. Within terminally differentiated umbrella cells, where F-actin
is localized primarily at basolateral surfaces, UPEC can break into the host cytosol and subsequently multiply to form IBCs. These bacterial communities are not
long-lived and are most apparent during the acute phase of a UTI. The disruption or exfoliation of IBC-containing umbrella cells, as well as the transient
formation of filamentous bacteria, can facilitate the efflux and dissemination of UPEC. Bacteria released from within IBCs can infect neighboring host cells,
including the immature urothelial cells that appear to serve as the primary home for persistent UPEC reservoirs within the bladder. Released bacteria and
exfoliated bladder cells that are flushed from the urinary tract with the flow of urine likely facilitate the spread of UPEC between hosts.
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and animal hosts. For example, UPEC hosts may include pets and
farmed poultry and pigs, with time spent between hosts in soil or
wastewater or in the meat department of the local grocery store
(100–110). The capacity ofUPECand related pathogens to inhabit
such a diverse range of niches has helped prompt researchers to
develop a variety of model systems to understand the virulence
potential, adaptability, and evolution of these ubiquitous patho-
gens.
MODEL SYSTEMS FOR DEFINING THE PATHOGENICITY OF
UPEC AND RELATED BACTERIA
Model systems employed to study the pathogenic behaviors of
UPEC isolates have incorporated the use of humans and other
primates, rodents, pigs, chickens, zebrafish, and nematodes in ad-
dition to primary and cancer cell lines derived from the bladder,
kidneys, or other host tissues (Fig. 3). These model systems act as
approximations of natural human infections and allow various
aspects of the infectious process to be dissected in controlled set-
tings. Thanks to advances in sequencing technology and molecu-
lar biology techniques, the genomes of multiple UPEC strains are
known and can be manipulated fairly easily by using molecular
genetic approaches to generate isogenicmutants and recombinant
strains. Pairing molecular and genetic techniques with model sys-
tems allows researchers to delineate key bacterial and host factors
involved in the pathobiology of UTIs, with a major goal being the
identification of novel therapeutic targets. Although our focus
here is on UPEC, it should be noted that many of the model sys-
tems discussed in the following sections have also been valuable
for analyzing bacterium-host interactions involving a diverse ar-
ray of other uropathogens (for a few of many examples, see refer-
ences 111–117).
Humans and Other Primates
To date, there have been few experimental UTI studies carried out
in humans or other primates. This is in large part due to ethical
concerns and the high costs associated with studies in which pri-
mates or human volunteers are deliberately infected. Primates are
generally employed as part of preclinical trials aimed at testing the
efficacy and safety of vaccine and drug candidates. Human studies
often involve epidemiological analyses, with the primary aims fre-
quently being to correlateUPEC strain characteristics with patient
history and disease information. These studies can be either ret-
rospective or prospective, often centered on the phenotypic and
genotypic analysis of bacteria recovered from urine samples pro-
vided by human volunteers as well as genetic analysis of the hosts
themselves. This sort of work has highlighted the increasing prev-
FIG 3 Model systems for investigating the pathogenesis of UPEC and related pathogens. Some of the key pros and cons for each system are indicated.
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alence of multidrug-resistant isolates such as ST131 strains and
revealed emergent patterns in the types of antibiotic resistance
genes and virulence factors carried by UPEC isolates (32, 118–
126). For example, analysis of bacterial isolates recovered from the
urine of childrenwith febrileUTI indicated thatUPEC strains that
express type 1 pili cause more severe clinical symptoms than
pathogens lacking these adhesins (127). These findings were sub-
sequently verified inmouse and cell culture-based infectionmod-
els (128, 129).
More recently, techniques like transcriptome sequencing
(RNA-seq) have allowed researchers to obtain transcriptional
profiles of UPEC isolates recovered directly from the urine of hu-
man patients with UTIs. This work indicated important roles for
ion transport systems and anaerobicmetabolic processes inUPEC
within human urine but was limited in its ability to analyze tissue-
associated pathogens (130). Still, the results suggested a number of
bacterial factors that may be of value as therapeutic targets. Spe-
cifically, it was noted that a copper efflux system was highly up-
regulated inUPEC isolates fromhuman urine, spurring follow-up
experiments in which it was shown that copper supplementation
can significantly decrease UPEC colonization in a mouse UTI
model (130).
Analysis of human-derived samples is especially useful as a
means to validate and expand observations made in other exper-
imental systems. For instance, carefulmicroscopic examination of
urothelial cells that are shed by human patients during the course
of a UTI indicates that the ability of UPEC to invade andmultiply
within host cells is not a mouse- or cell culture-specific phenom-
enon, as some have argued (131–135). Instead, the capacity of
UPEC strains to act as facultative intracellular pathogens likely
contributes to their success as human pathogens. The imaging of
UPEC in association with intact human bladder tissue is more
problematic, as this requires the acquisition of biopsy specimens
or whole bladders, which are not easily obtained.
Taking amore host-centric approach, population-based studies
have revealed behavioral, situational, and genetic factors that in-
fluence host susceptibility to UTI. Some of the key groups identi-
fied as being at greater risk for developing UTI include sexually
active females, pregnant women, elderly individuals, and cathe-
terized patients (2, 136). In sexually active women, the use of
spermicide or antibiotics escalates the risk of UTI, with the latter
also increasing the incidence of infections due to drug-resistant
pathogens (137–140). Both spermicide use and antibiotics can
disrupt the vaginal microbiota, which normally protects against
the ascension of uropathogens into the urinary tract (2, 37, 141).
Shifts in the composition of the vaginal microbiota may also ac-
count for the increased frequency of UTIs in elderly women (2,
142). This phenomenon is in part attributable to the diminish-
ment of estrogen levels that occurs as women age. Pregnancy sub-
stantially increases the risk of pyelonephritis but has little effect on
the risk of cystitis. Although pregnancy can alter vaginal secretions
and the microbiota (143), the elevated risk of pyelonephritis in
pregnant women ismore likely attributable to pregnancy-induced
increases in blood volume and glomerular filtration rates and the
decreased contractility of the ureteric smooth muscle (2). These
physiological changes create an environment within the urinary
tract that is more conducive to the dissemination and growth of
uropathogens. UTI during pregnancy can have serious repercus-
sions, contributing to premature birth, low birth weight, pre-
eclampsia, and the need for cesarean delivery (144). In light of
these correlations, researchers are developing mouse models to
better understand the mechanisms by which localized UTIs can
influence intrauterine fetal growth and other adverse pregnancy
outcomes (145, 146).
Specific genetic variables that alter host susceptibility to UTI
have been more difficult to nail down, although their existence is
suggested by the fact that women with a predisposition for recur-
rent UTIs often have family members with the same problem (2,
44, 147). Susceptibility factors for pyelonephritis include reduced
expression levels of interferon regulatory factor 3 (Irf3) or of the
chemokine receptor CXCR1 (147). Polymorphic variants of other
surfacemolecules, including certain blood group antigens and the
pattern recognition receptors Tlr4 and Tlr5, may also constitute
risk factors, as they can serve as attachment sites for uropathogens
or as regulators of host inflammatory responses (147–151). The
effects of these and other identified risk factors can be subtle and
maynot be evident in all studies (152). It is likely that the spectrum
of genetic modifiers of UTI susceptibility will continue to expand
as researchers learn more about the pathogenic mechanisms and
host defenses associated with these infections.
The added complexity of UTI research using epidemiological
approaches and samples from human volunteers is assuaged by
the opportunity to assess pathogenic processes in a natural envi-
ronment of direct medical importance. However, this work is not
without its drawbacks, which may include, in addition to high
costs, the use of avirulent isolates rather than full-fledged patho-
gens for deliberate infections and the genetic heterogeneity of hu-
man volunteers. Consequently, in order to better define the mo-
lecular mechanisms of UTI in a more controlled setting, many
scientists employ surrogate infection models, keeping in mind
how their findings may relate to the situation in human patients.
Cell Culture
Cell culture-based assays have been used extensively to investigate
the mechanisms and consequences of UPEC interactions with
host cells. These assays typically utilize primary, immortalized, or
cancer cell lines derived from the bladder urothelium or from the
kidneys (e.g., proximal tubule epithelial cells). Host bladder cells
are usually grown as undifferentiated monolayers but can be in-
duced to stratify and partially differentiate when grown with
appropriate media on membrane scaffolds in dishes or under
microgravity conditions generated within rotary walled vessel
bioreactors (153–155). Recently, culture systems that incorpo-
rate different types of host cells, such as neutrophils plus bladder
epithelial cells, have been established to better approximate the
cellular complexity of the inflamed urothelium (156). By using
small interfering RNA (siRNA) as well as plasmid and viral con-
structs, host genes within cultured cells can be specifically silenced
or, alternatively, overexpressed, facilitating the functional analysis
of host factors that may contribute to the pathogenesis of UTIs
(58, 90, 157–159). Pharmacological reagents can also be used to
interfere with host enzymes and signaling cascades, but consider-
ation should always be given to dosage and off-target effects aswell
as potential interference with bacterial processes. Emerging tech-
nologies, such as engineered clustered regularly interspaced short
palindromic repeat (CRISPR)-Cas9 systems, will allow easier dis-
ruption and high-throughput functional analyses of specific ge-
netic loci within host cells (160, 161).
The use of cultured eukaryotic cells has been instrumental in the
identification of host receptors that are bound by UPEC as well as
Barber et al.
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the delineation of downstream signaling events that modulate in-
flammation and the internalization and trafficking of bacteria (58,
72, 77, 90, 129, 157–159, 162–171). Cell culture-based assays are
also commonly used to define how secreted toxins and other
UPEC-associated virulence factors affect host cell functions and
viability (172–180). The ease of use, low cost, and amenability to
high-throughput assays, genetic manipulation, and biochemical
analysis make cell culture-based systems attractive alternatives to
many animal infection models. Recent advances with flow cell
technology even make it possible to examine UPEC-host interac-
tions using bladder cell monolayers in the presence of urine flow,
mimicking conditions within the urinary tract during an actual
UTI (181).
Despite the proven utility of cell culture-based model systems,
they cannot fully recapitulate the complexity of the host environ-
ment with its myriad cell types, complicated tissue architecture,
variable nutrient levels, and teeming host defenses. For example,
key features of terminally differentiated superficial umbrella cells,
including their multiple nuclei and quasicrystalline arrays of api-
cal uroplakin complexes, are exceptionally difficult to mimic in
cell culture, although notable progress in this area has been made
with primary urothelial cells in recent years (154, 182). Therefore,
detailing the molecular consequences of UPEC interactions with
bladder umbrella cells is currently limited in the context of cell
culture-based models. Nonetheless, cell culture models continue
to expand our understanding of UTI pathogenesis, oftentimes
propelling more insightful follow-up studies in humans and ani-
mal model systems.
Murine
The murine UTI model system, which is the predominant animal
model for the study of UTIs, usually entails the transurethral cath-
eterization of rodents and subsequent instillation of bacteria di-
rectly into the bladder lumen. For consistent colonization be-
tween animals, researchers will typically inoculate animals with
!107 CFU, which is likely far higher than the titers that would be
present at the onset of a natural UTI. The mouse model is excep-
tionally pliable and can bemodified to assess polymicrobial infec-
tions as well as catheter-associated UTIs and chronic cystitis (146,
183–188). Rodents share much in common with humans, includ-
ing conserved immunological factors and similar anatomical fea-
tures within the urinary tract (183). While direct instillation of
bacteria into the bladder bypasses some steps required during nat-
ural infections, this model system still allows detailed investiga-
tion of many key aspects of ascending UTIs. Specifically, rodent
models have been used extensively for comparative analysis of the
fitness and virulence potentials of wild-type and mutant UPEC
strains as well as for the examination of host responses to UTI.
Bacterial titers associated with the bladder or kidneys can bemon-
itored by plating of tissue homogenates collected at various time
points postinoculation or by the use of luminescent bacteria that
can be visualized in live animals using biophotonic imaging (189–
191). Host responses can be examined by various means, includ-
ing transcriptional profiling and histological analysis of tissue sec-
tions. The use of inbredmouse strains reduces experimental noise
arising from host genetic variability, and recombinant genetic en-
gineering technologies allow the generation of whole-animal and
tissue-specific gene knockouts.
While the pathogenesis of UTIs in femalemice has been studied
extensively, relatively little work has been done to understand the
impact of these infections on males. This disparity echoes the un-
equal effects that UTIs have on females in the human population,
in which nearly half of all women will endure at least one UTI,
compared with only about 12% of males (1). The longer male
urethra is thought to hinder bacterial ascension into the bladder,
and in the laboratory, this feature renders male mice technically
muchmore difficult to catheterize. One way around this hurdle is
to bypass the need for catheterization by instilling bacteria directly
into the bladder lumen by way of surgical inoculation via an inci-
sion in the abdominal wall (192). By using this approach, it was
recently determined that IBC formation and other key events that
occur during the development of cystitis are quite similar inmales
and females. However, notable differences between males and fe-
males were observed at later time points. Specifically, male mice
had a much higher incidence of chronic cystitis, defined as persis-
tent bacteriuria and protracted inflammation, and were more
likely to develop severe pyelonephritis and renal abscesses. These
effects were linked with the higher testosterone levels present in
malemice, although themechanisms bywhich this androgen fuels
UTI progression remain unclear (192). Interestingly, older studies
indicate that testosterone promotes the secretion of lysosomal hy-
drolases into the urine (193, 194), a phenomenon that could po-
tentially affect host defenses, including the barrier function of the
urothelium.
The availability of genetically distinct mouse strains as well as
many mutant knockout and transgenic mouse lines has enabled
researchers to assess the specific impact of numerous host genes
and immune cells on the progression and outcome of UTIs (44,
195, 196).Mouse lines that vary in their susceptibility to UTI have
helped identify host susceptibility factors and provide a platform
for assessing the functionality of bacterial fitness determinants.
Consider, for example, a recent analysis of isogenic UPEC mu-
tants that lack the cya or crp gene (197). These genes enable UPEC
to synthesize and respond to the second messenger cyclic AMP
(cAMP). In vitro, the UPEC cystitis isolate UTI89 requires both
cya and crp to effectively utilize alternate carbon sources like
amino acids, the principal nutrients available to UPEC within the
urinary tract (96, 197, 198). In broth culture assays, the cya and crp
mutants also have increased sensitivities to the damaging effects of
reactive nitrogen species and superoxide radicals, akin to those
generated by host inflammatory cells (197). In wild-typemice, the
cya and crp mutants are each impaired in their ability to colonize
the bladder, whereas in C3H/HeJ mice, the mutants are no longer
defective. Due to mutations in the pattern recognition receptor
Tlr4 and possibly other immune regulators, C3H/HeJ mice are
hyporesponsive to lipopolysaccharide and therefore have very
limited inflammatory responses during experimental UTI (196,
199–201). Together, these observations indicate that Tlr4-depen-
dent innate host defenses within wild-type mice, and not nutrient
availability per se, are themajor factors that restrict colonization of
the bladder by the cya and crp UPEC mutants (197).
Microscopy has played a particularly important role in defining
pathogenic processes inmurineUTImodels, revealing howUPEC
strains interact with host tissues and bringing inflammatory re-
sponses into better focus. In one intriguing example, researchers
surgically exposed kidneys in anesthetized rats and imaged living,
infected tissue by using multiphoton microscopy following direct
infusion of fluorescently labeled UPEC (71, 202). This work re-
vealed an unexpected synergism between type 1 pili and other
adhesive organelles known as P pili in promoting UPEC coloniza-
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tion and biofilm formation within the proximal tubules of the
kidneys.
Rodents, and mice in particular, have also been used to model
systemic infections, mimicking episodes of bacteremia and uro-
sepsis that can arise in human patients as serious complications of
UTI (203–208). In these models, UPEC is inoculated directly into
the bloodstream or delivered systemically via a subcutaneous or
intraperitoneal injection. These approaches sidestepmore natural
routes in which UPEC disseminates systemically from sites within
the urinary tract but have nonetheless provided valuable insight
into the pathogenesis of urosepsis and related pathologies.
Murine models of UTI and associated infections have tremen-
dous practical utility, being themajor in vivo platform for address-
ing the efficacy and safety of new antibacterial therapeutics and
vaccine candidates prior to testing in primates or humans. How-
ever, it should be emphasized that not all data obtained from
murine studies are directly relevant to human UTIs. For example,
by sensing bacterial products like flagellin, Toll-like receptor 11
(TLR11) stimulates host inflammatory responses, resulting in a
modest but significant reduction in bacterial colonization of the
kidneys in the mouse UTI model system (209, 210). However, in
humans, the gene encoding TLR11 is not expressed due to the
presence of a premature stop codon within an early exon and is
therefore likely inconsequential as a defense against UTIs in hu-
man patients. Nonetheless, the identification of a functional role
for TLR11 inmice highlights interesting questions concerning the
evolution and operative redundancy of host defense factors. In the
long run, these sorts of observationsmay also aid the development
of new approaches to augment host resistance against UTIs and
other infections.
Porcine
Like humans,many domesticated animals are susceptible to infec-
tion by UPEC and related pathogens (106, 211–215). Each year,
thousands of pigs are diagnosed with pyelonephritis and culled in
order to prevent widespread infection and contamination (216).
Using porcine infection models, researchers have investigated the
spectrumof host responses to pyelonephritis as well as the onset of
renal scarring that can occur as a consequence of UTI (216–218).
The latter problem is often associated with vesicoureteric reflux
(VUR) and is especially problematic in human infants, but as chil-
dren age beyond 4 years, the risk of renal scarring due to UTI
drops precipitously (219, 220). In an E. coli infection model using
both adult pigs and piglets with VUR, it was found that older
animals were not any better protected from kidney scarring than
piglets (218, 219). Extrapolating from these data, it was argued
that aging does not intrinsically decrease the risk of kidney scar-
ring but rather that children who are inherently more vulnerable
to kidney scarring will already have developed scars before reach-
ing the age of 4 years. In susceptible individuals, polymorphisms
that affect signaling via TLRs or other host pathogen recognition
receptors or that reduce the expression levels of cytokines like
transforming growth factor ! (TGF-!) may result in aberrant
inflammatory responses that lead to increased bacterial growth
and dissemination and decreased renal tubular function, ulti-
mately causing host cell death and scarring (6, 44, 221). Bacterial
toxins like alpha-hemolysin and adhesins like type 1, P, and F1C
pili may initiate and/or exacerbate these pathological events. Al-
though porcinemodels have proven utility in defining pathogenic
processes during UTI, they currently lack the genetic tractability
offered by some other animal model systems and are relatively
expensive, precluding the use of large sample sizes. On the other
hand, the ability of the porcine UTI model to recapitulate many
important aspects of pyelonephritis in large mammals makes it a
potentially highly relevant system for the assessment of novel ther-
apeutics in preclinical trials prior to human studies.
Avian
UPEC strains are closely related to another group of bacteria
known as avian-pathogenic E. coli (APEC), the causative agent of
avian colibacillosis (222–225). This similarity suggests that analy-
sis of APEC strains in their natural avian hosts might provide
insight into UPEC-associated virulence mechanisms and vice
versa. Work addressing this possibility has employed infection
models in whichUPEC or APEC strains are inoculated into the air
sac of adult chickens, given via subcutaneous injection of young
chicks, or injected into the allantoic cavity of fertilized chicken
eggs (222, 226–228). In some studies, bacterial pathogenicity
within the chicken model correlates well with virulence in the
mouse urinary tract, highlighting the zoonotic potential of APEC
strains (227–229). However, as a model for UTI, chickens and the
embryonic chick model have some notable disadvantages. Chief
among them is the fact that chicks lack a urinary bladder and likely
present UPEC and related strains with stresses and opportunities
distinct from those encountered within mammalian hosts. De-
spite these limitations, the low cost and ease of the embryonic
chick model system provide an enticing alternative approach for
screening UPEC-associated virulence determinants within a nat-
urally susceptible vertebrate host. Furthermore, because UPEC
may acquire many antibiotic resistance and virulence genes from
APEC strains via horizontal gene transfer (227, 230), avian infec-
tion models might allow researchers to better discern selective
pressures that affect the evolution of uropathogens.
Zebrafish
Recently, the teleost fish Danio rerio, commonly known as ze-
brafish, was developed as an additional host model system for the
analysis of infections caused byUPEC and related pathogens (231,
232). To initiate infection, zebrafish embryos at 48 h postfertiliza-
tion (hpf) are injected with UPEC at one of two sites: a fluid-filled
sac surrounding the heart, referred to as the pericardial cavity, or
the blood, via the circulation valley. Inoculation of the pericardial
cavity limits bacterial dissemination within the embryo and serves
as a model for localized infection. The introduction of UPEC into
the circulation valley leads to the dispersal of bacteria throughout
the bloodstream of the embryo, mimicking a systemic, sepsis-like
infection. Each route of inoculation is thought to present UPEC
with distinct challenges in terms of the types and levels of antimi-
crobial factors, phagocyte numbers, and nutrient availability (204,
231). At 48 hpf, zebrafish have only innate immune defenses,
including antimicrobial peptides, complement, cytokines,
TLRs and other microbial pattern recognition receptors, neu-
trophils, and macrophages (233–237). Homologous host de-
fenses are central to the ability of both mice and humans to
effectively resist UPEC (43, 44).
Relative to many other available model systems, zebrafish em-
bryos are inexpensive and readily amenable to genetic manipula-
tion and to medium- to high-throughput screens. Consequently,
the growth and survival of large numbers of wild-type andmutant
UPEC strains can be rapidly screened within the zebrafish host,
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and pathogen effects on zebrafish morbidity and mortality can be
readily assessed. Within a single day, hundreds of fish can be in-
jected, with minimal costs, taking up only a rack or two within an
incubator. Zebrafish embryos are also transparent, allowing easy,
real-time observation of the infection process, including visualiza-
tion of fluorescent gene expression reporters as well as fluores-
cently tagged bacteria, proteins, and host cell lineages (207, 231).
Heart rate and blood flow are also easily monitored in the trans-
parent embryos, alongwith bacterial dissemination and the devel-
opment of necrotic lesions or other anomalies in host tissues. The
effects of specific host genes on the infection process can be exam-
ined by using multiple approaches common to many model sys-
tems, including microarray analysis and RNA-seq. In addition,
zebrafish genes can be silenced by using antisense RNAmolecules
known asmorpholino oligomers (231) or specifically knocked out
by using TALEN- or emerging CRISPR-Cas9-mediated genomic
modification approaches (238, 239). Transgenic zebrafish that ex-
press foreign genes under the control of constitutive or cell-spe-
cific promoters can also be generated by using relatively straight-
forward approaches (240, 241).
In some instances, the zebrafish model is able to discern patho-
genic phenotypes that are sometimes less clear-cut in mice or
other host model systems. For example, the pore-forming toxin
alpha-hemolysin (HlyA), which is produced by about 50% of all
UPEC isolates, can promote the lysis of red blood cells, potentially
freeing much-needed iron for use by the pathogens (98). Alterna-
tively, at sublytic concentrations, HlyA can inhibit host cell in-
flammatory and survival pathways and indirectly stimulate the
degradation of host cytoskeletal components (98, 174, 175, 242).
In wild-type zebrafish, the survival of a reference UPEC isolate
known as UTI89 is entirely dependent upon the expression of
HlyA (231). However, in fish that lack phagocytes due tomorpho-
lino-mediated knockdown of the host transcription factor PU.1,
UTI89 does not require HlyA for survival or virulence. This find-
ing, along with microscopic imaging of infected zebrafish, indi-
cates that a primary function of HlyA is to incapacitate phago-
cytes, with effects on red blood cell lysis and iron acquisition being
secondary. Interestingly, HlyA is not required by all UPEC isolates
for survival in zebrafish, suggesting that these pathogens can uti-
lize various mechanisms to counter host phagocytes.
Despite the many benefits afforded by the zebrafish infection
model, there are some caveats to this host system. Foremost is the
lack of a mammal-like urinary tract in zebrafish, which prevents
specific analysis of UTI pathogenesis. In addition, zebrafish are
typically maintained at 28.5°C, notably lower than the tempera-
ture in most mammalian hosts. Nonetheless, zebrafish have
proven to be remarkably useful for delineating UPEC-associated
fitness and virulence factors that are relevant to the infection pro-
cess in mammals (203, 204, 207, 231, 243). The discovery and
functional analysis of both bacterial and host factors of impor-
tance to UPEC pathogenesis will likely advance in strides as imag-
ing and genetic approaches in the zebrafish model continue to be
developed and improved.
Nematodes
The nematodeCaenorhabditis elegans, which probably comes into
contact with E. coli within soil environments, is an attractively
facile tool for exploring the virulence potential of UPEC and re-
lated E. coli isolates (232, 244, 245). These transparent worms
consume bacteria as their main food source, which makes bacte-
rial infections of these animals a trivial task. Once placed onto
medium containing a pathogenic bacterial strain, the nematodes
will graze and consequently become infected. By monitoring the
death rate of worms infected with wild-type UPEC strains or iso-
genic mutants, the effects of defined loci on UPEC virulence can
be ascertained. In addition, the roles of specific host genes during
infection can be easily assessed by usingRNA interference (RNAi),
a process initiated by feeding the worms nonpathogenic bacteria
that express double-stranded RNA molecules with homology to
host messages of interest (246, 247). Nematodes encode a number
of innate host defenses and signaling pathways with analogues in
mammals, but the worms lack a true vertebrate-like immune sys-
tem and have no urinary tract (248). As with zebrafish and embry-
onic chickmodels, limitations associated with the use ofC. elegans
as a surrogate host for UPEC may be countered by the low cost,
genetic tractability, and amenability to high-throughput analysis.
CONCLUDING REMARKS
The virulence traits associatedwithUPEC are likely adaptations of
genes that evolved long before modern humans arrived on the
planet. For example, genetic factors that enabled ancestral E. coli
strains to better avoid killing by predatory amebas in the environ-
ment may have later been coopted by UPEC to evade professional
phagocytes within human hosts (249). Such conservation of func-
tion means that information gleaned by analysis of UPEC-associ-
ated fitness and virulence factors within onemodel systemmay be
relevant in other environments. Consequently, the use of surro-
gate hosts like C. elegans and zebrafish, or even larvae of the wax
moth Galleria mellonella (250–252), is not so tangential to UTI
research and has the potential to drive important discoveries in
human patients. Findings made by using animal model systems
can be complemented and extended in broth culture or on agar
plates using genetic and biochemical assays that are designed to
examine howUPECmutants andwild-type strains handle specific
stresses such as reactive oxygen species or serum components like
complement (197, 243).Mathematical and computermodeling of
infectious processes and gene regulation in UPEC provides addi-
tional insight into the pathogenesis of UTIs and can suggest new
hypotheses to be tested in vivo (46, 253, 254). In total, these vari-
ous experimental approaches have helped define the molecular
pathology of UTIs and the virulence potentials of UPEC isolates,
highlighting numerous processes and gene products that may one
day be of significant value as therapeutic targets.
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The Cpx Stress Response System Potentiates the Fitness and Virulence
of Uropathogenic Escherichia coli
Irina Debnath, J. Paul Norton, Amelia E. Barber, Elizabeth M. Ott, Bijaya K. Dhakal, Richard R. Kulesus, Matthew A. Mulvey
Division of Microbiology and Immunology, Pathology Department, University of Utah, Salt Lake City, Utah, USA
Strains of uropathogenic Escherichia coli (UPEC) are the primary cause of urinary tract infections, representing one of the most
widespread and successful groups of pathogens on the planet. To colonize and persist within the urinary tract, UPECmust be
able to sense and respond appropriately to environmental stresses, many of which can compromise the bacterial envelope. The
Cpx two-component envelope stress response system is comprised of the inner membrane histidine kinase CpxA, the cytosolic
response regulator CpxR, and the periplasmic auxiliary factor CpxP. Here, by using deletion mutants along with mouse and ze-
brafish infection models, we show that the Cpx system is critical to the fitness and virulence of two reference UPEC strains, the
cystitis isolate UTI89 and the urosepsis isolate CFT073. Specifically, deletion of the cpxRA operon impaired the ability of UTI89
to colonize the murine bladder and greatly reduced the virulence of CFT073 during both systemic and localized infections within
zebrafish embryos. These defects coincided with diminished host cell invasion by UTI89 and increased sensitivity of both strains
to complement-mediated killing and the aminoglycoside antibiotic amikacin. Results obtained with the cpxP deletion mutants
were more complicated, indicating variable strain-dependent and niche-specific requirements for this well-conserved auxiliary
factor.
Urinary tract infections (UTIs) afflict a large proportion of thehuman population, representing an enormous health and fi-
nancial burden worldwide (1). Most UTIs are caused by a geneti-
cally diverse group of bacteria known as uropathogenic Esche-
richia coli (UPEC). These pathogens can survive and grow within
urine and the lumen of the bladder, but many can also bind and
invade uroepithelial cells (2–4). Within the bladder, entry into
uroepithelial cells can promote UPEC survival and persistence,
rendering the pathogens protected from a variety of stresses and
commonly used antibiotics (3, 5, 6). Prior to introduction into the
urinary tract, UPEC likely first colonizes the host nasopharynx
and gastrointestinal tract, where it does not appear to elicit any
overt pathology (7–9). Within these varied host environments,
and while in transit between hosts, UPEC will encounter an as-
sorted array of stresses, including reactive nitrogen and oxygen
species, nutrient limitation, shearing forces, professional phago-
cytes, complement and other antimicrobial compounds, compe-
tition with other microbes and, potentially, antibiotics (10–15).
The ability to deal with these stresses is of paramount importance
to the success of UPEC as a pathogen.
The envelope of Gram-negative bacteria interfaces with the
extracellular environment, functioning as both a sensor of exter-
nal conditions and as a selectively permeable physical barrier. En-
velope stress response pathways are likely critical to the ability of
UPEC to detect and respond to potentially fatal environmental
insults during the course of infection.UPEC, aswell as otherE. coli
strains, encode a number of envelope stress response systems, in-
cluding sigma E (!E), Rcs, Psp, and the BaeSR and CpxRA two-
component systems (16–19). The Cpx system is comprised of the
inner membrane histidine kinase CpxA and the cytoplasmic re-
sponse regulator CpxR (20–22). Autophosphorylation of CpxA in
response to envelope stress results in the phosphorylation of
CpxR, which then functions as a transcriptional regulator. CpxR
controls the expression of protein folding and degrading factors
involved in relieving envelope stress and can also regulate biofilm
formation (23–26), bacterial adherence (23, 27, 28), motility and
chemotaxis (29, 30), type III and type IV secretion systems (31–
35) and, possibly, the synthesis of bacterial toxins (27, 36, 37).
Studies using E. coli K-12 strains like MG1655 and MC4100 have
indicated that CpxR may regulate the expression of well over 100
genes (38, 39).
In E. coli and other microbes, the Cpx system is subject to
negative feedback through CpxP, a small CpxR-regulated
periplasmic protein that can bind the sensor kinase CpxA, keeping
it in an inactive state (40, 41). CpxR binding sites are situated
upstream of the cpxP gene within a conserved 146-bp region that
separates cpxP from the cpxRA operon. CpxP is the most highly
inducible member of the Cpx regulon so far identified, and it has
elevated expression in response to both envelope stress and entry
into stationary-phase growth (40, 42). In addition to its role as a
negative regulator of CpxA, CpxP also functions as an adaptor
protein, interacting with subsets of misfolded periplasmic pro-
teins and delivering them to the protease DegP for degradation
(43, 44). In this process, CpxP is degraded alongwith itsmisfolded
substrate, suggesting a mechanism by which bacteria can post-
translationally modulate CpxP levels. By varying the amounts of
CpxP within the periplasm, bacteria may be able to fine-tune the
Cpx stress response, limiting inappropriate activation of CpxA in
the absence of envelope stress and permitting rapid shutoff of the
system once the stress is under control (20, 45).
The Cpx system appears to have a key role in regulating the
virulence potential of a number of pathogens (17), including Sal-
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monella spp. (46, 47), Legionella pneumophila (31, 48), Shigella
spp. (33–35), enteropathogenic E. coli (32, 49, 50), Actinobacillus
suis (51),Haemophilus ducreyi (52, 53), Xenorhabdus nematophila
(37, 54), and Yersinia pseudotuberculosis (55–57). However, direct
evidence that the Cpx system can affect pathogen fitness and vir-
ulence in vivowithin an animal host is limited to only a few studies
(47, 50, 53, 54). In UPEC, the Cpx system has been examined
primarily with respect to its ability tomodulate the expression of P
pili, filamentous adhesive organelles that can promote bacterial
interactions with host kidney cells (27, 28, 58). Here, by using
isogenic deletion mutants, we assessed how components of the
Cpx stress response system affect the fitness and virulence of two
referenceUPEC isolates. Employing in vitro assays coupledwith in
vivo mouse and zebrafish infection models, we demonstrate that
cpxP and cpxRA can have profound and sometimes divergent ef-
fects on the pathogenic potential of UPEC.
MATERIALS AND METHODS
Bacterial strains andplasmids.The bacterial strains and plasmids used in
this study are listed in Table 1. Targeted gene knockouts were created in
the human cystitis isolate UTI89 and the urosepsis isolate CFT073 by
using lambda Red-based homologous recombination as previously de-
scribed (59, 60). Briefly, the chloramphenicol resistance cassette (clmr)
was amplified from the template plasmid pKD3with flanking 40-bp over-
hangs specific for the target cpxP or cpxRA loci. PCR products were elec-
troporated into UTI89 and CFT073 carrying the plasmid pKM208, which
encodes an isopropyl-!-D-thiogalactopyranoside (IPTG)-inducible
lambda Red recombinase. The yiiP (fieF) gene was knocked out by using a
similar approach. Knockout strains were selected on Luria-Bertani (LB)
agar plates containing chloramphenicol (20 "g/ml) and verified by PCR
using the primers listed in Table 2.
Expression constructs were made using the low-copy-number plas-
mid pGEN-MCS and standard molecular biology techniques (61). The
cpxP gene and the cpxRA operon were cloned by PCR from the UTI89
chromosome. The primers used (Table 2) to amplify each locus were
designed to include 250 bp of upstream and 100 bp of downstream se-
quences, along with terminal PstI and SalI restriction sites. PCR products
were cut using PstI and SalI and ligated into pGEN-MCS to create the
CpxP andCpxRA expression constructs pJLJ41p and pJLJ42, respectively.
TABLE 1 Bacterial strains and plasmids




UTI89 UPEC, cystitis isolate (O18:K1:H7) 6, 95
CFT073 Urosepsis isolate (O6:K2:H1) 96
Recombinant strains
UTI89#cpxP UTI89 #cpxP::clmr This study
UTI89#cpxRA UTI89 #cpxRA::clmr This study
UTI89#fieF UTI89 #fieF::clmr This study
CFT073#cpxP CFT073 #cpxP::clmr This study
CFT073#cpxRA CFT073 #cpxRA::clmr This study
CFT073#fieF CFT073 #fieF::clmr This study
Plasmids
pKM208 IPTG-inducible Red recombinase expression plasmid, Ampr 60
pGEN-MCS High-retention plasmid containing empty multiple-cloning site, Ampr 61
pJLJ41p cpxP sequence with native promoter from UTI89 cloned into pGEN-MCS; Ampr This study
pJLJ42 cpxRA sequence with native promoter from UTI89 cloned into pGEN-MCS; Ampr This study
pNLP10-lux Low-copy-number cloning vector with promoterless luxCDABE operon; Kanr 39
pJW1-cpxP-lux pNLP10 with PcpxP::luxCDABE, Kanr 39
































a Added restriction sites underlined. KO, knockout.
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Growth curves. Bacteria were grown from frozen stocks at 37°C with
shaking overnight in 5 ml of LB broth or modified M9 minimal medium
(6 g/liter Na2HPO4, 3 g/liter KH2PO4, 1 g/liter NH4Cl, 0.5 g/liter NaCl, 1
mM MgSO4, 0.1 mM CaCl2, 0.1% glucose, 0.0025% nicotinic acid, 16.5
!g/ml thiamine, and 0.2% casein amino acids). Cultures were then di-
luted 1:100 into the indicated medium, and the growth of quadruplicate
200-!l samples in shaking 100-well honeycomb plates at 37°C was as-
sessed using a Bioscreen C instrument (Growth Curves USA). For com-
petition assays, wild-type and mutant strains diluted 1:200 were mixed at
a 1-to-1 ratio in 5 ml modified M9 medium and grown with shaking at
37°C. After 2, 4, and 6 h of growth, titers of the mutant and wild-type
strains were determined by plating serial dilutions on LB agar with or
without chloramphenicol (to distinguish wild-type and mutant strains).
Competitive indices were calculated as follows: log10[(mutantoutput/wild-
typeoutput)/(mutantinput/wild-typeinput)]. Media and other reagents used
in these assays were purchased from Sigma-Aldrich.
Amikacin susceptibility assays. Bacteria were grown from frozen
stocks with shaking at 37°C in 5mlmodifiedM9mediumwith or without
100 !g/ml ampicillin (used to maintain plasmids). Overnight cultures
were diluted 1:100 into 1mlmodifiedM9mediumcontaining amikacin at
concentrations ranging from 1 to 40 !g/ml. Each culture was then grown
with shaking at 37°C for 24 h. The MIC of each strain was determined as
the lowest concentration of amikacin needed to prevent growth.
cpxP promoter activity assays. Bacteria carrying pNLP10-lux or
pJW1-cpxP-luxwere grown from frozen stocks at 37°Cwith shaking over-
night in 5mlmodifiedM9medium containing 50!g/ml kanamycin (39).
Overnight cultures were diluted 1:100 into 5 ml modified M9 medium
containing 50!g/ml kanamycin and incubated with shaking at 37°C for 4
h to reach stationary phase (optical density at 600 nm, "1.0). Triplicate
100-!l aliquots of each sample were then transferred into a 96-well white,
opaque-walled polystyrene microplate (Dynex Technologies), and lumi-
nescence was measured immediately with a Synergy HT multidetection
microplate reader (BioTek Instruments, Inc.).
Hemagglutination assays. Hemagglutination titers were determined
using guinea pig red blood cells (Colorado SerumCompany) as described
previously (62). Bacteria used in these assays were grown statically from
frozen stocks in 20mlmodifiedM9medium or LB broth for 48 h at 37°C.
MouseUTImodel. Seven- to 8-week-old female CBA/Jmice (Jackson
Laboratory) were used, following IACUC-approved protocols as previ-
ously described (5, 63, 64). Wild-type and mutant bacterial strains were
grown from frozen stocks in 20ml static modifiedM9medium for 24 h at
37°C. Prior to inoculation, bacteria were pelleted by centrifugation for 10
min at 8,000 # g and then resuspended in phosphate-buffered saline
(PBS). Mice were anesthetized by using isoflurane inhalation and care-
fully inoculated by transurethral catheterization with 50 !l of a bacterial
suspension containing 1 # 107 CFU. For competitive assays, wild-type
UTI89 was mixed 1:1 with either the $cpxP or $cpxRA mutant prior to
inoculation. For noncompetitive assays, each strain was inoculated sepa-
rately. Bladders were harvested aseptically at 3 days postinoculation,
weighed, and homogenized in sterile PBS containing 0.02%TritonX-100.
Bacterial titers present in the input pools and in the bladder homogenates
were determined by plating serial dilutions on LB agar plates. For com-
petitive assays, LB agar plates with or without chloramphenicol (20 !g/
ml) were used to distinguish the wild-type and mutant strains. Competi-
tive indices were calculated as follows: log10[(mutant CFU inoculated/
wild-type CFU inoculated)/(mutant CFU recovered/wild-type CFU
recovered)]; based on this equation, values of less than 0 indicated that the
wild-type strain outcompeted the mutant. Experiments were repeated
two to three times, and combined data are shown.
Zebrafish infections. Zebrafish used in this study were handled in
accordancewith IACUC-approved protocols and following standard pro-
cedures (www.zfin.org), as previously described (65). *AB zebrafish em-
bryos were collected from mixed egg clutches in a breeding colony that
was maintained on a 14-h light/10-h dark cycle. Embryos were grown at
28.5°C in E3 medium (5 mM NaCl, 0.27 mM KCl, 0.4 mM CaCl2, 0.16
mM MgSO4) containing 0.000016% methylene blue as an antifungal
agent. At 48 h postfertilization (hpf), embryos were manually dechori-
anated, briefly anesthetized with 0.77 mM ethyl 3-aminobenzoate
methanesulfonate salt (Tricaine; Sigma-Aldrich), and embedded in low-
melting-point agarose (Mo Bio Laboratories) without Tricaine. Agarose-
embedded embryos were then transferred to E3 medium lacking methyl-
ene blue and infected individually with wild-type CFT073 or the cpx
mutants. Bacteria were grown from frozen stocks, held static in 12 ml
modified M9 medium at 37°C for 24 h. One milliliter from each culture
was pelleted, washed once with 1ml PBS, and resuspended in PBS prior to
inoculation into either the pericardial cavity or circulation valley by using
an Olympus SZ61 or SZX10 stereomicroscope together with a YOU-1
micromanipulator (Narishige), a Narishige IM-200 microinjector, and a
JUN-AIR model 3 compressor setup. For each bacterial strain, 500 to
1,000 CFU suspended in 1 nl PBS was injected per fish. Inoculation titers
were determined by adding 10 drops (1 nl each) to 1ml 0.7%NaCl, which
was then serially diluted and plated on LB agar plates. Following injection,
embryos were carefully removed from the agar, placed individually into
wells of a 48-well plate (Nunc) containing E3 medium, and incubated at
28.5°C. Fish viability was assessed at regular intervals for 72 h following
injection by monitoring heart beats and blood flow.
Bacterial host cell association and invasion assays.Host cell associ-
ation and gentamicin protection-based invasion assays were performed as
previously described (66, 67). Strains used in these assays were grown at
37°C for 48 h in static LB broth to induce expression of type 1 pili. Human
bladder epithelial cells, designated 5637 (HTB-9; ATCC), were grown at
37°C in 5% CO2 using RPMI 1640 medium (Invitrogen) supplemented
with 10% heat-inactivated fetal bovine serum (HyClone). Bladder cells
were infected with amultiplicity of infection of%15 bacteria per host cell.
Serum resistance assays. Frozen aliquots of pooled human sera, taken
from 7 healthy volunteers by using standard protocols approved by the
University of Utah Institutional Review Board, were provided by Andrew
Weyrich. Care was taken to not freeze and thaw samples multiple times.
Bacteria from overnight cultures grown with shaking at 37°C in modified
M9 medium were pelleted by spinning at 8,000 # g for 5 min, washed
twice, and resuspended in PBS to obtain %1 # 106 CFU/ml. About 5 #
104 CFUof each bacterial strain wasmixed individually withmodifiedM9
medium containing 20% serum, and 200-!l aliquots of each suspension
were immediately placed in a 96-well microtiter plate and incubated with
gentle shaking for 2.5 h at 37°C. Plates were then placed on ice, and sur-
viving bacteria were enumerated by plating serial dilutions on LB agar.
Results were normalized to input titers. Heat-inactivated serum (treated
at 55°C for 30 min) was used as a negative control.
Statistical analysis. The Mann-Whitney U test, Wilcoxon matched
pair test, log-rank (Mantel-Cox) test, and Student’s t test were performed
using Prism 5.01 software (GraphPad Software). P values of less than 0.05
were defined as significant.
RESULTS
TheCpx systemmodulates UPEC resistance to amikacin.By us-
ing lambda Red-mediated linear recombination, the cpxRA
operon and the cpxP gene were individually deleted from two
reference UPEC strains, the cystitis isolate UTI89 and the urosep-
sis isolate CFT073. As the first step in our efforts to phenotypically
characterize these mutants, we assessed their sensitivities to the
aminoglycoside antibiotic amikacin. Previous studies showed that
laboratory K-12 E. coli strains lacking cpxA or cpxRA have in-
creased sensitivity to amikacin, whereas induction of the Cpx
pathway or the expression of constitutively active cpxA mutants
(cpxA*) provides strains with improved resistance to amikacin
(68–70). Resistance has been attributed to the ability of the Cpx
system to activate transcription of drug exporters as well as factors
that help alleviate the stress of mistranslated proteins that may
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accumulate within the bacterial envelope due to amikacin effects
on ribosome activity (25, 70, 71).
In agreement with results obtained using K-12 strains (68, 69),
we observed that both UTI89!cpxRA and CFT073!cpxRA were
highly sensitive to amikacin relative to their wild-type counter-
parts, as determined by MIC assays (Table 3). Plasmid pJLJ42,
which carries the cpxRA operon under the control of its native
promoter, complemented both !cpxRA mutants, whereas the
empty vector pGEN-MCS had no effect (Table 3 and unpublished
observations). Deletion of cpxP, which leaves CpxA less repressed
(40, 45), rendered UTI89 and CFT073 notably more resistant to
amikacin (Table 3). Expression of recombinant cpxP using plas-
mid pJLJ41 restored the resistance of the !cpxPmutants to wild-
type levels. Of note, deletion of the gene yiiP (fieF) located imme-
diately downstream of cpxP did not affect the sensitivity of either
UTI89 or CFT073 to amikacin (unpublished observations).
These results indicate that the Cpx response in the UPEC iso-
lates operates, not unexpectedly, similarly to the Cpx response in
K-12 strains. To further address this point, we utilized a low-copy-
number reporter construct containing the cpxP promoter fused to
a promoterless luxCDABE operon (39). In both CFT073 and
UTI89, the deletion of cpxRA ablated expression of the cpxP re-
porter in early-stationary-phase cultures, whereas deletion of cpxP
greatly enhanced expression (Fig. 1). These data parallel those
reported for similar assays carried out with K-12 strains, support-
ingmodels in whichCpxP functions in part as a negative regulator
of Cpx activation (40, 45).
The Cpx system provides UPEC with a fitness advantage
within the bladder.To address whether or not theCpx system can
affect the fitness of UPEC within the urinary tract, we utilized a
well-established UTI model system, focusing on bladder coloni-
zation by the cystitis isolate UTI89. Adult female CBA/Jmice were
inoculated via transurethral catheterization with wild-type
UTI89, UTI89!cpxRA or UTI89!cpxP, and 3 days later bacterial
titers within the bladder were determined. In noncompetitive as-
says, in which equal numbers of the wild-type and mutant strains
were inoculated separately into different mice, the !cpxRA mu-
tant was recovered in significantly lower numbers than wild-type
UTI89 (Fig. 2A). In contrast, no significant difference was ob-
served between wild-type UTI89 and the !cpxP mutant. Similar
results were obtained in competitive assays, inwhich thewild-type
strain was mixed 1:1 with each mutant strain prior to inoculation
(Fig. 2B and C). These results indicated that cpxRA, but not cpxP,
is required by UTI89 to effectively colonize the bladder.
During the course of a UTI, UPEC comes across a variety of
environmental stresses that can potentially limit its survival and
growth within the host (10–15). These stresses include reactive
nitrogen and oxygen radicals and numerous membrane-damag-
ing substances. In LB broth andmodifiedM9medium, the cpxRA
and cpxP deletion mutants grew normally, whether on their own
inmonoculture or in direct competitionwith thewild-type strains
(Fig. 3). Likewise, no defects were observed with the !cpxRA or
!cpxPmutants when challenged in vitro with nitrosative stress (1
mM acidified sodium nitrite), oxidative stress (0.5 or 1 Mmethyl
viologen), or envelope stress generated by addition of 0.1% so-
dium dodecyl sulfate (unpublished observations). These findings
indicate that deletion of cpxRA or cpxP does not alter the ability of
UPEC to handle generalized stresses.
Divergent effects of the Cpx system on host cell invasion by
UPEC. Effective colonization of the bladder by UPEC generally
requires the expression of functional type 1 pili (63, 72–75). These
filamentous adhesive organelles mediate bacterial attachment to
and invasion of bladder epithelial cells, promoting the establish-
FIG 1 Deletion of cpxP enhances Cpx activation in both CFT073 and UTI89.
Graphs indicate expression levels (" standard deviations) of the luxCDABE
operon driven by the cpxP promoter in wild-type UTI89 (A) and wild-type
CFT073 (B) and their mutant derivatives, following growth to early stationary
phase inmodifiedM9medium.The pNLP1-luxplasmid carries a promoterless
luxCDABE operon. Each graph shows the means " standard errors of the
means of three independent experiments performed in triplicate.














a The assay was repeated three times and the same results were obtained.
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ment and persistence of UPEC within the urinary tract (5, 6, 63,
76). In yeast agglutination assays, as well as hemagglutination as-
says performed using guinea pig red blood cells, we observed no
overt differences in the expression of type 1 pili by the !cpxRA or
!cpxP mutants relative to the wild-type UPEC isolates (unpub-
lished observations). However, UTI89!cpxRA did show a slight,
but significant ("20%), decrease in its ability to adhere to human
bladder epithelial cells in culture (Fig. 4A). This reduction in ad-
herence corresponded with a similar ("30%) decrease in host cell
invasion by UTI89!cpxRA, as determined in gentamicin protec-
tion assays (Fig. 4B). These modest defects in host cell adherence
and invasion could be rescued by complementation of the!cpxRA
mutant with pJLJ42. In contrast to UTI89!cpxRA, the!cpxPmu-
tant had no defect in its ability to bind bladder epithelial cells (Fig.
4A), but it was able to invade the host cells at a much higher
frequency than either wild-type UTI89 or the !cpxRA mutant
(Fig. 4B). Complementation of UTI89!cpxPwith pJLJ42 reduced
the invasion frequencies of thismutant towild-type levels. Impor-
tantly, wild-type UTI89 and the!cpxRA and!cpxPmutants grew
similarly in the cell culture medium, and all three strains were
equally susceptible to killing by gentamicin at the concentration
(100 #g/ml) used in these invasion assays.
Cpx components promote UPEC virulence in zebrafish. To
assess effects of theCpx systemonUPECvirulence, and not fitness
per se, we next focused on CFT073 in a zebrafish infection model
that was recently developed in our laboratory (65). In this model
system, bacteria are microinjected into 48-hpf zebrafish embryos
via either a fluid-filled sac surrounding the heart, known as the
pericardial cavity (PC), or directly into the bloodstream through
the circulation valley. UPEC does not usually spread from the PC,
whereas the pathogens rapidly disseminate systemically following
inoculation of the bloodstream.At 48 hpf, zebrafish are dependent
upon innate host defenses that include phagocytes, antimicrobial
peptides, and complement—the same sort of defenses that mam-
malian hosts employ against UPEC (77–81). The use of zebrafish
has proven to be an effective way to identify and functionally
define virulence factors of relevance to UPEC and related patho-
gens that can colonize an assorted array of hosts and host tissues
(unpublished observations and references 65 and 82).
Relative to UTI89 and many other UPEC isolates, CFT073 is
especially lethal to zebrafish embryos (65). Here, we compared
the lethality of wild-type CFT073 to CFT073!cpxRA and
CFT073!cpxP following inoculation of 500 to 1,000 CFU of
each strain individually into the PC or blood. In this infection
model, increased bacterial growth correlates with decreased
host survival (65). Wild-type CFT073 killed most of the ze-
brafish embryos within 24 h, irrespective of the site of inocu-
lation (Fig. 5). In comparison to the wild-type strain, the viru-
lence of both the !cpxRA and !cpxP mutants was significantly
decreased. Virulence defects associated with CFT073!cpxRA
and CFT073!cpxP were particularly evident following inocu-
lation of the blood (Fig. 5B), which in general appears to be a
more challenging and stressful environment than the PC (65).
Wild-type CFT073 and the !cpxRA and !cpxP mutants grew
similarly in modified M9 minimal medium at 28.5°C, the tem-
perature at which the zebrafish embryos are maintained. Plas-
mid pJLJ42 (cpxRA) and pJLJ41 (cpxP) rescued the virulence
defects associated with CFT073!cpxRA and CFT073!cpxP, re-
spectively, but the wild-type strain carrying empty vector was
attenuated, complicating interpretation of our in vivo comple-
mentation assays (unpublished observations).
Strain-dependent effects ofCpx components on serumresis-
tance.Urine, like serum, contains numerous antibacterial factors,
including heat-labile components of the complement system that
can mediate bacterial opsonization and the formation of mem-
brane attack complexes (14, 83–85). By modulating the composi-
tion and resilience of the bacterial envelope, we hypothesized that
FIG 2 The Cpx system promotes UPEC fitness within the bladder. Adult
female CBA/J mice were infected via catheterization with wild-type UTI89,
UTI89!cpxP, orUTI89!cpxRA in noncompetitive (A) and competitive (B and
C) assays. Graphs show bacterial titers present in the bladder at 3 days postin-
oculation. Bars denote median values for each group (n! 12 mice). The data
in panel B are graphed in panel C as competitive indices. P values were deter-
mined using the Mann-Whitney U test (A) or Wilcoxon-matched paired
signed rank test (B). ns, no significant difference.
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the Cpx system can alter the sensitivity of UPEC to serum com-
ponents. To examine this possibility, serum resistance assays were
performed using wild-type UTI89 and CFT073 along with the
!cpxRA and !cpxPmutants. In these assays, both UTI89!cpxRA
and CFT073!cpxRA were significantly more sensitive to pooled
human sera than their wild-type counterparts (Fig. 6A).
UTI89!cpxP was likewise sensitive, whereas CFT073!cpxP
showed no decrease in serum resistance relative to wild-type
CFT073. Serum resistance defects associated with UTI89!cpxRA,
CFT073!cpxRA, and UTI89!cpxP were rescued by plasmids car-
rying CpxRA (pJLJ42) or CpxP (pJLJ41), as appropriate (Fig. 6B).
In assays that used heat-inactivated serum, which lacks functional
complement, no differences were observed between the wild-type
and mutant strains (Fig. 6C). Together, these data indicate that
CpxRA, with strain-dependent input from CpxP, can enhance
UPEC resistance to serum and, specifically, complement.
DISCUSSION
This study was aimed at delineating the impact of the Cpx enve-
lope stress response system on the fitness and virulence of UPEC.
Our results demonstrated that CpxRA and the auxiliary factor
CpxP can affect the ability of UPEC to colonize distinct host en-
vironments. Employing a well-established mouse UTI model, we
found that deletion of cpxRA limited the ability of the reference
cystitis isolate UTI89 to effectively colonize the bladder, whereas
deletion of cpxP had onlymodest effects. In laboratory K-12 E. coli
strains, CpxP is not an essential regulator of the Cpx system, and
instead it appears tomodulate how quickly CpxA can be activated
or inactivated in response to changing levels of envelope stress (20,
40, 43, 45). Within the bladder, the regulatory effects of CpxP are
apparently dispensable to UTI89, at least at the 3-day time point
that was analyzed. In contrast, deletion of either cpxRA or cpxP
markedly attenuated the virulence of the urosepsis isolate CFT073
during both localized and systemic infections in zebrafish em-
bryos. These data suggest that CpxP is differentially required by
UPEC, depending upon strain background and the host environ-
ment. This idea was further supported by in vitro assays that
showed that the resistance of UTI89 to complement-mediated
killingwas dependent uponbothCpxRAandCpxP,while CFT073
required only CpxRA.
The Cpx system is intercalated within a complex web of signal-
ing cascades and linked up with multiple biosynthetic and meta-
bolic pathways (25, 38, 39, 41, 45, 86–88), making it difficult to
FIG 3 CFT073 andUTI89mutants lacking either cpxP or cpxRA grow normally in LB broth andmodifiedM9medim. (A and B)Growth of wild-typeUTI89 and
associated!cpxP and!cpxRAmutants grown in LB broth (A) andmodifiedM9medium (B). Graphs are representative of at least three independent experiments
performed in quadruplicate. (C to F) Results of competitive growth assays carried out inmodifiedM9mediumwithwild-typeCFT073 andUTI89 versus isogenic
!cpxRA or !cpxP mutants, as indicated. Data are presented as box-and-whiskers plots, with means " the minimum and maximum values from three
independent experiments.
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discern with clarity the specific mechanisms by which Cpx com-
ponents moderate UPEC stress resistance and virulence pheno-
types. It is clear, however, that basic regulation of the Cpx system
in UPEC functions similarly to the Cpx system in nonpathogenic
K-12 E. coli strains. In K-12 strains, CpxP regulates Cpx activation
via a negative feedback loop (40), and this also appears to be the
case in UPEC (Fig. 1). Furthermore, deletion of cpxRA rendered
both UTI89 and CFT073 highly sensitive to the aminoglycoside
amikacin (at 3!g/ml), whereas deletion of cpxP increased amika-
cin resistance. These data are in agreement with work carried out
in K-12 strains (68–70) and support the notion that activation of
the Cpx system safeguards against aminoglycoside antibiotics.
Protection is likely afforded by Cpx-mediated upregulation of
proteases and other factors that alleviate envelope stress initiated
by the mistranslation of inner membrane proteins in the presence
of amikacin (70). Cpx activation may also heighten bacterial re-
sistance to antibiotics via effects on the expression of drug trans-
porters (25, 71).
The protective effects of Cpx activation are limited andwill not
shield against all concentrations and types of antibiotics, includ-
ing the aminoglycoside gentamicin, used in our host cell invasion
assays (70). This means that the slight but significant decrease in
host cell invasion by UTI89"cpxRA and the elevated invasion fre-
quencies seenwithUTI89"cpxP are likely not attributable to Cpx-
regulated effects on the susceptibility of UTI89 to gentamicin.
Instead, the Cpx system may affect bacterial survival during or
immediately after internalization or, alternatively, modulate the
efficacy of the invasion process directly by affecting the surface
characteristics of UPEC. The latter possibility is buoyed indirectly
by observations showing that disruption of the Cpx system can
alter bacterial interactionswith hydrophobic abiotic surfaces (89).
Of note, UPEC mutants lacking either cpxRA or cpxP were not
obviously different from the wild-type strains with respect to mo-
tility, biofilm formation in microtiter plate assays, or the expres-
sion of curli or type 1 pili (unpublished observations). This indi-
cates that many of the phenotypes commonly associated with
UPEC virulence are unaffected by disruption of the Cpx system.
The reduced capacity of UTI89"cpxRA to bind and invade
bladder epithelial cells may contribute to the inability of this mu-
tant to effectively colonize the bladder. However, it is probable
that additional CpxRA-regulated activities also play a role. These
activities may include Cpx-mediated alterations of the bacterial
envelope and peptidoglycan layer that enable bacteria to better
deal with antimicrobial peptides and proteins like complement
(90). The complement system canmediate bacterial opsonization
and the formation of membrane attack complexes, thereby facili-
tating the clearance of bacteria during both localized and systemic
infections (83). The strain-dependent requirement for CpxP in
UPEC resistance to complement-mediated killing, as reported
here (Fig. 6), highlights the individuality of UPEC isolates, which
are often genetically diverse, while also raising questions regarding
the functionality of highly conserved proteins like CpxP.
In addition tomodulating the activity of CpxA,CpxP can func-
FIG 4 Cpx effects on bladder cell invasion by UTI89. Human bladder epithe-
lial cells were infected with the indicated strains for 2 h, followed by an addi-
tional 2-h incubation in medium containing gentamicin (100 !g/ml). Graphs
show the total cell-associated bacterial titers prior to addition of gentamicin
(A) and for gentamicin-protected, intracellular bacteria (B). Data are ex-
pressed relative to wild-type UTI89 (black bars) or UTI89 carrying the control
plasmid pGEN-MCS (gray bars) as the means# standard errors of the means
of at least three independent experiments performed in triplicate. The indi-
cated P values were calculated using Student’s t test.
FIG 5 The Cpx system is required for full virulence of CFT073 in zebrafish
embryos. The PC (A) or blood (B) of 48-hpf zebrafish embryos was inoc-
ulated with 500 to 1,000 CFU of wild-type CFT073, CFT073"cpxP, or
CFT073"cpxRA, as indicated. Fish were scored for death at 0, 24, 48, and 72
h postinoculation. Data are expressed as the percent survival over time
(n ! 17 embryos). P " 0.0008 for the "cpxP and "cpxRA mutants versus
control wild-type CFT073, as determined using Mantel-Cox log rank tests.
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tion as a periplasmic chaperone and may act as a sensor for metal
ions, like zinc and copper (43, 44, 91, 92). UTI89 is apparently
more dependent upon one or more of these activities when chal-
lenged with complement, whereas CFT073 can make do without
CpxP. It is feasible that structural homologues of CpxP, such as
Spy and ZraP (92–94), can substitute for CpxP under specific con-
ditions in strains like CFT073. The Cpx system is best known for
its effects on the expression of periplasmic chaperones and pro-
teases in response to envelope stress, and the misregulation of
these and other factors likely contribute to the myriad defects
observed with the !cpxP and !cpxRAmutants in our assays.
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Abstract 
The pathogenicity of Escherichia coli O78 strain K46, originally isolated 
from an outbreak of septicemia in neonatal lambs, was investigated in zebrafish 
embryo and murine models of infection. Its biofilm potential, cellulose production, 
and the expression of type 1 pili and curli fimbriae were measured by in vitro 
assays. The strain was highly pathogenic in the zebrafish embryo model of 
infection, where it killed all embryos within 24 hours post inoculation at doses as 
low as 1000 colony forming units. Zebrafish embryos inoculated with similar 
doses of commensal E. coli strains showed no signs of disease, and cleared the 
bacteria within 24 hours. E. coli K46 colonized the murine gut at the same level 
as the uropathogenic E. coli (UPEC) reference strain CFT073 in CBA/J mice, but 
infected the murine bladder significantly less than CFT073. Type 1 pili were 
clearly expressed by E. coli K46, while curli fimbriae and cellulose production 
were weakly expressed. The ability to produce biofilm varied in different growth 
media, but overall E. coli K46 was a poorer biofilm producer compared to the 
reference strain E. coli UTI89.  
 
Introduction 
Escherichia coli is a Gram-negative, facultative anaerobic rod-shaped 
bacterium commonly found as part of the intestinal microbiota of warm-blooded 
vertebrates. Though often viewed as innert commensals, some strains of E. coli 
are able to cause disease. Pathogenic E. coli are genetically diverse and cause a 
variety of infections in animals and human beings. Pathogenic strains are 
 186 
frequently categorized into diarrhogenic E. coli (DEC) or extraintestinal 
pathogenic E. coli (ExPEC). DEC and ExPEC are further subcategorized into 
specific pathogroups based on the site or mode of infection (Johnson and Russo, 
2002). Among the diseases caused by ExPEC are septicemia, neonatal 
meningitis, and urinary tract infections (UTI). Despite causing disease outside the 
gut, such bacteria have been shown to colonize the gastrointestinal (GI) tract of 
the host, in some cases even more efficiently than commensal E. coli strains 
(Johnson and Russo, 2002). The GI tract is the main reservoir for pathogenic E. 
coli (Welch et al., 2002), and in septicemic disease, the GI tract together with the 
urogenital tract, are important portals of E. coli entry (Lefort et al., 2011).  
ExPEC are genetically diverse and as such, there are no conserved 
virulence factors (VFs) or genetic characteristic that defines the ExPEC 
pathogroup or are essential for development of disease. Instead, septicemic 
bacteria possess a combination of VFs within the main groups of virulence traits 
(i.e., the adhesins, capsular synthesis, toxins, invasins and iron uptake systems). 
The set of VFs present in each septicemic strain enables the bacteria to defeat 
the host’s defense mechanisms and cause an infection (Russo and Johnson, 
2000). The lack of common VFs among septicemic strains and the numerous 
possible combinations of VFs make the recognition of septicemic strains and the 
assessment of their pathogenic potential challenging.  
Genomic analysis can provide clues to a strain’s virulence and 
demonstrate its similarity to other pathogenic isolates. However, to truly assess a 
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strain’s pathogenic potential, it must be tested in a biological assay or animal 
model. Cell culture as well as invertebrate and vertebrate models have been 
developed to study septicemic disease and ExPEC virulence specifically. These 
models range from murine models aimed to differentiate pathogenic from 
nonpathogenic E. coli strains (Picard et al., 1999) to the unicellular amoeba 
model, Dictyostelium discoideum, measuring the level of bacterial pathogenicity 
(Adiba et al., 2010). 
Zebrafish (Danio rerio) embryos have been shown to be a useful model 
organism for the study of host-pathogen interactions and the virulence potential 
of ExPEC strains (Wiles et al., 2009). During the early stages of development, 
the zebrafish immune system is composed solely of innate defenses, including 
phagocytes, NK cells, complement and toll-like receptors, and this corresponds 
to the immune system of neonatal lambs (Trede et al., 2004; Meeker and Trede, 
2008; Meijer and Spaink, 2011).  
E. coli O78 strain K46 was isolated from an outbreak of septicemia in 
neonatal lambs in Norway in 2008 (Kjelstrup et al., 2013). Previous genetic 
characterization could not explain the observed high virulence of this strain 
(Kjelstrup et al., 2013). The aim of this study was thus to investigate the virulence 
potential of E. coli K46 in in vivo virulence assays such as a zebrafish septicemia 
model, a mouse gut colonization model, and a murine urinary tract model, and in 
in vitro assays for the production of pili/fimbriae. In addition, the survival potential 
in the environment in a biofilm assay was examined. 
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Materials and Methods 
Bacterial strains 
The septicemic E. coli K46 was used in all the experiments in this study. 
Two uropathogenic E. coli strains, CFT073 and UTI89, and four nonpathogenic 
E. coli strains, designated Ctr 1- Ctr 4, were used as reference and control 
strains, respectively, for one or more of the experiments in this study (Table D.1).  
 
Media and conditions 
The minimal media M9 (6 g/l Na2HPO4, 3 g/l KH2PO4, 1 g/l NH4Cl, 0.5 g/l 
NaCl, 1 mM MgSO4, 0.1 mM CaCl2, 0.1% glucose, 0.0025% nicotinic acid and 
16.5 µg/ml thiamine), YESCA (0.5 g/l yeast extract, 10 g/l Casamino Acids) and 
Luria-Bertani (LB) broth were used in one or more of the experiments. The 
cultures were grown overnight in an aerobic atmosphere at 37 °C shaking at 225 
rpm if not otherwise specified.  
In the zebrafish trial, inoculums were prepared by centrifugation of 1 ml of 
static, 24 hours M9 culture at 8000 rpm for 2 min, and the pellet was washed 
once with 1 ml sterile PBS (Hyclone) and resuspended in 275–550 µl PBS to 
obtain appropriate bacterial densities for microinjection.  
In the mice gut colonization trial, 12 ml of a static overnight M9 culture was 
centrifuged at 8000 rpm for 10 min. The pellet was washed with 1 ml PBS, the 
centrifugation step repeated, and the pellet was resuspended in 500 µl sterile 
PBS. The number of colony forming units (CFU)/ml was measured after serial 
dilutions and plating to LB plates. For recovery of E. coli K46 and the reference 
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strain CFT073 in the mouse gut colonization study, tetracycline (5 mg/ml) and 
chloramphenicol (10 mg/ml), respectively, were added in the LB plates as 
selective agents.  
In the mouse UTI trial, 20 ml of a static overnight M9 culture was 
centrifuged at 8000 rpm for 10 min at 20 °C and the pellet was resuspended in 8 
ml sterile PBS and diluted 1:10. Serial dilutions and plating to LB plates were 
done to quantify the infection dose. 
 
Zebrafish septicemia trials 
The zebrafish septicemia model was used as in Wiles et al. (2009). Briefly, 
48-54 hours old zebrafish embryos inoculated with approximately 103 CFU of E. 
coli into the bloodstream via the circulatory valley, resulting in rapid, systemic 
dispersal. Death was defined as the complete absence of heart rhythm and blood 
flow. To quantify bacterial burden during the course of infection, embryos from 
each infection group were collected at 6 and 12 hpi and individually homogenized 
with a mechanical PRO 250 homogenizer (PRO Scientific) in 0.5 ml PBS 
containing 0.5% Triton X-100. Homogenates were serially diluted and plated on 
LB agar, incubated overnight at 37 ºC and CFUs were counted.  
To visually track the course of infection in real time, zebrafish embryos 
were also injected with 1-2×103 CFU of E. coli carrying pGEN-GFP (LVA) (REF 
Wiles et al., 2009) for constitutive expression of destabilized green fluorescent 
protein (GFP) protein (GFP-marked strains). At 12 hpi embryos were fixed by 
incubation overnight at 4 °C in PBS containing 4% paraformaldehyde in a light 
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proof container. Fixed embryos were washed in PBS containing 0.8% Triton X-
100 in the dark for 4×20 minutes and then incubated for 10 min each in 30% and 
50% glycerol before being transferred to a lightproof container and stored at 4 °C. 
Samples were imaged using an Olympus SZX10 stereomicroscope equipped 
with an Olympus DP72 camera. 
Mouse gut colonization trials  
Six-to-seven-week-old female CBA/J mice (Jackson Laboratory, USA) 
were anesthetized by inhalation of isoflurane gas and gavaged with 50 µl of 
approximately 3×109 CFU of either E. coli K46 (resistant to tetracycline) or 
CFT073-ClmR (resistant to chloramphenicol). The two groups were kept in 
separate cages, and each mouse was marked individually. Fecal matter from 
each mouse was collected at the day of inoculation to ensure the absence of any 
tetracycline and chloramphenicol resistant bacteria in the commensal microbiota. 
Fecal samples were thereafter collected daily. Approximately 100 mg of 
feces/mouse/day was resuspended in 900 µl 0.7% NaCl. Serial dilutions were 
plated on LB agar with either chloramphenicol or tetracycline and incubated 
overnight at 37ºC for quantification of CFT073-ClmR and E. coli K46, respectively. 
At 14 dpi the mice were anesthetized and euthanized by cervical dislocation, and 
the liver, kidney, bladder and intestines from the mice homogenized in 0.25% 
Triton X-100, serial diluted in 0.7% NaCl and plated on LB plates with 
tetracycline. The mice showed no overt signs of sickness throughout the trial. 
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Mouse UTI trials  
Seven- to eight- week- old female CBA/J mice (Jackson Laboratory, USA) 
were anesthetized by isoflurane inhalation and slowly inoculated via transurethral 
catheterization as described by Wiles and coworkers (Wiles et al., 2013). Mice 
were inoculated with a 50 µl bacterial suspension of 1.6×106 - 2.4×105 CFU of E. 
coli K46. The mice were euthanized 3 days later by cervical dislocation under 
anesthesia, and the bladder and left kidney were homogenized separately in 1 ml 
of 0.025% Triton X-100. The suspensions were serially diluted, spread onto LB 
agar plates, and incubated for about 18 hours at 37 °C, and CFU/g tissue were 
calculated.   
 
Expression of fimH, curli fiber and cellulose biosynthesis 
The expression of fimH (adhesin of type 1 pili) was tested using a yeast 
agglutination assay. The strains were grown in static overnight LB cultures at 37 
°C. 50 µl of PBS with 1% yeast (Saccharomyces cerevisiae) and 150 µl of 
overnight culture were pipetted onto a sterile microscope slide and mixed, and 
the ability to agglutinate was visually observed.  
The expression of curli fiber was detected by growing the strains on 
Congo red plates (1% tryptone agar plates containing the dye Congo red) 
overnight at 30 ºC. Red pigment in the colonies was deemed as positive for curli 
fiber (Hernandes et al., 2011).  
Since the expression of cellulose could reduce the production of biofilm 
(Zogaj et al., 2001), the bacterial strains were tested for their ability to synthesize 
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cellulose on LB agar with 0.02 % (w/v) calcofluor white. Plates were incubated for 
24 and 48 hours at 30 °C, and then observed under UV light (366 nm) for the 
presence of fluorescence and thereby positive for the synthesis of cellulose 
(Zogaj et al., 2001). 
 
Growth curves and biofilm formation 
E. coli strains were tested for their ability to form biofilm in three different 
media; LB, M9 and YESCA. Each overnight culture was diluted 1:100 in fresh 
medium, and four technical replicates of 100 µl of these dilutions were transferred 
to a flat-bottomed polystyrene 96-well microtiter plates with lids (NUNC). The 
plates were incubated at 30°C statically for 48 hours, the media was withdrawn, 
and the wells rinsed with water to remove any planktonic bacteria. 150 µl of 0.1% 
crystal violet solution was added to each well and incubated for 10 minutes at 
room temperature. The solution was removed and the wells were washed with 
water to remove any crystal violet unbound to biofilms before the microtiter plates 
were air dried without a lid for 30 min. 200 µl of solvent solution (DMSO) was 
added to solubilize stained biofilms and the plates were covered and incubated at 
room temperature, while shaking for 15 min. Absorbance was obtained using a 
SynergyHTTR/KC4 fluorimeter/luminometer (BioTek Instruments, Inc.) at 562 
nm. Three biological replicates were made for each strain. The biofilm produced 
was measured by arbitrary units, where the mass of biofilm produced by the 
various strains was compared to the mass of biofilm produced by the reference 
strain UTI89. 
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To ensure that the observations were due to the strains’ ability to form 
biofilm in each medium and not their ability to grow in these media, growth curves 
for the five strains in the three media were obtained using a Bioscreen C plate 
reader system (Growth Curves USA, Piscataway, NJ). The setup was parallel to 
the biofilm protocol regarding the preparation of the cultures, but 200 µl diluted 
culture was used instead of 100 µl in each well. The trays were inserted into the 
microplate reader (Bioscreen) for 24 hours with shaking, and bacterial growth 
was measured every 30 min at OD600.  
 
Ethics statement 
Mice used in this study were handled in accordance with protocols 
approved by the Institutional Animal Care and Use Committee (IACUC) at the 
University of Utah (Protocol number 10-02014), following US federal guidelines 
indicated by the Office of Laboratory Animal Welfare (OLAW) and described in 
the Guide for the Care and Use of Laboratory Animals, 8th Edition. 
Zebrafish used in this study were handled in accordance with IACUC-
approved protocols following standard procedures (www.zfin.org). 
 
Results 
E. coli K46 is highly virulent in the zebrafish bloodstream 
E. coli K46 proliferated readily in the zebrafish embryos and approximately 
2 and 3 magnitude higher levels of bacteria were retrieved at 6 and 12 hpi, 
respectively, compared to the time point of inoculation (Figure D.1B). Ctr 1 and 
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Ctr 2 did not reach higher levels in the embryos (Figure D.1B), and the bacteria 
were eliminated within 24 hpi (data not shown). All of the embryos infected with 
Ctr 1 and Ctr2 were still alive at 72 hpi  (Figure D.1A) and no signs of obvious 
disease were observed in these fish. Conversely, all the embryos challenged with 
E. coli K46 died between12 and 18 hpi (Figure D.1A).  
Infection with GFP-labeled E. coli K46 showed that bacteria were located 
throughout the vasculature at 12 hpi (Figure D.2), while the zebrafish embryos 
inoculated with the GFP-marked Ctr 1 and Ctr 2 were undetectable by eye at 12 
hpi (data not shown). Together these results show that E. coli K46 is highly lethal 
in a zebrafish embryo model of infection and can replicate readily within the 
zebrafish bloodstream. 
 
E. coli K46 stably colonizes the gastrointestinal tract of mice 
Following oral gavage into the gastrointestinal tract, E. coli K46 colonized 
the gut of all mice at an average concentration of 106 CFU/g feces throughout the 
twelve days of experiment. This was similar to what was seen for ExPEC 
reference strain CFT073 (Figure D.3), indicating that E. coli K46 is an efficient 
colonizer of the mouse intestine.   
 
E. coli K46 colonizes the bladder poorly 
Following transurethral catheterization of K46 into the bladder, bacteria 
could not be detected at 3 dpi in half of the mice. In the remaining mice, 103-104  
CFU/g tissue were isolated at this time point (Figure D.4). When bacterial titers in 
 195 
the kidneys were examined, two of the mice with bacteria in the bladder also had 
105-107 CFU/g bacteria present in the kidneys. A similar titer of bacteria was also 
found in the kidney of one mouse with no bacteria in the bladder (Figure D.4). 
The finding of bacteria in the kidneys indicates that E. coli K46 has the ability to 
invade host tissue, although it does not seem to be a primary pathogen of the 
urinary tract.    
 
E. coli K46 expresses fimH, curli fiber  
and produces cellulose 
E. coli K46 and Ctr 1, Ctr 3 and Ctr 4 were positive for fimH expression as 
measured by yeast aggultination. E. coli K46 and E. coli Ctr 4 were weakly 
positive for the expression of curli fiber and cellulose production as determined 
by growth on Congo Red and Calcofluor White plates (Table D.2). These results 
suggest that E. coli K46 has all the requirements needed for biofilm production. 
 
E. coli K46’s ability to produce biofilm depends  
on the trial conditions 
In LB broth, both E. coli K46 and the control strains Ctr 1-Ctr 4 were poor 
biofilm producers (Figure D.5A). In YESCA media, Ctr 4 formed equal amount of 
biofilm as ExPEC reference strain UTI89, while the other strains produced 
approximately 50% less (Figure D.5C). In modified M9 minimal media, E. coli 
K46 and Ctr 1-Ctr 3, formed biofilm at the same or higher level than UTI89, while 
Ctr 4 formed approximately 20% less biofilm than UTI89 (Figure D.5B). The 
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growth characteristics of all E. coli strains tested were similar within each media, 
but differences in growth rate and final OD were observed between different 
media conditions (Figure D.5A-C). Together these data show that E. coli K46 
produces biofilm most efficient under stringent conditions. 
 
Discussion 
 Fewer virulence factors (VFs) were detected in E. coli K46 than in the 
control strains isolated from healthy lambs, but none of the detected VFs were 
sufficient to explain the observed lethality in the septicemic outbreak among the 
neonatal lambs (Kjelstrup et al., 2013). Despite this lack of specific VFs, we show 
that E. coli K46 is exceptionally virulent in the zebrafish model, as it killed all the 
infected embryos within 24 hpi, while none of the E. coli control strains caused 
any lethality. This is underscored by the zebrafish trial with the GFP marked E. 
coli K46, where the bacterial path from the infection site through the vasculature 
of the embryo is confirmed. The zebrafish trials correspond with the high 
virulence observed in the septicemic outbreak among the neonatal lambs, where 
all six lambs died after acute illness (Kjelstrup et al., 2013). The clearance of the 
E. coli control strains from the zebrafish embryos is in accordance with other 
studies where a virulent E. coli K12 (DH5α) was phagocytosed and eliminated 
within 5 hours after infection (Lavigne et al., 2012). While the zebrafish results do 
not explain the specific mechanisms behind the microbial pathogenesis, they do 
support our conviction that E. coli K46 is highly pathogenic. Our data also support 
the conclusion that bacterial factors and not only host factors, contributed 
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significantly to the lethality in the lambs.  
The results obtained in the zebrafish trials further support the use of 
zebrafish as a suitable model organism for studying pathogenicity in E. coli. The 
zebrafish (Danio rerio) has a well-developed immune system, which is similar to 
the mammalian immune system (van der Sar et al., 2003). The model is also 
sensitive and hence applicable for examining pathogenicity and even closely 
related strains of ExPEC have been shown to display differences in virulence 
capability in the zebrafish model (Wiles et al., 2009). 
The bacterial species in the GI tract of humans and sheep are different 
from those in mice, but the conditions and factors affecting bacterial competition 
within the mouse gut can to some extent be extrapolated to humans (Hao and 
Lee, 2004). Nevertheless, it was somewhat surprising that E. coli K46 colonized 
the murine gut at the same high levels as the reference strain CFT073, which is 
recognized to be a very efficient colonizer of the mouse intestine. In neonatal 
septicemia, the ewe may be the source of infection through contaminated fleece 
and udder after shedding pathogenic bacteria in the feces. The bacteria 
subsequently enter the lambs per os through suckling. From there the ingested 
bacteria likely colonize the infant gut and enter the bloodstream, resulting in 
septicemic disease. The portal of entry is not known in the E. coli K46 outbreak, 
but the strain’s significant ability to colonize the murine gut indicate that the 
gastrointestinal tract as a possible entry route. If nothing else, the high and stable 
level of E. coli K46 in the mouse gut despite the absence of any selective 
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pressure shows that this strain has the essential prerequisites to outcompete an 
intact microbiota and colonize the gut. Whether E. coli K46 would establish itself 
as part of the normal murine gut flora permanently is not known, as the mice 
experiment was ended after 2 weeks duration when the level of E. coli K46 was 
still high. 
Infection in the bladder and a subsequent ascending infection to the 
kidneys is a common infection route of septicemia in humans (Cusumano et al., 
2010). E. coli K46 colonized the murine bladder poorly, which corresponds with 
the lack of pathological findings in the kidneys at autopsy of the mice (data not 
shown). This indicates that the urogenital tract is not a preferred entry route for 
the entrance of E. coli K46 into the bloodstream, at least not in mice. In two of 
three mice with E. coli in both the kidney and the bladder, the bacteria likely 
reached the kidney through an ascending infection. Bacterial reflux into the 
kidneys during transurethral catheterization is rare (Blango and Mulvey, 2010), 
but this might explain the retrieval of E. coli only in the kidney, and not in the 
bladder, in one of the mice.  
E. coli K46 expressed curli fiber and the type 1 fimbriae fimH, in addition to 
possessing genes for other adhesins like afaE VIII, f17 fimbriae, prfB, bmaE and 
lpfA (Kjelstrup et al., 2013). The expression of different fimbriae and the level of 
their expression may give the strain a selective advantage during colonization, 
but may also play a role in the ability to form biofilm. Along with their role in the 
formation of secreted IgA-mediated biofilm within the gut, several groups have 
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reported that type 1 fimbriae (fimH) are critical for E. coli biofilm formation on 
abiotic surfaces (Pratt and Kolter, 1998; Moreira et al., 2003; Bollinger et al., 
2006). Mutations in fimH have been reported to reduce E. coli attachment to 
polyvinyl chloride and other abiotic surfaces (Pratt and Kolter, 1998; Beloin et al., 
2004). The expression of fimH has significance in the formation of biofilm in M9, 
while the expression of curli fiber is an important factor in biofilm formation in 
YESCA (Hadjifrangiskou et al., 2012). This is not supported by our study, where 
Ctr 2 (fimH-negative) formed biofilm at the same level as the reference strain in 
M9, while Ctr 4 (fimH-positive) did not. In YESCA, Ctr 4 formed biofilm on the 
same level as the reference strain, and at significantly higher level than E. coli 
K46, despite both strains being weakly positive for curli fiber. In addition, a direct 
antibiofilm role has been demonstrated for group II capsular polysaccharides 
(Naves et al., 2008), but since neither E. coli K46 nor Ctr 1-Ctr 4 contained genes 
for capsular synthesis this cannot explain the difference in biofilm production in 
the current study. Furthermore, one should keep in mind that this method of 
measuring biofilm only measures biomass and not cell viability in the biofilm 
(Crémet et al., 2013). 
Cellulose is usually produced as an extracellular component for 
mechanical and chemical protection and the expression of cellulose can reduce 
biofilm production (Zogaj et al., 2001). However, the co-expression of cellulose 
and curli fiber can form a highly inert, hydrophobic extracellular matrix, called 
“bacterial wood” which surrounds the bacterial surface and functions as a survival 
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mechanism. The production of both cellulose and curli fiber in E. coli K46 could 
increase its persistence in a farm environment.  
 
Conclusion 
The zebrafish lethality model supports our belief that E. coli K46 is highly 
pathogenic, and that the lamb lethality seen in the septicemic outbreak was likely 
due to a collection of known and unknown bacterial virulence factors. The murine 
models show that E. coli K46 can stably colonize the intestinal microbiota and 
potentially provide a route of entry for infection. Virulence genes essential for the 
high pathogenicity are not identified, but bacterial knockout mutants used in 
zebrafish challenge could be an interesting approach in future studies. 
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Table D.1. E. coli strains used in the study. 
 
Strain Source Characteristics Reference 
E. coli wildtype strains 





Phylogenetic group C* 
(Kjelstrup et al., 
2013) 
 Ctr 1 Feces, healthy 
lamb 
Phylogenetic group B2 (Kjelstrup et al., 
2013) 
 Ctr 2 Feces, healthy 
lamb 
Phylogenetic group B1 (Kjelstrup et al., 
2013) 
 Ctr 3 Feces, healthy 
lamb 
Phylogenetic group B2 (Kjelstrup et al., 
2013) 
 Ctr 4 Feces, healthy 
lamb 








(Mobley et al., 
1990) (Welch et 
al., 2002) 
 UTI89 Cystitis-derived, 
human 
O18:K1:H7 (Chen and Hung, 
2006) 
E. coli recombinant strains 




K46 Expresses destabilized 














*Previously referred to as belonging to phylogenetic group A, but is now 





Table D.2. The expression of fimH and curli fiber and the production of 
cellulose in E. coli K46 and four control strains Ctr 1-Ctr 4.  
 
Strains fimH expression Curli fiber Cellulose synthesis 
K46 + + a +a 
Ctr 1 + - - 
Ctr 2 - - - 
Ctr 3 + - - 
Ctr 4 + + a +a 
 
a
 Weak reaction 
  
 206 












































6 hpi 12 hpi
A
B
Figure D.1. Survival and bacterial titers in zebrafish embryos challenged with 
E. coli K46 and two control strains. 
(A) Representative Kaplan-Meier survival plot of zebrafish embryos inoculated 
with 103 CFU of E. coli K46, Ctr 1 or Ctr 2, n = 18-20 embryos per group. 
(B) The level of bacteria retrieved from the inoculated zebrafish at 6 and 12 
hours post inoculation (hpi). The horizontal bars indicate the median values 






























Figure D.3. Gastrointestinal tract colonization of adult female CBA/J mice 
gavaged with 1.5x108 CFU of E. coli K46 (tetracycline resistant) or the 
reference strain UPEC strain CFT073-ClmR (chloramphenicol resistant). 
The colonization was assessed at each of the indicated time points by enumerating 
CFU per gram feces of the inoculated strains. Data represent CFU/g feces ± SEM 
(n = 5 mice).  
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Figure D.4. Bacterial numbers of E. coli K46 present in the bladder and kidney 
of female CBA/J mice 3 days after transurethral catheterization of 105-106 
CFU of E. coli K46. 
The colonization was assessed at each of the indicated time points by enumerating 
CFU per gram feces of the inoculated strains. Data represent CFU/g feces ± SEM 
(n = 5 mice).  
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D E F 
Figure D.5. Biofilm formation in E. coli K46 and four control strains (Ctr 1-Ctr 
4) in LB, M9 minimal salts medium, and YESCA
(A-C) Representative growth curves in LB, M9, and in YESCA.
(D-F CRUUHVSRQGLQJ ELRÀOP IRUPDWLRQ PHDVXUHG UHODWLYH WR WKH UHIHUHQFH VWUDLQ 
87, AOO ELRÀOP GDWD DUH WKH DYHUDJHV IURP WKUHH LQGHSHQGHQW H[SHULPHQWV 
SHUIRUPHG LQ TXDGUXSOLFDWH EUURU EDUV LQGLFDWH WKH VWDQGDUG GHYLDWLRQ
